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SUMMARY 
 Multiple myeloma (MM) is a B cell malignancy characterized by clonal 
proliferation of plasma cells in the bone marrow. With the advent of novel 
targeted agents, the median survival rate has increased to 5 -7 years. However, 
majority of patients with myeloma suffer relapse or develop chemoresistance to 
existing therapeutic agents. Thus, there is a need to develop alternative 
therapies for the treatment of myeloma. Activation of pro-inflammatory 
transcription factors NF-κB and STAT3 is one of the major contributors to both 
pathogenesis and chemoresistance in MM. These transcription factors regulate 
diverse genes involved in various hallmark capabilities of MM cells namely 
proliferation, survival, angiogenesis, migration and invasion and 
chemoresistance. Natural compounds have been considered a good source of 
anti-cancer therapies since ancient times. Thus in the present study, we 
investigated whether celastrol, a triterpenoid derived from Chinese medicinal 
plant Tripterygium wilfordii could suppress the proliferation and induce 
chemosensitization in myeloma cells and xenograft mouse model by interfering 
with NF-κB and STAT3 activation pathways. The anti-inflammatory effects of 
celastrol have been previously investigated in various inflammatory disease 
models. In fact, the extract derived from the plant Tripterygium wilfordii has 
been tested before clinically in rheumatoid arthritis patients. A number of 
studies have also described its anticancer efficacy in diverse tumor models in 
the last few years.  
 We aimed to investigate the untapped potential of celastrol as an anti-
MM agent and found that celastrol can significantly inhibit the proliferation of 
various myeloma cell lines regardless of their sensitivity to conventional 
  xii 
chemotherapeutic agents. As a single agent, celastrol induced apoptosis, and 
abrogated migration and invasion of myeloma cells. Celastrol also enhanced 
the apoptosis induced by novel targeted therapies namely bortezomib and 
thalidomide in synergistic manner in MM cells. Interestingly, celastrol also 
reduced the activation of upstream non-receptor tyrsoine kinase JAK2 and 
thereby abrogated STAT3 phosphorylation, nuclear translocation and DNA 
binding. Interestingly, we also found that celastrol's thiol reactive function is 
critical for its observed inhibitory effects on STAT3 activation cascade in MM 
cells. Celastrol also suppressed the phosphorylation of p65 subunit of the NF-
κB transcription factor, its nuclear translocation, DNA binding ability and these 
effects were found to be mediated via inhibition of activation of IKK-α/β and 
AKT kinases. Celastrol also potentiated the ability of bortezomib to cause 
inhibition of NF-κB DNA binding ability in MM cells. Modulation of STAT3 
and NF-κB pathways were associated with the downregulation of various 
oncogenic gene products involved in MM proliferation, survival, invasion and 
angiogenesis.  
               Finally, whether celastrol can overcome chemoresistance and enhance 
the activity of bortezomib was also investigated in MM xenograft model in 
nude mice.  Interestingly, we observed that celastrol significantly potentiated 
the antitumor effects of bortezomib in vivo and this correlated with suppression 
of various markers survival and angiogenesis. Overall, our cumulative findings 
suggest that celastrol overcomes chemoresistance and sensitizes myeloma cells 
to thalidomide and bortezomib by abrogating STAT3/NF-κB signal 
transduction cascades and thereby highlights the enormous potential of this 
triterpene as a novel anti-myeloma agent.  
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Figure 1.3 Schematic diagram of NF-κB activation pathway 
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Figure 2.1 Schematic representation of in vivo experimental protocol    
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Figure 3.1.1 Predictive analysis of anti-myeloma effects of celastrol upon 
HSP90 activity knock-down along with HO-1 induction 
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Figure 3.2.2.1 Celastrol causes accumulation of MM cells in sub G1 phase 
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Figure 3.2.2.2 Celastrol causes loss of membrane integrity in a time-
dependent manner in MM cells 
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Figure 3.2.2.4 Celastrol activates caspase-3 and causes PARP cleavage 
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Figure 3.2.2.5 Celastrol causes the activation of both extrinsic and intrinsic 
caspase cascades in MM cells 
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Figure 3.2.2.6 Celastrol downregulates expression of various anti-apoptotic 




Figure 3.2.2.7 Celastrol causes downregulation of expression of various 
anti-apoptotic proteins involved in survival of MM cells at 
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transcriptional level 
 
Figure 3.2.2.8 Celastrol causes upregulation of pro-apoptotic members of 
Bcl-2 family proteins in MM cells 
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Figure 3.2.2.9 Celastrol induces JNK activation and celastrol-induced JNK 
activation is inhibited by JNK inhibitor (SP600125) 
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Figure 3.2.2.10 JNK inhibition blocks celastrol-induced apoptosis 
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Figure 3.2.3 Celastrol modulates the expression of proteins involved in 
cell cycle progression 
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Figure 3.2.4 Celastrol downregulates the expression of proteins involved 
in myeloma angiogenesis 
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Figure 3.2.5.1 Celastrol inhibits CXCL12-induced MM cell migration 
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Figure 3.2.5.2 Celastrol inhibits CXCL12-induced MM cell invasion 
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Figure  3.2.5.3 Celastrol downregulates the expression of proteins involved 
in MM cell migration and invasion  
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Figure 3.3.2 RPMI-8226 cells and its resistant clones phosphorylate 
STAT3 upon induction with IL-6 
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Figure 3.3.3 Celastrol inhibits the constitutively activated STAT3 in a 
dose- and time- dependent manner 
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Figure 3.3.4 Celastrol inhibits IL-6-induced phosphorylation of STAT3 
in a time-dependent manner 
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the induction of phosphatases in MM cells 
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Figure 3.3.8 Celastrol inhibits phosphorylation of Janus Kinase and Src 
kinase in MM cells 
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Figure 3.4.1.1 Myeloma cells express constitutively activated p65 
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Figure 3.4.1.2 Celastrol inhibits the phosphorylation of IκB and p65 
proteins in MM cells 
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Figure 3.4.2 Celastrol augments the NF-κB inhibitory effects of 
bortezomib in MM cells 
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Figure 3.4.3 Celastrol augments apoptosis induced by novel anti-




Figure 3.5.1 Celastrol enhances the inhibition of tumor growth induced 




Figure 3.5.2 Celastrol exhibits no obvious side effects in vivo 
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Figure 3.5.3 Celastrol donwregulates p-STAT3 and p65 expression in 
vivo in MM xenograft mouse model 
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Figure 3.5.4 Celastrol modulates proteins involved in myeloma 








Figure 4.1 Schematic diagram depicting inhibition of STAT3 and NF-
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1. INTRODUCTION 
1. 1. Cancer 
 Cancer is a major public health problem worldwide. According to 
World Cancer Research Fund International, there were an estimated 12.7 
million cancer deaths (13% of all deaths) worldwide in 2008, males accounting 
for 6.6 million and females accounting for 6 million. According to Singapore 
Cancer Registry Interim Annual Registry Report detailing the trends in cancer 
incidence in Singapore 2007-2011, a total of 54,001 cases were diagnosed 
between 2007 and 2011. Of these,  26,267 (48.6%) were men and (51.4%) 
cases were women. The understanding of the biology of cancer has increased 
tremendously in the past few years. Accordingly, the treatment modalities and 
supportive care have also seen a lot of improvement.  
 In modern times, it has been established that cancer originates from the 
normal mammalian cells when they undergo multistep mutagenesis each of 
which confer a survival advantage to the cancer cells [1]. Weinberg and 
Hanahan have described the key hallmark principles that control the 
transformation of a normal cell into a tumor cell. These include 1. Self-
sufficiency in growth signals 2. Insensitivity to antigrowth signals  3. Evasion 
of apoptosis 4. Limitless replicative potential 5. Sustained angiogenesis and 6. 
Tissue invasion and metastasis. These properties are attained by the cells 
through 'the oncogenes' resulting from the gain of function mutations and 
'tumor suppressor genes' resulting from loss of function mutations [2]. 
Additional hallmark capabilities described recently include genomic instability 
and mutations, tumor promoting inflammation, deregulated cellular energetics 
and avoiding immune destruction [3].    
 
1. 2. Multiple Myeloma (MM) 
 Multiple myeloma (MM) is a B cell malignancy involving the post 
germinal center B cells. The disease is characterized by presence of blood and 
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urinary monoclonal proteins, osteolytic bone lesions and infiltration of bone 
marrow with malignant plasma cells [4]. Generally, MM is preceded by two 
premalignant conditions namely monoclonal gammopathy of undetermined 
significance (MGUS) and smouldering (asymptomatic) multiple myeloma 
(SMM) [5, 6].  
 
1. 2. 1. Epidemiology 
  MM is mainly a disease of elderly people. It is twice more common in 
African Americans than Caucasians [7, 8]. MM is the second most common 
hematological malignancy next only to non-Hodgkin’s lymphoma, contributing 
1% of all neoplasias [9]. The advent of existing treatment modalities, has 
increased the median survival rate to 5-7 years [10]. MGUS is prevalent in 2% 
of white males of older than 50 years. The risk of progression of SMM to MM 
or other MM related conditions is 10% over the first 5 years [6]. According to 
Singapore General Hospital website as dated on October 2011, about 80 new 
patients with MM are diagnosed every year. 
 
1. 2. 2. Diagnosis 
 According to International Myeloma Working Group (IMWG) the 
criteria for the diagnosis of MGUS is presence of less than 10% of  bone 
marrow plasma cells, serum intact immunoglobulin of less than 3g/100 ml with 
the absence of any clinical symptoms. Diagnosis of SMM requires greater than 
10% bone marrow plasma cells, greater 3g/100 ml of serum intact 
immunoglobulin with the absence of any clinical symptoms. MM is diagnosed 
when there is greater than 10% of plasma cells in the bone marrow, greater 
than 3g/100ml of serum intact immunoglobulin with the presence of clinical 
symptoms. The clinical symptoms defining the diagnosis of MM are 
hypercalcemia, renal involvement, anemia and bone lesions that can be 
attributed to the plasma cell disorder and are not related to any other disease or 
disorder present in the  patient [11]. 
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1. 2. 3. Normal B cell development  
 Understanding of normal B cell development is crucial to study the 
pathogenesis of MM. Occurrence of programmed mutations during B cell 
development help in the immune function by increasing diversity of antibodies 
that can be produced in response to the exposure to any foreign antigen. This 
interesting phenomenon in the development of B cells (also in T cells) enables 
body to fight with the diverse environmental antigens. These regulated 
mutations occur during various steps of B cell development. Naive B cell that 
resides in the bone marrow expresses IgM (immunoglobulin M) which binds 
with foreign antigen. They undergo first step of mutation (VDJ recombination) 
resulting in immunoglobulin genes recombination and move to the lymph node. 
These naive B cells upon exposure to antigen move to the germinal center of 
the lymph nodes and undergo somatic hypermutation to increase the affinity 
with their antigens. Then, these B cells undergo immunoglobulin class switch 
recombination to produce various isotypes of immunoglobulins. The B cells 
that enter the bone marrow to produce functional immunoglobulins are called 
'plasma cells' or 'post germinal center B cells' [12]. Few plasma cells undergo 
apoptosis when the immune response wanes. However, remaining plasma cells 
find their way into the specialised bone marrow niche where they survive as 
'long lived plasma cells' to function as memory cells waiting for the next 
encounter with the same antigens. The differentiation of centroblast residing in 
the lymph node to the mature plasma cells requires reprogramming to increase 
their functional efficacy. They undergo cell cycle arrest, condensation of 
chromatin and silencing of cellular functions which are not necessary for the 
production of antibody. Simultaneously, processes required for the production 
of antibody are turned on which are mediated by various transcription factors 
[13]. The transcription factors required for the plasma cell differentiation 
include IRF4 (interferon regulatory factor 4), XBP1 (X box-binding protein 1) 
and BLIMP-1 (transcriptional repressor B lymphocyte-induced maturation 
protein 1) [14, 15]. Erroneous immunoglobulin translocations and 
dysregulation in the differentiation of centroblast to the plasma cell leads to of 
MM [13].  
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Multi-Step model of MM progression 
 













IM MM - Intramedullary MM  EMMM - Extramedullary MM 
Figure 1.1. Multi-step molecular model of MM initiation and progression 
In the process of B cell development, germinal center B cells develop into long 
lived plasma cells, which home to bone marrow and survive in the specialized 
bone marrow niche. Erroneous translocations and other cytogenetic events lead 
to the development of MGUS. In interaction with the bone marrow 
microenvironment and with the advantage offered by other genetic events like 
Ras mutations MGUS progress through SMM to MM. Additional cytogenetic, 
genetic and epigenetic alterations offer an advantage such that the MM cells no 
longer require the BMME for their survival, leading to development of EMMM 
and PCL. 
  29 
1. 2. 4. Pathogenesis and Classification 
 The pathogenesis of MM involves characteristic genetic abnormalities 
and the interaction between the clonal plasma cells and the bone marrow 
microenvironment [16]. Unlike other hematological malignancies and similar 
to solid tumors, the genetic abnormalities of MM are heterogeneous and the 
transformation is not driven by a single gene mutation. The genetic 
abnormalities include copy number changes of chromosomes, translocations 
and point mutations which lead to activation of oncogenic pathways or 
inhibition of tumor suppressor pathways [17].  
 
1. 2. 5. Initiating cytogenetic events 
 Broadly, based on the initiating cytogenetic events MM can be 
classified into two groups which are hyperdiploid and non-hyperdiploid.  
Hyperdiploid MM is characterized by trisomies of odd number chromosomes 
with low prevalence of IgH (Immunoglobulin heavy chain) translocations. 
Non-hyperdiploid MM is typified by high prevalence of translocations, 
hypodiploid, near diploid, pseudodiploid and tetraploid [18]. As a result of 
these translocations, IgH enhancer loci cause activation of juxtaposed genes 
leading to their oncogenic activation. The recurrent translocation partners most 
commonly involved are cyclin D1 [t(11;14)(q13;q32) translocation] in about 
15% of MM patients, FGFR (fibroblast growth factor receptor 3) and MMSET 
(MM set domain gene) [(4;14)(p16;q32) translocation] about another 15% of 
MM patients, C-Maf  [t(14;16)(q32;q23) translocation] in 5% of MM patients 
and cyclin D3 [t(6;14)(p21;q32)] in 4% of MM patients [12]. Cyclin D 
dysregulation is an early perhaps the initiating event in both the groups but it 
occurs by different mechanisms and leads to variable progression of MM in 
each group [19].  
 
1. 2. 6. Progression of MGUS to MM 
 The progression of MGUS to MM has been an interesting area of study. 
Chromosome 13 abnormalities, especially monosomy 13 or deletion of 13q14 
is present in about 50 % of patients with MM [20]. Initially, it was thought that 
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chromosome 13 abnormalities lead to the progression of MGUS to MM. 
However, with recent advances in the techniques used in cytogenetics, it has 
become clear that patients with chromosome 13 abnormality had this 
chromosomal abnormality even before they had progressed to MM [21-23]. 
Though in subset of patients, activating mutations of Ras [24] and FGFR3 [25] 
have been thought to lead the transformation of MGUS to MM, the majority of 
oncogenomics studies have failed to show any significant difference in the 
genomic profile of MGUS and MM. So, it is yet to be determined what 
molecular even is linked to the progression of MGUS to MM. However, the 
significant difference between MGUS and MM lies in the dysregulated 
interaction between the MM cells and the bone marrow microenvironment [17, 
26]. Though few studies implicate the role of epigenetic events involved in the 
pathogenesis of MM, their casual role remains yet to be determined. It can be 
concluded that the progression of normal plasma cell to MM through MGUS 
involves complex interplay of genetic events, epigenetic events and the bone 
marrow microenvironment [27].  
 
1. 2. 7. Molecular events in the progression of MM  
 Thus developed MM, through complex genetic and epigenetic events 
further progresses and is no longer dependent on bone marrow 
microenvironment for survival leading to extramedullary MM where in 
malignant plasma cell seed themselves in various parts of the body and PCL 
(plasma cell leukemia) wherein MM cells flood the blood stream. Elucidating 
evolving genetic and epigenetic events have lead us identify dysregulation of 
few oncogenic and tumor suppressor pathways and their specific role in the 
further progression of MM.  These secondary cytogenetic events rarely involve 
IgH locus unlike primary initiating events. 
 
1. 2. 7. 1. Mutations involving Ras 
 Mutations affecting Ras are consistently less common in MGUS than in 
newly diagnosed MM and in primary plasma cell leukemia [24]. Activating 
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Ras mutations are considered to play important role in the transformation of 
MGUS to MM, at least in the t(11;14) subtype [13]. 40% of newly diagnosed 
MM patients are found to have Ras mutations [28]. Their role in the 
progression has also been supported by increase in the prevalence of the 
mutation in treated patients when compared with newly diagnosed patients [29]. 
Moreover, ectopic expression of K-ras or N-ras in the interleukin 6 (IL-6)–
dependent ANBL6 MM cell line leads to cytokine-independent growth [30]. 
Ectopic expression of K-ras or N-ras can lead to constitutive activation of 
MEK 2 (mitogen activated extracellular kinase 2)/ ERK (extracellular signal- 
regulated kinase), PI3K (phosphatidylinositol-3 kinase)/Akt, mTOR 
(mammalian target of rapamycin)/p70S6-kinase (ribosomal protein S6 kinase), 
and NF-κB (nuclear factor kappa B) pathways in the IL-6-dependent ANBL6 
multiple MM cell line [31] and thereby lead to IL-6-independent growth [30].  
 
1. 2. 7. 2. Mutations involving Myc: 
 Translocations involving Myc are quite complex and often involve 
more than two chromosomes. The typical translocation  involving 
immunoglobulin locus found in mouse plasmacytoma [32-34] and Burkit's 
lymphoma [35] are rarely found in MM. Since, these mutations were found in 
advanced MM and in even at greater percentage in HMCLs (human myeloma 
cell lines) they were considered to play role in progression of MM in advanced 
disease state [36]. However, recent studies support the hypothesis that similar 
to Ras mutations, Myc mutations might be co-operatively transform MGUS to 
MM along with mutations leading dysregulated cell  cycle [37]. 
 
1. 2. 7. 3. Mutations involving p53 and Rb 
  Inactivating mutations involving p53 and Rb are not found in MGUS 
and progressively increase through newly diagnosed MM patients to advanced 
disease stage indicating that they are not initiating events but are involved in 
progression of MM [38]. Other inactivating mutations rarely also involve p15, 
p18 and PTEN (phosphatase and tensin homolog) and their biological 
consequences are not well determined yet [39]. 
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1. 2. 8. Role of bone marrow microenvironment in the 
pathogenesis of MM 
 
 Normal plasma cells need bone marrow niche for survival. However, 
genetic events leading to the development of MM alter their interaction with 
the bone marrow microenvironment [13]. The bone marrow microenvironment 
can be broadly divided into cellular and non-cellular components. Cellular 
components include MM cells, BMSCs (bone marrow stromal cells) or bone 
marrow fibroblasts, hematopoietic precursor cells, osteoclasts, osteoblasts, 
endothelial cells and immune cells [40, 41].  The BMSCs and osteoclasts 
provide the MM cells with the ability to grow and survive, either by direct 
adhesion and/or by secreting growth and survival cytokines [42]. Of these, the 
supportive role of stromal cells in MM has been studied extensively. The 
interactions between MM cells and osteoclasts have also been studied to an 
extent [43].   
 The non-cellular compartment is comprised of the ECM (extracellular 
matrix) and the soluble factors. Extracellular matrix consists of various 
proteins like collagen, fibronectin and laminin. The extracellular matrix not 
only acts as depots for the growth factors, but also provides the MM cells with 
the ability to resist cell death induced by chemotherapeutic agents [41]. The 
survival advantage offered by the bone marrow microenvironment to the MM 
cells is achieved through the soluble growth factors secreted by various cellular 
components, insoluble growth factors bound to the extracellular matrix 
component and adhesion molecules that help MM cells adhere to the 
extracellular matrix and the cellular compartment [44].  In fact, in a recent 
study, 22 out of the 51 MM growth factor genes that could be analyzed by 
affymetrix, were found to be significantly overexpressed by at least one bone 
marrow environment population in comparison to others [45].  
 SDF-1α/CXCL12 (Stromal derived factor-1α), secreted by the BMSCs, 
play an important role in homing of MM cells to the bone marrow, which 
expresses its receptor CXCR-4 (C-X-C chemokine receptor type 4). Moreover, 
adhesion of MM cells to stromal cells or fibronectin, induces chemoresistance 
in MM cells, mediated by integrins [46]. The adhesion molecules namely 
VLA-4 (very late antigen), VCAM-1 (vascular cell adhesion molecule) and 
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LFA-1 (lymphocyte function–associated antigen 1), ICAM–1 (intercellular 
adhesion molecule) mediate integrin-induced chemoresistance [47]. The 
resistance is mediated partly due to the activation of NF-κB, which upregulates 
anti-apoptotic gene products [48].   
 Adhesion of MM cells to the stromal cells induces the latter to secrete 
IL-6. IL-6 is the main growth factor for the MM cells. In turn  IL-6 then 
induces Janus kinase (JAK)/Signal transducer and activator of transcription3 
(STAT3), PI3K/Akt and MAPK (mitogen-activated protein kinase) survival 
pathways in MM cells [49].  Thus activated STAT3 transcription factor can 
upregulate the expression of its target genes namely cyclin D1 and Mcl-1 
(induced myeloid leukemia cell differentiation protein), which promote cell 
proliferation and anti-apoptosis respectively. In addition to the IL-6-induced 
activation of STAT3, DNA methylation has also been reported to silence the 
negative regulators of STAT3 [50]. AKT promotes cell proliferation by 
phosphorylating GSK3β  (glycogen synthase kinase 3β), which regulates cyclin 
D1 proteolysis [51]. Activated MAPK pathway can further drive MM growth 
and survival [52, 53]. Numerous novel targeted therapies that act by 
modulating these diverse players involved in these complex cellular 
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Diagrammatic representation depicting the interaction between MM cell 
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Figure 1.2. Complex interaction between MM cells and BMME 
Adhesion of MM cells to the BMSCs induces secretion of various cytokines, 
chemokines and growth factors mainly by NF-κB-mediated mechanism. 
Adhesion also confers resistance to MM cells. MM cells further secrete various 
growth factors which act on BMSCs. Also involved in the reciprocal 
interaction are osteoclasts and endothelial cells. Adapted from [54].  
 
  35 
1.2.8.1. Role of IL-6 in MM pathogenesis 
 IL-6, a pleiotropic cytokine, is involved in the physiological processes 
such as haematopoiesis, immunity and inflammation. It was discovered as a 
factor secreted from mitogen stimulated T cells, which helps mature B cells 
transform into antibody producing plasma cells [55]. Because of the pleiotropic 
nature of IL-6, various laboratories have identified its different functions, 
giving it different names: BSF II (B cell stimulating factor II) for its ability to 
stimulate B cells to turn into plasma cells and secrete antibodies,  interferon-ß2 
[56] for it was thought to have the properties of interferon  but later it was 
proven that IL-6 does not have properties of interferon, 26 kDa protein- named 
after its molecular weight, a hybridoma/plasmacytoma growth factor for it 
induced plasmacytoma in Balb/c mice injected with mineral oil [57], and a 
hepatocyte-stimulating factor for it stimulated hepatocytes to produce acute 
phase proteins [58].  
 IL-6 binds to its receptor, which is either membrane bound gp130 or in 
soluble form. It then activates ubiquitously expressed receptor gp130 [59]. 
Once gp130 gets activated, IL-6 acts by the three of the following signaling 
pathways: JAK-STAT pathway, MAPK-ERK and PI3K/AKT pathway. Most 
of the actions of IL-6 are executed by JAK-STAT pathway [60]. IL-6 is also 
found to be involved in the growth of many solid tumors like prostate cancer 
and renal cancer [61, 62]. Pathogenesis of Kaposi sarcoma has been proven to 
be due to dysregulation of the secretion of IL-6 [63]. 
 IL-6 is one of the main growth factors in MM [63]. In fact, it has been 
found that IL-6 knock out mice fail to develop MM [64]. Moreover, serum 
level of IL-6 and soluble IL-6 receptor has been proven to be a prognostic 
marker for tumour load, disease progression and survival [65-69]. Serum levels 
of IL-6 in patients with smouldering MM and MGUS are comparable with 
healthy individuals indicating the important role of IL-6 in the disease 
progression [70].  
 Initially, it was thought based on the following findings that MM cells 
secrete and respond to IL-6 in an autocrine manner. Firstly, IL-6 induces in 
vitro growth of freshly isolated MM cells. Secondly, MM cells express the IL-
6R (IL-6 receptor). Thirdly, purified MM cells produce IL-6 and lastly, in vitro 
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growth of MM cells is inhibited by anti-IL-6 antibody [71]. But, again 
controversies prevailed among various scientific groups on the autocrine 
secretion of IL-6 by MM cells. Because, though all MM derived cell lines and 
patients cells express IL-6 receptor, only subset of cell lines express IL-6 
mRNA [72]. It was also found that BMSCs are the main source of IL-6 [73-75]. 
Interestingly, when MM cells were co-cultured with BMSCs, they tend to 
adhere to each other tightly and the IL-6 secretion by these cells reaches the 
peak. But, when the BMSCs were fixed by paraformaldehyde, there was no 
increase in the level of IL- 6, confirming that the source of IL-6 was BMSCs 
and not MM cells.  
 Moreover, it was found that the stromal cells secrete IL-6 when 
stimulated by the adhesion of MM cells to the stromal cells. This is evident 
from experimental set up where these cells were cultured in transwell chambers 
without any physical contact with the MM cells. As a result, the bone marrow 
cells failed to secrete IL-6, emphasising the importance of adhesion molecules 
in the cross talk between group of cells and pathophysiology of MM [76]. The 
adhesion-mediated secretion of IL-6 was found to be NF-κB-dependent [77]. In 
addition to BMSCs, adhesion of MM cells to the peripheral blood derived 
osteoclastic cells protected MM cells from serum deprivation-induced 
apoptosis and doxorubicin-induced apoptosis. Thus osteoclast-induced survival 
is also at least partially mediated by IL-6 [78].  
 IL-6-induced survival of MM cells is mediated by STAT3, which 
upregulates anti-apoptotic proteins Bcl-xL (B-cell lymphoma-extra large) and 
Mcl-1 and cell cycle proteins like cyclin D1, c-Myc and proto-oncogene coding 
for serine/threonine-protein kinase Pim-1. The IL-6-induced proliferation is 
mediated by MAPK-ERK pathway [53]. PI3K/AKT pathway mediates 
proliferation and induces survival by phosphorylating Bad and activating cell 
cycle proteins and NF-κB [79]. Gene expression profiling studies demonstrated 
that out of 138 genes shown to be regulated by IL-6 in MM cells, 54% 
regulated cell cycle progression. This finding emphasizes the role of IL-6 in 
MM cell proliferation [80]. IL-6 was also shown to abrogate Fos-induced 
apoptosis [81]. IL-6 can inhibit dexamethasone-induced apoptosis of MM cells 
by gp130 induced activation of SHP-2 (Src homology region 2 domain-
containing phosphatase-2) which deactivates RAFTK (RAFTK related 
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adhesion focal tyrosine kinase) [82, 83] and activates the PI3K/AKT pathway 
[84]. Partial reduction in the levels of IL-6 can sensitize the MM cells to 
chemotherapeutic agents [85, 86]. 
 Various strategies including IL-6 antagonist, IL-6 receptor inhibitor 
(CNTO 328), antisense oligonucleotides against IL-6 and IL-6 super antagonist 
(SANT7), has been investigated for MM treatment. But, even after effectively 
blocking IL-6 receptor by the monoclonal antibody, the results were 
disappointing in clinical trials as a single therapy [87]. Accordingly, in the 
presence of BMSCs, IL-6 receptor inhibition did not induce apoptosis, 
indicating the significance of the pleotropism offered by other growth and 
survival factors present in the bone marrow microenvironment [88, 89].  
 
1.2.8.2. Role of VEGF in MM pathogenesis 
 VEGF  (vascular endothelial growth factor) is a signal protein that 
stimulates formation of new blood vessels, through vasculogenesis and 
angiogenesis [90]  The activity of VEGF is mediated through three receptor 
tyrosine kinases: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 
[91]. VEGFR-1 is expressed on endothelial cells and monocytes and mediates 
cell motility [92]. The mitogenic activities of VEGF, as well as vascular 
permeability, are mediated primarily through VEGFR-2 [93]. Lastly, VEGFR-
3, is believed to mediate lymphoangiogenesis [94-96]. VEGF isoforms, upon 
binding to their respective receptors, initiate a tyrosine kinase signaling 
cascade and initiates the production of distinct growth factors that can 
stimulate vessel permeability, proliferation/survival, migration and finally 
differentiation into mature blood vessels [97]. Dysregulation of VEGF has 
been shown to be a major contributor to tumor angiogenesis as well, promoting 
tumor growth, invasion and metastasis [98] . Upon stimulation by VEGF, 
bovine capillary endothelial cells were shown to proliferate and show signs of 
capillary like tube structures [99]. Significantly elevated levels of VEGF are 
observed in a variety of hematological malignancies [100-104]. Several studies 
link VEGF inactivation to observed antitumor effects in various malignancies 
[105].  
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 Angiogenesis appears to play a key role in hematological malignancies 
[106]. There is growing evidence that increased bone marrow angiogenesis 
occurs in MM [107, 108] and is related to disease activity [109, 110] . 
Angiogenesis in MM also appears to be correlated with the PCLI (plasma cell 
labelling index) [109]. MVD (micro vessel density) can be measured by 
histological analysis of tumor samples for markers of angiogenesis and serve as 
prognostic indicators for various cancers. Interestingly, MVD have been 
reported to increase five-to-six fold in magnitude during progression from 
MGUS or SMM to the active MM [111, 112]. Moreover, after chemotherapy, 
MVD decreases significantly in patients in complete or partial remission [113]. 
A number of studies implicate dysregulation of VEGF in MM pathogenesis 
and associated clinical features, including lytic lesions of the bone and immune 
deficiency. VEGF protein was found in malignant cells from 75% of MM 
patients studied [114]. Increased serum levels of VEGF have been correlated 
with a poor prognosis in patients with advanced stages of MM [115]. In fact, 
Iwasaki et al. reports predicted treatment responses and disease progression in 
MM using serum vascular endothelial growth factor [116]. Another patient 
study claims that the levels of VEGF, along with FGF, parallel disease activity 
[117]. VEGF may also affect the immune response in MM patients. Sera from 
MM patients' bone marrow inhibits antigen presentation by DCs (dendritic 
cells); conversely, anti-VEGF antibodies neutralized this inhibitory effect, 
confirming that VEGF can mediate immunosuppression in MM patients [118]. 
The cytokine is probably involved in the progression of MM to PCL [119]. 
VEGFR-1 is also widely expressed on both MM cell lines and patient MM 
cells, confirmed both by RT-PCR (reverse-transcriptase polymerase chain 
reaction) analyses and immunoprecipitation [120-122]. 
 MM cells release angiogenic factors such as FGF (fibroblast growth 
factor) and VEGF [112, 117] and are shown to induce angiogenesis in vivo in 
the chick chorioallantoic membrane assay [112]. They secrete MMP-2 and 
MMP-9 (matrix metalloproteinase-2 and -9) and urokinase-type plasminogen 
activator [112] and cytokines recruiting inflammatory cells, such as mast cells 
that then induce angiogenesis through secretion of angiogenic factors in their 
granules [123]. VEGF is generally present in the bone marrow 
microenvironment of patients with MM and associated with neovascularization 
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at sites of MM cell infiltration [124].  The induction of VEGF enhances the 
microvascular density of bone marrow and accounts for the abnormal structure 
of MM tumor vessels [125]. VEGF increases both osteoclastic bone-resorbing 
activity [126] and osteoclast chemotaxis [127] and inhibits maturation of 
dendritic cells [128]. Marrow neovascularization parallels disease activity in 
MM and this is postulated to be due to VEGF-induced time- and dose-
dependent increase in stromal cell secretion of IL-6, a known MM growth 
factor [129]. Another cytokine, TNF-α (tumor necrosis factor-α), has been 
reported to be involved in the control of VEGF production by MM cells [130]. 
Moreover, VEGF directly, or indirectly through its stimulatory activity on 
TNF-α and IL-β1 (interleukin- β1), stimulates the activation of osteoclasts and 
thus contributes to the lytic lesions in MM [126]. 
 Other factors modulating VEGF secretion include Interleukins: IL-1β 
[131], IL-10 (interleukin -10) and IL-13 (interleukin 13) [132]; secretion of IL-
6 [121, 129, 133] or VEGF by both BMSCs and tumor cells 
(paracrine/autocrine loop); hypoxia and the presence of mutant oncogenes (ie, 
mutant Ras which up-regulate VEGF expression); secretion of growth factors 
such as IGF-1 (insulin like growth factor-1) [134, 135], FGF-4 [136], PDGF 
(platelet-derived growth factor) [137], TGF-β (transforming growth factor-β) 
[138], TNF-α [139], and gonadotropins [140]; c-maf–driven expression of 
tumor integrin β7 [141]. 
 Binding of VEGF to MM cells triggers VEGFR tyrosine 
phosphorylation, activating several downstream signaling pathways, 
particularly involving PI3K [142, 143]. PI3K-dependent cascade mediates MM 
cell migration [142]. This signal transduction pathway is mediated by focal 
adhesion proteins [144] such as FAK (focal adhesion kinase), paxillin and 
cortactin, which are responsible for the stabilization of focal adhesion plaques 
and the reorganization of actin fibers [145]. VEGF also regulates MM cell 
survival by modulating the expression of Mcl-1 and survivin [146].  
 MAPK are the final effectors of the signal to the nucleus, thereby 
activating genes for proliferation, migration and survival [147]. The three well-
characterized families of MAPK are ERK1/2, SAPK1 (stress-activated protein 
kinase-1) and SAPK2/p38 kinases. Treatment of  endothelial cells with VEGF 
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activates both ERK1/2 and SAPK2/p38 MAPK and increases cell migration 
[148]. This increased migration and cell proliferation is because of the 
activation of VEGFR-2, since it is totally inhibited by a VEGFR-2 blocking 
antibody [149]. In fact, MEK-ERK pathway is shown to mediate MM cell 
proliferation, as evidenced by use of anti-VEGF antibody and PD098059 [120]. 
 Approaches to disrupt the VEGF/VEGF receptor signaling pathways 
range from small molecule VEGF/ VEGFR inhibitors, anti-VEGF and anti-
VEGF receptor antibodies such as bevacizumab [150, 151], and VEGF 
transcription inhibitors. Of interest are various kinase inhibitors that block the 
signal transduction mediated by VEGF. The VEGF receptor tyrosine kinase 
inhibitor PTK787 has been found to be active preclinically and undergoing 
clinical protocol testing in MM [152, 153]. It acts directly on MM cells to 
inhibit VEGF-induced MM cell growth and migration and inhibits paracrine 
IL-6–mediated MM cell growth in the BM milieu. Pazopanib [154], another 
VEGF receptor tyrosine kinase inhibitor, is also being studied for cancer 
therapy.  
 
1.2.8.3. Role of TNF-α in MM pathogenesis 
 In 1894, William Coley, noticed that an injection of bacterial extracts 
into the tumor, could induce necrosis of tumors [155]. O’Malley et al 
demonstrated that serum from mice injected with bacterial endotoxins can 
induce tumor regression [156]. The factor that can induce anticancer activity in 
vivo and in vitro, present in the sera of mice treated with endotoxin or LPS 
(lipopolysacharide) was identified as tumor necrosis factor α [157, 158]. The 
gene expressing human TNF-α was cloned in 1984 [159]. Thereafter, the 
recombinant TNF-α was used for experimental and therapeutic purposes. The 
therapeutic dose of TNF-α induced serious hemodynamic instability and septic 
shock like symptoms preclinically. TNF-α can induce necrosis of tumor by 
selective destruction of the blood vessels, only when injected at higher 
concentrations loco-regionally [160]. Its induction of apoptosis is highly 
context dependent.  Its dysregulation is involved in number of inflammatory 
and autoimmune conditions including rheumatoid arthritis and Crohn’s disease 
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[161].  Recent research has demonstrated the potent protumorigenic effect of 
TNF-α [162, 163]. TNF-α KO and TNFα-R1 KO mice do not develop 
chemical carcinogen-induced skin cancers [164, 165]. TNFα-R1 KO mice do 
not develop chemical carcinogen-induced liver cancer [166]. 
 In MM, TNF-α also acts as an important growth factor although not as 
potent as IL-6 [167]. But, it is an important factor secreted from MM cells to 
act on BMSCs to stimulate the secretion of IL-6. TNF-α induces the expression 
of adhesion molecules on both MM cells and BMSCs.  TNF-α secreted by MM 
cells acts both directly, and by increasing the adhesion between MM cells and 
the BMSCs to secrete IL-6 by an NF-κB-mediated mechanism in BMSCs [76, 
77, 168]. TNF-α is very potent when compared to other growth factors [169]. 
TNF-α also participates in transendothelial migration of MM cells by acting via 
TNF-R2 and upregulating the secretion of MCP-1 (monocyte chemoattractant 
protein-1) in MM cells  [170]. Clinically, the agents which are known to inhibit 
TNF-α such  as thalidomide and other immunomodulatory agents have 
exhibited significant anti-myeloma activity [171].   
 
1.2.8.4. Role of chemokines in MM pathogenesis 
 Chemokines are a family of cytokines originally found to be 
responsible for chemotaxis of inflammatory cells, thus deriving their name 
‘chemotactic cytokines – chemokines’. They are expressed by injured tissue 
and inflammatory cells. Thus the resulting chemokine gradient helps in the 
recruitment of the inflammatory cells towards the site of high concentration of 
chemokines [172]. They are involved in various biological processes like 
wound healing, lymphoid recruitment etc. However, their role in angiogenesis, 
metastasis and cancer progression has also been unraveled [173-176].   
 In MM, chemokines mainly help homing the MM cells to the bone 
marrow microenvironment [177].  Their role in proliferation and survival of 
MM cells can be either direct, or mediated indirectly by inducing the secretion 
of IL-6, VEGF or any other growth factor involved in the growth and survival 
of MM cells [178].  The potential role of chemokines, especially that of MIP 
(macrophage inflammatory proteins), in osteolytic bone lesions is well 
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established [179].  Homing is defined by transendothelial migration of cells 
from the blood stream towards the chemokine gradient.   This involves 
adhesion of cells to the endothelial layer, transendothelial migration and 
eventually residing in the microenvironment. This process is also aided by the 
chemokine gradient in the bone marrow microenvironment because certain 
chemokines are said to be present in higher concentrations in bone marrow 
microenvironment than in bone marrow endothelial cells which ensures that the 
cells are confined to the bone marrow microenvironment  [180]. 
 CXC12 is a member of CXC family of cytokines and its cognate 
receptor is CXCR4. It has been implicated in progression, migration, invasion 
and metastasis of various cancers [181]. The role of CXC12/CXCR4 has been 
well established in the homing of hematopoietic progenitor cells [182-184].  
BMSCs secrete this chemokine, with the MM cells from the patient sample and 
MM derived cell lines expressing the cognate receptors [177]. 
 This chemokine mediates the secretion of IL-6 and VEGF and induces 
proliferation, migration and inhibits dexamethasone-induced cell death [178]. 
In the 5TMM mouse model, BMSCs and endothelial cells secrete CXC12 and 
MM cells express the receptor. In vitro, CXC12 induces moderate proliferation 
of MM cells, which was abrogated by blocking antibody. 5T MM cells 
migrated towards stromal cell-conditioned medium which was partially 
inhibited by CXCR4 inhibitor. CXC12 also stimulated MM cells to secrete 
MMP9. Accordingly, CXC12 induces invasion and the CXCR4 inhibitor 
inhibits CXC12-induced invasion. In vivo, CXCR4 inhibitor decreased the 
tumor burden and the immediate homing to about 40% [179].  
 Adhesion molecules and CXCL12/CXCR4 signaling play an important 
role in the homing and mobilization of hematopoietic stem cells. Among the 
various adhesion molecules, very late antigen 4 is critical for homing and 
mobilisation of myeloma cells. Moreover, when the MM cells are mobilized, 
the CXCL12/CXCR4 axis is generally downregulated. Interestingly, there is 
also a downregulation in the expression of adhesion molecule very late antigen 
4 in the peripheral blood MM cells after mobilization. This results in a 
suppression of the adhesion of MM cells to the BMSCs, which can be rescued 
by induction with IL-6 [185]. Moreover, bone marrow endothelial cells are also 
shown to secrete CXCL12 and induce migration of MM cells towards the bone 
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marrow endothelial cells. Thus, angiogenesis-induced migration of MM cells is 
also mediated by CXCL12 chemokine [186]. The expression of CXCR4 was 
higher in bone marrow plasma cells of patients with MM than in patients with 
MGUS. Moreover, the bone marrow plasma of MM patients has higher CXC12 
levels than that of peripheral blood of MM cells and bone marrow plasma of 
healthy individuals [187]. Consistent with its effect on migration, invasion, 
homing, proliferation and survival, CXCL12/CXCR4 axis can also induce 
activation of MAPK/ERK, AKT, PKC (protein kinase C) and NF-κB pathway 
[178, 187]. 
 
1.2.8.5. Role of MMPs in MM pathogenesis 
 MMPs belong to a family of proteases, capable of degrading all kinds 
of extracellular matrix proteins [188]. In 1962, Gross and colleagues 
discovered MMP, when they found collagenase activity in the tail of a tadpole 
during metamorphogenesis [189]. These proteins function not only to remodel 
the extracellular matrix, but also are involved in the cleavage and thereby 
activation and inactivation of various biologically significant proteins like 
chemokines and growth factors [188].  In the context of cancer, both the cancer 
cells and stromal cells secrete MMPs. Their involvement in invasion and 
metastasis was examined in various clinical models. Recent evidences suggest 
the role of MMPs in various hall marks of cancer progression [190].  
 Culture supernatants of bone marrow derived stromal cells from MM 
patients were found to have higher levels of MMP-1 and MMP-2 compared to 
the  control samples [191]. Moreover, endothelial cells secrete hepatocyte 
growth factor,  which acts on MM cells to stimulate the secretion of MMP-9 
[192]. In addition, 5T mouse model of MM bone marrow expresses various 
distinct MMPs such as MMP2, MMP8, MMP9 and MMP13. Adequate 
inhibition of these MMPs by a broad spectrum MMP inhibitor SC-964 can 
suppress angiogenesis, reduce tumor load and osteolytic lesions [193]. 
 
  44 
1.2.8.6. Role of adhesion Molecules in MM pathogenesis  
 Adhesion molecules mediate cell-cell and cell-ECM interactions [194] 
and are also involved in intracellular signaling after engagement with their 
receptors. Broadly, there are five groups of adhesion molecules. They are 1) 
the integrins-mediating cell-ECM and cell-cell adhesion 2) the cadherin 
family- mediating homotypic cell-cell adhesion 3) the selectin family-
mediating heterotypic cell-cell adhesion 4) the immunoglobulin superfamily-
mediating cell-cell adhesion and 5) other transmembrane proteoglycans such as 
CD44 adhesion molecules and syndecan that mediate cell-extracellular matrix 
adhesion [47]. Dysregulated expression or function of adhesion molecules are 
involved in various steps of cancer progression [195].   
 In MM, adhesion molecules mediate homing of MM cells to the bone 
marrow, secretion of cytokines and growth factors and development of 
chemoresistance [46, 196].   Out of all the adhesion molecules, VLA-4 and 
VLA-5 expressed by the MM cells play a crucial role in the MM pathogenesis 
[197]. VCAM-1 and fibronectin are the receptors for VLA. VLA adheres to the 
BMSCs by binding to VCAM, CS-1 fragment and H1 region of fibronectin 
[198]. Inhibition of VLA using blocking antibodies can abrogate the adhesion 
of MM cells to the BMSCs and fibronectin [199]. VLA-dependent adhesion to 
the bone marrow, is regulated by the CXCL12/CXCR4 axis [200]. This is 
further supported by the finding that disruption of CXCL12/CXCR4 axis 
results in downregulation of VLA-4 and decreased adhesive capacity in the 
mobilised MM cells when compared to pre-mobilization bone marrow MM 
cells [185].  
 VLA-dependent adhesion of MM cells to the BMSCs induces secretion 
of IL-6 by an NF-κB-mediated mechanism [76, 77]. Drug-sensitive 8226 
human MM cells, expressing both VLA-4 and VLA-5 receptors, are relatively 
resistant to the apoptotic effects of doxorubicin and melphalan, when pre-
adhered to fibronectin and compared with cells grown in suspension.   Upon 
exposure to chemotherapeutic agents, MM cells expressing high level of VLA-
4 have survival advantage than those that express them at low level [168]. It 
has shown that adhesion of MM cells to fibronectin activates NF-κB and its 
regulated gene products, leading to drug resistance [48]. It is also possible that 
fibronectin augments IL-6-induced STAT3 activation [201]. 
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1.2.8.7. Role of JAK/STAT3 pathway in MM pathogenesis 
 STAT3 is a member of the STAT family of transcription factors. STAT 
family proteins were first discovered in the context of the specificity of the IFN 
signaling [202]. STAT3 was first described as a DNA-binding factor, in IL-6 
stimulated  hepatocytes, capable of selectively interacting with an enhancer 
element in the promoter region of acute-phase genes [203]. Later, it was found 
that STAT3 can be activated by the entire IL-6 family of cytokines and some 
other growth factors. STAT3 has diverse functions in various biological 
processes [204, 205].  STAT3 is involved in the induction of an acute-phase 
response in hepatoma cells, stimulation of proliferation in B lymphocytes, 
activation of terminal differentiation, growth arrest in monocytes and 
maintenance of the pluripotency of embryonic stem cells [206].  
 Soon after its discovery, the oncogenic role of STAT3 has been 
established by the presence of constitutively activated STAT3 in cancer cell 
lines. STAT3 is constitutively phosphorylated in v-Src–transformed cells and 
has been found to be necessary for the v-Src-induced carcinogenesis [207, 208]. 
Expression of a constitutively active version of STAT3 on its own, can lead to 
fibroblast transformation, showing that STAT3 is an oncogene  [209].  In 
addition to its role in cellular transformation, its role in various stages of cancer 
progression has been established [210].   Genes regulated by STAT3 that are 
involved in proliferation and growth, include c-myc, p21, cyclin D1, Bcl-xL 
[211]. STAT3-mediated angiogenesis is mediated by VEGF; STAT3 also 
regulates MMP family members MMP2 and MMP9 [212]. STAT3 is vital for 
development, as evidenced from STAT3 knock out mice which succumb to 
embryonic lethality [213]. This observation is critical for the development of 
therapeutic strategies with higher therapeutic index. 
 Unlike NF-κB pathway there are no activating mutations involving 
JAK/STAT3 pathway. However, around 48% of MM patient samples have 
constitutively activated STAT3 [214]. Dysregulated STAT3 activation in MM 
is mainly thought to be due to the aberrant secretion of cytokines in the bone 
marrow microenvironment by both MM cells and BMSCs [215]. SOCS1 
(suppressor of cytokine signaling1) is important for the differentiation of 
normal lymphocytes. It negatively regulates JAK/STAT3 pathway induced by 
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various cytokines including IL-6 and 4, leukaemia inhibitory factor, oncostatin 
M, and interferon. In a study, almost 60% of MM patients had 
hypermethylation of SOCS1 gene. However, in normal peripheral blood 
lymphocytes and in bone marrow cells there were no epigenetic silencing [216]. 
Moreover, epigenetic silencing of SOCS1 was also strongly associated with 
disease progression and poor survival in MM patients [217]. Overexpression of 
SOCS1 in IL-6-dependent MM cells induced apoptosis, implicating the 
importance of negative role played by SOCS in MM cell survival [218]. In 
another study, almost 79% of MM samples had hypermethylation of SHP-1 
(Src homology region 2 domain-containing phosphatase-1). SHP-1 is a 
phosphatase that negatively regulates JAK/STAT pathway by 
dephosphorylating STAT3 [50]. Although there is no strong evidence for the 
presence of activating mutations involving JAK/STAT3 pathway to date in 
MM, it is conceivable from the above studies that presence of constitutively 
activated STAT3 in MM samples can at least be partially explained by the 
epigenetic silencing involving the negative regulators of JAK/STAT3 pathway.  
 In MM, STAT3 plays an important role in survival. It can upregulate 
antiapoptotic proteins like Bcl2, Bcl-xL and Mcl-1 [219-221]. Constitutive 
expression of STAT3 confers MM cells resistance to apoptosis [222]. Out of 
all the antiapoptotic proteins regulated by STAT3, Mcl-1 seems to be more 
important. While antisense inhibition of Bcl-xL did not inhibit survival, knock 
down of Mcl-1 was sufficient to inhibit survival in MM cells. Overexpression 
of Mcl-1 was able to promote proliferation of MM cells lines even in the 
absence of IL-6 [223]. Knock down of Bcl-2 can augment dexamethasone-
induced apoptosis [224].  But again, the importance of STAT3 in regulating the 
anti-apoptotic proteins and thereby the survival of MM cells remains 
controversial in the light of a lack of correlation between the constitutive 
expression of STAT3 and the anti-apoptotic proteins [214]. However, it is clear 
that STAT3 is not the only factor which regulates the survival of MM cells 
because MM cells become independent of IL-6-gp130-STAT3 pathway in the 
presence of BMSCs [89]. There are lot of therapeutic strategies that are being 
developed to target JAK-STAT3 pathway in MM. In fact, the novel agents that 
are being used nowadays namely; thalidomide and its derivatives and 
bortezomib, act partially to disrupt the NF-κB-induced activation of IL-6 and 
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thereby STAT3 activation. Numerous drugs that inhibit IL-6-JAK-STAT3 
pathway at various levels induce apoptosis both in vitro and in vivo [225-257].  
 
1.2.8.8. Role of NF-κB in MM pathogenesis 
 NF-κB is a Rel family of transcription factors consisting of p50, p52, c-
Rel, p65/RelA, and RelB subunits [258, 259]. It was discovered by Dr. 
Baltimore and colleagues in 1986 as a DNA binding protein, recognising 
specific sequences in the immunoglobulin kappa light chain joining (J) 
segment gene region in B cells [260]. NF-κB family of transcription factors 
consists of Rel (c-Rel), RelA (p65), RelB, NF-κB1 (p50 and its precursor 
p105), and NF-κB2 (p52 and its precursor p100) [261]. There are two pathways 
that lead to the activation of NF-κB. In canonical pathway, IKK-β (inhibitor of 
IkappaB kinase-β) activates the pathway by phosphorylating the negative 
regulator of p50/p65 subunits namely IκB-α (inhibitor of kappa B-α), thereby  
leading to the proteasomal-dependent degradation. In non-canonical or 
alternative pathway, NF-κB inducing kinase (NIK) activates this pathway by 
phosphorylating IKK-α (inhibitor of IkappaB kinase-α) which in turn 
phosphorylates p100. P100 is then processed to active p52 by proteasome-
dependent degradation of its inhibitory C-terminal inhibitory protein domain 
IκB-γ [262]. Canonical pathway is activated through TRAF 5, TRAF2 (TNFR-
associated factors), RIP (receptor-interacting protein) kinase and TAK1 (TGF-
beta activated kinase 1) and this pathway is involved in immune response and 
inflammation. Canonical pathway is negatively regulated by CYLD 
(cylindromatosis) and A20 proteins. The alternative pathway is involved in B 
cell maturation. Accordingly, it is activated by cytokines, including CD40L, 
LT-aß (lymphotoxin-aß), BAFF, RANKL (receptor activator of NF-κB ligand), 
and TWEAK (TNF-related weak inducer of apoptosis). This pathway is mainly 
regulated by stability of NIK, in which TRAF 3, TRAF 2 and cIAP1/cIAP2 
(cellular inhibitor of apoptosis 1 and 2) are critically involved [263]. However, 
both pathways often overlap and interplay [264]. Physiologically NF-κB 
functions to regulate immunity and inflammation [265]. NF-κB transcription 
factor regulates various players involved in inflammation including the 
expression of adhesion molecules both in leucocytes and endothelial cells [266, 
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267], recruitment of neutrophils [268], and the production of inflammatory 
mediators such as iNOS (inducible nitric oxide synthase) [269], prostaglandins 
[270-272], MMPs [273-275].  
 





Figure 1.3. Schematic diagram of NF-κB activation pathway 
 
Classical pathway is mediated by IKK-β and results in activation of p50/p65 
subunits followed by proteasome-dependent degradation of IκB-α. Conversely, 
alternative pathway is mediated by IKK-α and results in activation of P52/RelB 
subunits followed by proteasome mediated-degradation of C-terminal 
inhibitory domain IκB-γ. Adapted from [276]. 









The colors correspond to the different levels of the NF-κB activity  
 
low activity-blue 
high activity due to extrinsic or mutational activation - pink 
highest activity due to extrinsic plus mutational activation -red 
 
PC- plasma cell 
MMCL - multiple MM cell line 
 
Figure 1.4. Model of NF-κB activation in normal plasma cells and 
malignant plasma cells  
In normal plasma cells NF-κB pathway is activated by extrinsic signals from 
the bone marrow microenvironment. However, in malignant plasma cells this 
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pathway is activated by extrinsic signals and/or by mutations. Adapted from 
[263]. 
 
 NF-κB pathway is constitutively activated in many cancers either due to 
the mutations or dysregulation of cytokines involved in the activation of NF-
κB pathway [277]. Likewise, the role of NF-κB in various stages of tumor 
progression has been identified [278, 279]. NF-κB has been casually implicated  
in progression of various types of tumors [280]. Selective deletion of NF-κB in 
hepatocytes, or inhibition of TNF-α production by neighbouring parenchymal 
cells, induced programmed cell death of transformed hepatocytes and reduced 
the incidence of liver cancer [281]. In colitis-associated colon cancer model, 
NF-κB affects both tumor cells and inflammatory stromal cells to induce and 
promote cancer. In enteroctyes, NF-κB inhibits apoptosis and in inflammatory 
cells stimulates the secretion of various mediators of inflammation, which in 
turn act on enteroctyes to initiate cancer [282]. However, in some tissues, NF-
κB prevents cancer. For example, inhibition of NF-κB  in keratinocytes leads to 
squamous cell carcinoma of skin [283].  Many studies have shown that the NF-
κB signaling pathway plays an important role in anti-apoptosis and the drug 
resistance of tumor cells during chemotherapy. First, many chemotherapeutic 
drugs and radiotherapy induce NF-κB expression in vitro and in vivo [284, 
285]. Second, activation of NF-κB rescues cells from chemotherapy-induced 
apoptosis [286]. Third, induction of chemoresistance and radioresistance is 
mediated via genes regulated by NF-κB [287].   Fourth, inhibition of NF-κB 
and NF-κB-regulated gene products increases the sensitivity of cancer cells to 
apoptosis induced by chemotherapeutic agents and to radiation exposure [288, 
289].  
 NF-κB pathway is constitutively activated in normal plasma cells. 
Indeed, normal plasma cells shows the highest NF-κB among the all other B 
cells, mainly due to BAFF-, APRIL- mediated signaling from the bone marrow 
[290]. However, MGUS MM cells show even higher activation and in these 
cells it is due to the combined effect of extrinsic signaling stimuli from 
cytokines present in the BMME and also caused by activation due to mutations. 
Eventually, activating mutations of NF-κB pathway helps the MM cells 
become independent of the bone marrow, as they overcome the need for 
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external cytokines to activate the pathway [291].  MM patient samples show a 
constitutive activation of NF-κB to variable degree. Soluble cytokines 
belonging to TNF-α super family including TNF-α, BAFF (B-cell activating 
factor), APRIL (a proliferation inducing ligand), LTβ (lymphotoxin β) are 
known to activate NF-κB and are present in the bone marrow 
microenvironment. Adhesion of MM cells to the BMSCs and osteoclasts also 
activates NF-κB pathway in MM cells and osteoclasts and BMSCs  [292]. 
These cytokines are said to activate NF-κB mainly by the canonical pathway. 
15-20% of MM samples and 40% of the cell lines show mutations that lead to 
constitutive activation of NF-κB pathway [276, 291, 293]. There could also be 
some unidentified genetic mutations or epigenetic modifications that might 
explain the constitutive activation. Gain of function mutations involve 
receptors known to activate NF-κB namely CD40, LTβR, TACI (tumor necrosis 
factor receptor superfamily member 13B) or direct regulator of the non-
canonical pathway NIK (NF-κB-inducing kinase), and also direct mutations 
involving NF-κB1 p50/p105, and NF-κB2 p52/ p100. Loss of function 
mutations involve negative regulators of NF-κB activation namely TRAF3, 
TRAF2, CYLD and cIAP1/cIAP2, inactivation of TRAF3 being the most 
common. Also, CD40, LTβR, TAC1 receptor overexpression may be sufficient 
to activate the NF-κB pathway or might enhance the sensitivity of MM cells to 
factors in the tumor microenvironment to activate NF-κB. Overexpression of 
NIK or NF-κB1 p105 directly leads to constitutive activation of NF-κB. 
Deletion of sequences in the p100 IκB-like domain of NF-κB2, promotes 
processing of p100 to p52 and activation of the alternative NF-κB pathway 
[276, 293]. Though mutations mainly involve the alternative pathway, the 
canonical pathway is also activated. Mutations that selectively involve either 
the canonical or the non-canonical actually lead to activation of both the 
pathways and gene expression profiles induced by these pathways are quite 
similar if not the same. This could be because once dysregulated the  canonical 
or the alternative pathways may no longer relay the signal in orderly fashion 
[264]. Though, conventionally NIK was thought to activate the alternative 
pathway, NIK activation due to mutations mainly activate the classical 
pathway suggesting that IKK-β is a good target to inhibit consequences of 
deregulated NF-κB pathway activation [276]. However, total NF-κB activity is 
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the combined activity of both the canonical and the alternative pathways. Also 
proving the role of the alternative pathway in the pathogenesis of MM is the 
development of plasma cell tumors in the NF-κB2 mutant p80HT transgenic 
mice model [294]. Thus dual inhibition of both the canonical and the 
alternative NF-κB pathway may offer greater anti-myeloma activity [295].  
 Activation of NF-κB in MM cells induces proliferation, survival and 
chemoresistance. When compared to chemosensitive MM cell lines 
chemoresistant MM cells express higher levels of NF-κB, suggesting a link 
between NF-κB and development of chemoresistance [286, 296]. Moreover, 
dexamethasone-induced apoptosis is associated with a decrease in the NF-κB 
DNA binding activity. Interestingly, NF-κB can also serve as a prognostic 
indicator for response to dexamethasone. Only patients who responded to 
dexamethasone, demonstrated decreased NF-κB DNA binding activity in their 
samples. Enforced ectopic expression of Bcl-2 in MM cells conferred 
resistance to dexamethasone-induced apoptosis, and this was also associated 
with enhanced NF-κB  DNA binding [286]. Certain cancer cells when in 
contact with cell or extracellular matrix display substantial multi-drug 
resistance. This phenotype is called cell adhesion-mediated drug resistance 
(CAM-DR). The resistance is conferred by diverse mechanisms including 
alteration of intracellular target, upregulation of antiapoptotic proteins and 
increased p27 levels. In MM cells, NF-κB pathway activation plays a major 
role in cell adhesion-mediated drug resistance [48]. Alkylating agents used in 
the treatment of MM namely melphalan and doxorubicin can also induce the 
NF-κB activation in HMCLs. Interestingly, NF-κB activation was inhibited 
when bortezomib was added, suggesting that bortezomib sensitizes MM cells 
to alkylating agents by inhibiting NF-κB activation [297]. Inhibition of NF-κB 
by either proteasome inhibitor or inhibitors of IκB phosphorylation induces 
apoptosis in HMCLs. IKK inhibitor can abrogate the protective effect of IL-6 
on dexamethasone- induced apoptosis. It also potentiated TNF-α-induced 
apoptosis in MM cells. NF-κB inhibition abrogated the TNF-α-induced 
upregulation of ICAM-1 both in MM cells and in BMSCs. It also inhibited the 
MM cell adhesion-induced IL-6 secretion by BMSCs and resulting 
proliferation of MM cells. These findings indicate that pro-survival functions 
of bone marrow microenvironment is abrogated upon NF-κB inhibition  [298]. 
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The novel therapeutic agents namely bortezomib, a proteasome inhibitor and 
thalidomide and its immunomodulatory derivatives also act at least partially by 
inhibiting NF-κB [290].  
 
1. 2. 9. MM associated bone disease 
 Most of the cancers that metastasize to bone form osteolytic lesions, 
which are followed by new bone formation. However, in MM there is 
increased osteolysis and decreased new bone formation resulting in pure 
osteolytic lesions [299]. Consequently, patients with MM often present with 
bone fractures and is in fact an important cause of increased morbidity in MM 
[300]. MM cells increase the osteoclast formation and activation leading to 
osteolytic lesions. Conversely, osteoclast cells secrete many cytokines which 
provide survival advantage to MM cells. Thus, there is a symbiotic relationship 
between osteolysis and MM. Thus, MM  bone disease is not only a 
complication of MM but also a contributing factor to the progression of MM 
[301]. There are many factors involved in MM bone disease pathogenesis. The 
TNF receptor super family members RANK (receptor activator of NF-
κB)/RANKL/ OPG (oteoprotegerin) system plays an important role in the 
osteoclast activation. RANK is secreted by BMSCs and osteoblastic cells 
which act on its cognate receptor RANKL which is present on the osteoclastic 
cells to stimulate bone resorption. The soluble decoy molecule osteoprotegerin 
secreted by BMSCs and osteoblasts bind to RANK to inhibit its interaction 
with RANKL [302]. In addition to the RANK; VEGF, CXCL12/CXCR4 and 
MIP-1α also plays roles in osteoclastic activation. Factors leading to 
osteoblastic inhibition are inhibition of Wnt signaling, TGF-β, Runx2, IL-3 and 
HGF (hepatocyte growth factor) [303]. Apart from surgical intervention and 
radiation, there have been many improvements in the pharmacotherapy of MM 
bone disease including the advent of bisphosphonates which inhibit 
osteoclastic activity . Recent improvement in the understanding of MM bone 
disease has lead to the development of novel targeted therapies which are in 
various phase of clinical trials [304]. Interestingly, novel anti-myeloma agents 
including thalidomide and bortezomib also inhibit bone resorption by 
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inhibiting interaction of various players in the bone marrow microenvironment 
[305]. 
 
1. 2. 10. Treatment options 
 Treatment of MM is based fairly on whether the patient is eligible for 
bone marrow transplantation. Generally patients below 65 yrs old with no 
comorbidities are treated with non-melphalan based high dose chemotherapy 
followed by autologous stem cell transplantation. Those who do not qualify for 
stem cell transplant are treated with combination chemotherapy [306]. 
Common front line agents used in the induction therapy of MM are either two 
drug or three drug combinations of melphalan, dexamethasone, thalidomide, 
lenalidomide and bortezomib [307]. The treatment of relapsed and refractory 
MM has been updated with the approval of carfilzomib a new proteasome 
inhibitor by FDA (Food and Drug Administrative Agency). The regimens 
available for the treatment of relapsed and refractory MM are  carfilzomib, 
bortezomib-thalidomide-dexamethasone combination, lenalidomide-
bendamustine-dexamethasone combination [308]. Pomalidomide, a third 
generation immunomodulatory agent has also been recently approved by the 
FDA for the treatment of relapsed and refractory MM [309]. 
 
1. 2. 11. Drugs in the clinical trials 
 A number of pharmacological agents are being currently investigated 
for MM treatment. For example, histone deacetylase inhibitors vorinostat and 
panobinostat are in the phase III clinical trial in combination with bortezomib. 
Perifosine, a PI3K/Akt pathway inhibitor is in phase III clinical trial in 
combination with bortezomib. Elotuzumab, a monoclonal antibody against the 
surface-expressed glycoprotein CS-1 is in phase III clinical trial in combination 
with lenalidomide. As a survival mechanism, bortezomib-treated cells are 
found to activate heat shock response proteins; therefore, HSP 90 inhibitors are 
rational drugs to be tried in combination with bortezomib. These drugs are 
likely to be approved in the near future and expected to expand the 
armamentarium of anti-myeloma agents [307]. Apart from the above 
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mentioned drugs, there are several other drugs in clinical trials including but 
not limited to those that target the signaling cascades involved in the 
pathogenesis of MM, monoclonal antibodies against the receptors that are 
expressed over the cell membrane of plasma cells and various players involved 
in the MM bone disease [310]. However, there remains an urgent need to 
develop novel anti-myeloma agents because despite the availability of various 
anti-myeloma agents MM still remains incurable. Most of the patients relapse 
after initial response or develop chemoresistance. Moreover, most of the 
available drugs have severe dose-limiting toxicity including but not limited to 
bone marrow suppression, peripheral neuropathy, and reactivation of herpes 
zoster infection [310].  
 
1. 2. 12. MM animal models 
 Biologically relevant animal models are crucial in understanding the 
biology, evaluating potential targets and novel therapies of any disease. These 
preclinical models enable us  to quickly translate the results obtained to clinical 
studies [311]. Many types of animal models of MM have been used so far, each 
having its own advantages and disadvantages. Subcutaneous xenograft of MM 
in immunocompromised mice is the most commonly used model. They are 
relatively easy to establish and allow easy monitoring of the tumor volume. 
However, since the tumor in this model grow in subcutaneous 
microenvironment, this model does not account the role of bone marrow 
microenvironment in MM cell survival, proliferation and drug resistance. In 
addition, they do not form the typical MM bone disease. So, drugs evaluating 
MM bone disease cannot be effectively studied using this model [312]. Inspite 
of these limitations, it is interesting that many agents that have been approved 
recently by FDA for the treatment of MM have been tested in these model 
before they were brought into clinical trials [313]. SCID (severe combined 
immunodeficiency)-human model overcomes the disadvantages of the 
subcutaneous xenograft model. In this model, human foetal bone is 
transplanted bilaterally into the SCID mice and MM cells are injected into the 
human foetal bone marrow of one side. The MM cells infiltrate the human 
bone marrow and eventually metastasize to the foetal bone of the other side. 
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This model offers the advantage of addressing the role of bone marrow 
microenvironment in disease biology [314]. Interestingly, the effect of 
thalidomide on the MM cell-bone marrow microenvironment has been studied 
using the SCID-Human model [315]. SCID-rabbit model resembles the SCID-
Human model, except that rabbit bone tissue is used to avoid the ethical issues 
of using human foetal bone tissue [316]. To mimic the characteristic of MM in 
inducing multifocal osteolytic lesions in the skeletal system, MM cells were 
injected intravenously into the immunocompromised mice and these cells 
lodged into the mouse bone marrow and produced characteristic lesions in the 
bones [317]. Many anti-myeloma agents have been evaluated using this model 
including humanized-anti-IL-6 receptor antibody [317]. When fresh core bone 
marrow biopsies of patients were engrafted en bloc into the hind limb muscles 
of the mice, 3 of the 33 such patients' samples developed palpable tumors. 
These three tumors was further passaged in mice by intramuscular injections. 
One of these was derived from cells of an IgGλ-1producing patient who had 
MM, was used for further studies. When these cells were injected into the mice 
subcutaneously or intramuscularly they formed plasmacytomas and this animal 
model is described as LAGλ-1 model [318]. Aged C57BL/KaLwRij mice 
spontaneously develop MGUS and MM like features. When the these murine 
MM cells were injected into the young syngenic mice, the young mouse 
develop same features. This model is known as 5T MM model. This model 
differs from other mice models from its immunocompetent state. Moreover, 
this model has shed light into the involvement of cytokine, adhesion molecules 
in MM biology and offered better understanding of MM bone disease. In fact, 
the effects of bisphosphonates were evaluated using this model [312]. 
Transgenic mouse models of MM include AID (activation-induced deaminase) 
to a conditional Myc transgene leading to the development of plasma cell tumor 
resembling human MM [319] and p80HT transgenic mice model induced by 
NF-κB2 mutant p80HT [294], which lead to the  development of plasma cell 
tumor resembling human MM. Thus, transgenic models are invaluable in 
helping us dissect how each molecule is involved in the pathogenesis of MM. 
 
  57 
1. 3. Identification of celastrol as an anti-cancer agent 
 Interest in medicinal plants has been gaining momentum in the last few 
decades. Various native medicinal systems like Ayurveda (India) and Chinese 
natural medicine are based on plant derived medicinal products [320].  These 
plant derived medicinal compounds are good source of alternative therapy 
because of their effectiveness in various diseases and better understanding of 
their mechanisms of action nowadays [321].  Trypterigyum wilfordii commonly 
known as ‘Thunder of God Vine’ is a perennial creeper plant seen in China. 
The extract of this plant has been used in Chinese natural medicine for 
inflammatory conditions like arthritis, fever and edema. Numerous studies 
have been conducted with this extract using various in vitro and in vivo models. 
The beneficial effects of the this extract were tested in clinical trials conducted 
in patients with rheumatoid arthritis [322]. The extract has been found to 
contain numerous active compounds including triterpenoids, diterpenoids, 
alkaloids etc. Celastrol, a quinone methide triterpenoid, is one among these 
compounds, derived from the root bark extracts of T. wilfordii. Celastrol 
initially attracted attention because of its anti-inflammatory effects, though it 
was also found to have antimicrobial activities [323-325]. The effects of 
celastrol have been investigated in various models of inflammation.  
Interestingly, in the last few years, celastrol has been extensively studied for its 
potential anticancer effects in various in vitro and in vivo cancer models [326].  
 
Chemical structure of celastrol  
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Figure 1.5. Chemical structure of celastrol 
The thiol reacting quinone methide ring is circled in blue. 
 
 
Sources of Celastrol 
                                    
 
Celastrus orbiculatus 
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Tripterygium wilfordii (Thunder of God Vine) 
 




1.3.1. Identified key molecular targets of celastrol 
1.3.1.1. Proteasome 
 The ubiquitin-proteasome pathway functions to degrade cellular 
proteins. The 26S proteasome is made of two 19S regulatory particles and a 
20S coreparticle. The 20S core particle is a multicatalytic threonine protease 
with at least three distinct catalytic activities which are chymotrypsin-like, 
trypsin like and PGPH (peptidylglutamyl peptide-hydrolyzing)-like activities. 
By acting as a tag, a chain of ubiquitin can target a substrate protein to the 26S 
proteasome for destruction [327]. The ubiquitin/proteasome-dependent 
pathway is known to degrade many endogenous proteins including 
transcription factors, cyclins, tumor suppressor proteins and signaling proteins 
involved in tumorigenesis and also misfolded and damaged proteins.  Several 
studies have shown that inhibition of the proteasomal activity resulted in 
accumulation of several target proteins like IκB-α, Bax (Bcl-2–associated X 
protein), and p27 [328-331] and induction of apoptosis in various types of cells 
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[332, 333]. Proteasome is considered to be an attractive target for the treatment 
of cancer. Indeed, small molecule inhibitor bortezomib or velcade, a 
proteasome inhibitor has already been approved by US FDA for the treatment 
of MM [334]. Additionally, more potent, less toxic proteasome inhibitors are 
being investigated [335]. 
 Celastrol has been shown to inhibit proteasome in Xenopus laevis A6 
cells [336], human prostate cancer cells [337] RAW264.7 macrophage cells 
[331] and rat glioma cells [338]. Celastol-induced inhibition of proteasome was 
associated with upregulated expression of heat shock protein genes hsp30 and 
hsp70  [336]. Celastrol did not seem to inhibit the binding of ubiquitin to 
protein chains by binding to ubiquitin moieties [331]. However, celastrol has 
been found to inhibit chymotrypsin like activity of proteasome in RAW264.7 
cells [331] prostate cancer cells [337] and rat glioma cells [338]. This inhibiton 
of chymotrypsin activity was associated with accumulation of proteasome 
targets like Bax, IκB-α and p27 and was accompanied by apoptosis [337]. 
 
1.3.1.2. HSP (heat shock response protein) 90 
 HSR (heat shock response) is one of the conserved molecular pathways 
which is induced in response to various cellular stresses and rescues cells from 
subsequent and more lethal stresses.   In response to heat, the heat inducible 
transcription factor HSF-1 (heat shock factor-1) is activated. Upon activation, 
HSF-1 moves to nucleus, binds to DNA and gets hyperphosphorylated to 
modulate the expression of various genes involved in HSR including HSP90 
[339, 340]. Most of Hsp90 client proteins including HER-2 (human epidermal 
growth factor receptor-2), Akt, Cdk 4 (cyclin-dependent kinase 4), Bcr-Abl 
(Breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 
1), p53, and Raf-1 (rapidly accelerated fibrosarcoma -1) play crucial role in the 
pathogenesis of various cancers.  Targeting molecular chaperone Hsp90 might 
offer many advantages for cancer therapy by simultaneously modulating 
various key players involved in the pathogenesis of cancer [341]. 
 Celastrol has been shown to inhibit HSP90, its co-chaparones and their 
interactions [342-345].  Celastrol differed from conventional HSP90 inhibitors 
in the fact that celastrol did not act by binding to ATP binding site of HSP90. 
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In fact, celastrol did not compete with geldanamycin which is known to inhibit 
HSP90 by binding to ATP binding pocket. Consequently, celastrol can 
synergize with conventional HSP90 inhibitors in inhibiting HSP90 because of 
different mechanisms of action [343]. Celastrol’s ability to inhibit HSP90 
client kinases are found to be mediated by the inhibition of interaction between 
HSP90 and the co-chaparone cdc37 [342, 346]. However, Sreeramulu and 
coworkers have demonstrated using NMR spectroscopy and chemical 
mutational analysis that celastrol can directly bind to cdc37 but not to N-
terminal domain of HSP90 to inhibit HSP90-cdc37 interaction [347]. Moreover, 
Zhang and coworkers have demonstrated that celastrol can inhibit HSP90’s 
client transcription factors by inhibiting the interaction between HSP90/Hop 
and HSP90/transcription factors, indicating that celastrol's ability to inhibit 
HSP90 clients is not only mediated by the inhibition the co-chaparone cdc37 
but mediated by  other cochaperones as well [348]. Along this line, celastrol 
has also been demonstrated to inhibit the interaction of  HSP90 and its co-
chaperone p23 in breast cancer SKBR-3 cells [343] and in HeLa cells [344] 
though in pancreatic cancer cell lines HSP90-P23 interaction was found to be 
unaffected [342]. Celastrol-induced inhibition of HSP90 and/or its 
cochaperones lead to cell cycle arrest in monocytic leukemia U937 cell line 
[346], induced paraptosis and apoptosis in HeLa cells [349] and caused 
radiosensitization in lung cancer NCI-H460 cell line [350]. 
     Celastrol has been shown to activate heat shock response in human 
breast cancer MCF7 and BT474 cell lines, human non-small cell lung 
carcinoma H157 cell line, human neuroblastoma SH-SY5Y cell line and HeLa  
cell line,  Saccharomyces cerevisiae yeast and  in the amphibian Xenopus 
laevis A6 cells [336, 351-353]. Furthermore, celastrol synergistically induced 
heat shock response, in combination with mild heat and proteasomal inhibitor 
MG132 [336, 351]. Celastrol’s ability to induce heat shock response has been 
shown to offer cytoprotection in various other model systems [351, 354-356]. 
Celastrol’s ability to induce heat shock proteins is regulated at transcriptional 
level because, celastrol upregulated HSF-1 in L444P fibroblasts [357] and 
celastrol has also been found to induce DNA binding and 
hyperphosphorylation of HSF-1 in yeast and mammalian cells [351, 352]. 
Moreover, celastrol was unable to upregulate HSP70 accumulation in HSF1−/− 
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mouse embryo fibroblast cells [358] and celastrol-induced upregulation of HSP 
30 and HSP 70 were abrogated by the HSF-1 activation inhibitor KNK437 
[336].  
 UPR is a stress pathway induced by cells when cells are loaded with 
unfolded proteins by various stimuli. This pathway serves by increasing protein 
folding capacity and enhanced degradation of misfolded proteins within the ER 
(endoplasmic reticulum) through a process called ERAD (ER-associated 
degradation) [359]. Celastrol has been shown to induce unfolded protein 
response (UPR) in L444P GC Gaucher fibroblasts [357], HCC (human 
hepatocellular carcinoma) Bel-7402 and HepG2 cell lines. In HCC cell lines 
Bel-7402 and HepG2, celastrol-induced activation of UPR lead to upregulation 
of Noxa, cytochrome C release, caspase activation cascade and apoptosis [353]. 
However in Gaucher GC fibroblasts, celastrol-induced UPR offered 
cytoprotection [357]. How celastrol induced UPR leads to cell protection in 
Gaucher fibroblasts and apoptosis in hepatocellular carcinoma cell line has not 
been studied yet.  
 By modulating various pathways involved in protein homeostasis, 
celastrol has been found to be one of the hit compouds found during the 
screening for small molecule compounds as proteostasis regulator, suggesting 
its potential role in diseases involving dysregulated protein homeostasis [360]. 
Interestingly, Wang and coworkers found that celastrol treatment in HeLa cells 
induced features of apoptosis, paraptosis and autophagy at the same dose. This 
is explained by the fact that celastrol modulates various pathways involved in 
protein homeostasis including ubiquitin-proteasome pathway and heat shock 
response [349]. 
 Antioxidant defense is an important stress pathway activated by cells in 
response to oxidative stress [361].  Celastrol has been shown to not only 
upregulate HSR and UPR, but also, one other important cell stress pathway, 
antioxidant defense pathway [326]. Trott and coworkers have found that 
celastrol can induce an array of genes involved not only in heat shock response 
that are controlled by HSF-1, but also genes involved in antioxidant defense. In 
human colon carcinoma RKO cells, celastrol induced the transcription factors 
Nrf2 (NF-E2-related factor-2) and ATF-4 (activating transcription factor-4) 
which are involved in the regulation of antioxidant defense [352]. 
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 How celastrol induces cell stress pathways like HSR, UPR and 
antioxidant response is not well understood. Whether these are the primary 
effect caused by celastrol or induced by cellular stress caused by celastrol-
induced inhibition of proteasome, HSP90 and celastrol-induced ROS (reactive 
oxygen species) remains to be elucidated. It is also possible that the dose and 
cellular context also might play a role in deciding the outcome of celastrol 
treatment. It can be conceived that initially at low dose and short burst celastrol 
might prove to be a cytoprotective agent by inducing cell stress pathways. 
However, when the cells are already under physiological stress, as in case of 
cancer cells, addition of celastrol might induce cell death [362].  
 
1.3.1.3. NF-κB 
 Celastrol has been reported to inhibit NF-κB transcription factor in 
various inflammatory and tumor models. In fact, celastrol's NF-κB inhibiting 
ability is considered to be the main mechanism of its anti-inflammatory 
property [326]. The role of NF-κB in cancer initiation and cancer progression 
is well established [278, 279]. Celastrol has been shown to inhibit NF-κB in 
various cancer cells. Concurrent with our findings on NF-κB inhibitory effects 
of celastrol [363], Tozawa and coworkers have also shown that inhibition of 
NF-κB nuclear translocation is associated with apoptosis in U266 MM cells 
[364]. Celastrol-induced inhibition of nuclear translocation of NF-κB was 
associated with induction of cell cycle arrest and apoptosis in human leukemia 
U937 cells [365]. Inhibition of constitutive  NF-κB pathway and NF-κB- 
regulated gene products involved in proliferation, survival, migration and 
invasion  by celastrol was associated with induction of apoptosis, inhibition of 
migration and invasion in androgen-independent prostate cancer cell lines 
[366]. Celastrol inhibited NF-κB-mediated expression of MMP-9 and thereby 
inhibited PMA (phorbol 12-myristate 13-acetate) induced invasion and 
migration of MCF-7 breast cancer cell lines [367]. Osteolytic metastatic lesions 
to bones are common occurrence in the advanced stages of various 
malignancies [368].  Aberrant NF-κB activity has been implicated in osteolytic 
lesions induced by bone metastasis. Celastrol-induced inhibition of NF-κB 
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activity was associated with induction of apoptosis, inhibition of migration and 
downregulation of MMP9 and urinary plasminogen activator in rat W256 cells. 
Interestingly, celastrol also inhibited the W256 cells-induced osteolysis in rats 
[369]. TMPRSS2/ERG (transmembrane protease, serine2/ Erythroblast 
transformation-specific related gene) fusion gene has been sought as an 
attractive target in prostate cancer. NF-κB pathway has been shown to act 
downstream to this fusion gene product. Celastrol inhibited NF-κB activation 
in fusion gene expressing VCaP prostate cancer cells and inhibited cell growth 
in both in vitro and in xenograft mouse model [370]. 
 Celastrol has been reported to inhibit TNF-α-induced activation of NF-
κB in HT-1080 human fibrosarcoma cell line, leading to induction of apoptosis 
[371]. Celastrol can also potentiate TNF-α-, paclitaxel- and doxorubicin-
induced apoptosis and inhibited TNF-α-induced NF-κB activity [372]. 
Celastrol can also augment the apoptosis induced by temozolamide in 
melanoma cell line SK-MEL-173 by inhibiting TNF-α-induced NF-κB activity 
[373]. Celastrol sensitized oral squamous cell carcinoma Tca8113 cells to 
gambogic acid [374]. In mouse xenograft retinoblastoma model celastrol 
nanoparticles decreased the expression of NF-κB, phospho-NF-κB which was 
associated with significant decrease in tumor growth [375]. 
 How celastrol modulates NF-κB is not yet clear. However, celastrol has 
been demonstrated to act by inhibiting NF-κB by directly targeting cysteine 
179 of IKK by reactive quinine moiety [371]. Moreover, proteasome inhibition 
also leads to NF-κB pathway inhibition by accumulating IκB [337]. Inhibition 
of TNF-α-induced activation of NF-κB has been shown to be mediated by 
celastrol-induced abrogation of TAK1 activation [372].  
 
1.3.1.4. Other important molecular targets modulated by celastrol 
 Apart from the above discussed targets, celastrol has been shown to 
affect various other players involved in the pathogenesis of cancer. In human 
lung cancer 95-D and mouse melanoma cells, celastrol-induced activation of 
p38 MAPK partially inhibited β-1 integrin activity, inhibited the 
phosphorylation of focal adhesion kinase and the suppressed the adhesion of β-
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1 integrin to fibronectin [376]. How celastrol inhibits MAPKs is not known yet. 
However, molecular docking analysis shows that celastrol can directly bind to 
the large pocket ATP binding site to inhibit its kinase activity [377]. ATF-2 
(activating transcription factor-2) acts downstream to the MAPK signaling. 
Celastrol has been shown to modify ATF-2 activity to induce apoptosis in 
melanoma cells [378]. 
 Topoisomerase inhibitors have been used in the cancer chemotherapy 
since long time. They are known for their ability to induce apoptosis in cancer 
cells by inhibiting topoisomerase II. Nagase et al., have reported that in human 
promyelocytic leukemia HL-60 cells, the rank order of potency of celastrol and 
its derivatives in causing apoptosis correlated well with their potency of 
inhibiting the enzyme topoisomerase II [379]. Dysregulation of Wnt-β-catenin 
pathway is involved in the pathogenesis of various cancers. In HeLa cells, 
celastrol-induced apoptosis was found to be associated with the increased 
nuclear translocation of β-catenin [380]. Sp (Specificity protein) transcription 
factors are involved in the pathogenesis of myriad cancers including bladder 
carcinoma [381]. In human bladder cancer cells celastrol downregulated Sp 
transcription factors by both proteasome-dependent and proteasome- 
independent mechanisms. ROS induction by celastrol mediated the 
proteasome-independent downregulation of Sp proteins by celastrol [382].  
 HIF-1α (hypoxia inducible factor-1α) is upregulated in hypoxic tumor 
environment and induces angiogenesis by upregulating angiogenic factors 
thereby leading to the development of more aggressive phenotypic cancer cells. 
Celastrol inhibited hypoxia-induced proliferation and migration of human HCC 
HepG2 cells which was associated with the downregulation of HIF-1α and 
decrease in its transcriptional activity [383]. 
 Whether celastrol-induced modulation of these targets are secondary to 
its effect on proteasome and/or HSP90 or independent of proteasome and/or 
HSP90 inhibition has yet to elucidated. However, celastrol has been shown to 
directly bind to tubulin and affects its polymerization leading to mitotic arrest 
and cell death [384, 385]. In addition to tubulin, celastrol was also shown to 
directly bind to annexin II and eEF1A (eukaryotic translation elongation factor 
1A) [385]. 
 
















Figure 1.7. Reported molecular targets of celastrol 
 
 
  67 
1.3.2. Anti-cancer effects of celastrol in vitro 
1.3.2.1. Celastrol induces cell cycle arrest  
 Most of the anti-cancer drugs eventually inhibit tumor growth by 
inducing cell cycle arrest and apoptosis. In recent years, the anti-cancer effects 
of celastrol has been studied using various cancer models [326]. In the various 
tumor cell lines tested, celastrol induced cell cycle arrest and cell death mainly 
by apoptosis. Agents that could arrest cell cycle in G1 to S phase (G1/G0 arrest) 
or G2  to  M phase (G2 M arrest) or mitosis inhibitors are of potential interest in 
anti-cancer therapy [386]. Celastrol has been found to induce cell cycle arrest 
in various cell lines tested. For instance, celastrol has been shown to induce 
G1/G0 arrest in human monocytic leukemia U937 cells by modulating proteins 
invovled in cell cycle progression [346].
 
Celastrol has also been shown to 
induce G2/M cell cycle arrest in glioma C6 cells and this was found to be 
associated with the inhibition of cyclin B and its kinase cdk2 which are 
necessary for the progression of cell cycle from G2 to mitosis and upregulation 
of p21 and p27 which are known to induce cell cycle arrest [338]. In agreement 
with the study showing that celastrol binds directly to tubulin [385],  celastrol 
was also found to inhibit tubulin polymerization in an in vitro tubulin 
polymerization assay, suggesting its potential role of celastrol as mitosis 
inhibitor [387]. On a similar note, celastrol has been shown to suppress tubulin- 
mediated processes, resulting in mitotic arrest and mitotic arrest-mediated cell 
death [384]. 
 
1.3.2.2. Celastrol induces  apoptosis in cancer cells 
 Many drugs induce apoptosis by inducing ROS. Celastrol has also been 
found to induce ROS in various cancer cells and thereby leading to apoptosis. 
 Celastrol-induced ROS lead to suppression of breast cancer MCF-7 cell 
viability [388] and apoptosis of melanoma B16 cells [389], bladder carcinoma 
253JB-V cells [382] and Erb2 overexpressing breast cancer cell lines [390]. 
Celastrol in combination with ionizing radiation induced ROS and augmented 
ionizing radiation-induced cell death in human non-small cell lung cancer NCI-
H460 cells [391]. Celastrol induced accumulation of ROS-induced 
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phosphorylation of JNK (c-Jun NH2-terminal kinase), which in turn induced 
mitochondrial-mediated apoptosis in H1299 and HepG2 cells in a dose-
dependent manner [392].  
  Anti-cancer drugs induce apoptosis either by death receptor- 
mediated extrinsic apoptotic pathway or by mitochondria-mediated intrinsic 
apoptotic pathway or by both [393]. Celastrol induces apoptosis by engaging 
both the pathways. In human breast adenocarcinoma MCF-7 cells, celastrol 
induced both caspase-8-dependent extrinsic apoptotic pathway and 
mitochondria-dependent intrinsic apoptotic pathway [394]. The apoptotic 
pathways engaged in celastrol-induced apoptosis has been thoroughly 
examined in human non-small-cell lung cancer A549 cells. In this in vitro 
model, celastrol-induced apoptosis was associated with upregulation of Fas 
expression and loss of mitochondrial membrane potential resulting in 
activation of both extrinsic and intrinsic pathway of apoptosis [395]. Celastrol- 
induced ROS also has been shown to activate both intrinsic and extrinsic 
apoptotic pathways [390].  
 
1.3.2.3. Celastrol potentiates the cyokine-mediated apoptosis 
 TNF-α is a cytokine which belongs to the tumor necrosis factor 
superfamily. The response of cells to the activation of TNF-α is context 
dependent [396]. While identifying the effects of celastrol on TNF-α-mediated 
cell signaling, Sethi, G., et al., repoted that celastrol can potentiate apoptosis 
induced by  TNF-α [372]. Celastrol also potentiated TNF-α-induced 
cytotoxicity in HT-1080 fibrosarcoma cell line [371].  
 DR4 and DR5 death receptors provoke extrinsic apoptotic pathway 
upon binding of TRAIL, preferentially in transformed malignant cells without 
causing any significant side effects to normal cells. The agonistic antibodies 
that mimic the ability of TRAIL in activating death receptors and engaging 
apoptotic pathways are already in clinical trials for the treatment of various 
cancers [397]. However, cancer cells develop resistance to TRAIL-induced cell 
death by various mechanisms [398]. Hong Zhu and coworkers demonstrated 
the synergistic effect of celastrol with TRAIL in human ovarian carcinoma cell 
line OVCAR-8, human lung cancer cell line 95-D, and human colorectal 
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carcinoma SW620 cell line in inducing apoptosis. They have further shown 
that this combination engages both intrinsic and extrinsic pathways [399]. The 
same authors in a different study have demonstrated that augmentation of 
apoptosis induced by celastrol was due to the upregulation of death receptors 
DR4 and DR5 [400]. Sung and co-workers have also reported that celastrol can 
indeed enhance TRAIL-induced inhibition of tumor cell proliferation and 
induction of apoptosis. This was associated with upregulation of DR4, DR5, 
pro-apoptotic protein Bax and downregulation of anti-apoptotic proteins [401].  
 
1.3.2.4. Celastrol potentiates the apoptotic effects of chemotherapeutic 
agents  
  
 Combination strategies are often used in cancer treatment to increase 
the efficacy, decrease the possible development of chemoresistance and to 
decrease the side effects. Celastrol has enhanced the apoptotic effect of 
multiple chemotherapeutic agents in various cell lines tested. For instance, 
celastrol enhanced the apoptotic effect of gambogic acid in human oral 
carcinoma cell line Tca8113 [374], sensitized SK-MEL-173 melanoma cells to 
temozolomide [373], potentiated conventional chemotherapeutic agents 
daunorubicin- and cytarabine-mediated apoptosis in K-562 and Jurkat T human 
leukemia cells [402]. It also synergistically induced apoptosis in ErbB2-
targeted therapeutics trastuzumab and lapatinib in ErbB2 overexpressing breast 
cancer cells [390] and sensitized taxol-resistant HeLa cells to paclitaxel [384]. 
 
1.3.2.5. Celastrol potentiates the effects of radiotherapy  
 Development of acquired radioresistance remains a major therapeutic 
obstacle in hormone resistant prostate cancer and is associated with poor 
prognosis. Celastrol sensitized PC-3 prostate cancer cells to ionizing radiation 
in a dose- and schedule-dependent manner [403]. Celastrol sensitized NCI-
H460 lung cancer cells to radiation and this effect was associated with the 
inhibition of HSP90 and upregulation of p53 tumor suppressor gene [350]. 
Among the many quinone methide triterpenoids that were tested, celastrol had 
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the most potent radio-sensitizing ability in various human non-small cell lung 
cancer cell lines namely NCI-H460, NCI-H1299 and A549 [391]. 
 
1.3.2.6. Celastrol suppresses tumor angiogenesis 
 Tumor angiogenesis is another target that is being exploited in cancer 
therapy. Indeed, bevacizumab, a humanized monoclonal antibody has been 
approved by FDA for the treatment of colorectal cancer, non-small cell lung 
cancer, breast cancer, metastatic renal cell cancer and glioblastoma 
multiformae. Celastrol has been shown to inhibit TNF-α-induced upregulation 
of vasculogenic factor VEGF [372], to inhibit the proliferation, migration, and 
tube formation of ECV-304 endothelial cells [404]. It also suppressed the 
hypoxia-induced proliferation, migration and tube formation of endothelial 
cells by modulating HIF-1α [383]. In bone marrow endothelial progenitor cells, 
celastrol abrogated VEGF-induced proliferation, cell-cell adhesion, cell-ECM 
adhesion, migration response and vascular tube formation [405].  Celastrol 
inhibited VEGF-induced proliferation, migration, invasion, and capillary-like 
structure formation of cultured HUVEC (human umbilical vascular endothelial 
cells) by suppressing VEGF-induced activation of AKT/mTOR/P70S6K 
signaling [406]. Inhibition of β1-integrin-mediated  HUVEC-fibronectin cell 
adhesion and migration is also demonstrated to be a mechanism by which 
celastrol can modulate angiogenesis [407]. 
 
1.3.2.7. Celastrol abrogates tumor cell invasion and migration 
 In human lung cancer 95-D and mouse melanoma B16F10 cells 
celastrol inhibited focal adhesion-dependent cell migration and invasion by 
modulating β1-integrin ligand affinity, focal adhesion formation, which are 
accompanied by reduced phosphorylation of FAK (focal adhesion kinase) 
[376]. Celastrol has been shown to inhibit TNF-α-induced cell migration and 
invasion [372], suppress invasion and migration in breast cancer cell lines 
[408]; both of which were accompanied by the downregulation of NF-κB- 
mediated MMP9 expression. Celastrol inhibited the invasion and migration of 
colon and pancreatic cancer cells by modulating CXCL12/CXCR4 axis [409]. 
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Celastrol suppressed the migration and invasion of prostate cancer cells [366] 
and hypoxia-induced invasion of HCC cells [383]. In W256 cells, celastrol- 
induced inhibition of migration was associated with downreguation of MMP9 
and uPAR (urokinase type plasminogen activator receptor) [410]. 
 
1.3.2.8. Celastrol exploits oncogene addiction of cancer cells 
 Certain cancer cells are addicted to one particular molecule or one 
particular pathway for their proliferation and survival, which is termed as 
'oncogene addiction'. Oncogenes act as 'Achilles heel' which can be exploited 
for the treatment of cancers by using targeted therapies. Interestingly, in certain 
cancers tested, celastrol preferentially induced apoptosis in the oncogene- 
addicted cancer cell lines. This finding is not surprising considering many 
dysregulated oncogenes are regualated by proteasome and Hsp90 in cancer 
cells which are known to be inhibited by celastrol. 
 CML (chronic myeloid leukemia) is addicted to the fusion gene Bcr-Abl, 
which is targeted by tyrosine kinase inhibitor imatinib. Interestingly, in CML 
cells bearing Bcr-Abl, celastrol can downregulate Bcr-Abl and induce apoptosis 
regardless of their sensitivity to imatinib [402, 411]. Moreover, celastrol has 
also been shown to downregulate other mutant proteins which drive 
oncogenesis like FLT3 (Fms-like tyrosine kinase 3), EGFR (epidermal derived 
growth factor receptor) in Ba/F3 cell [343]. Certain prostate cancer cells are 
dependent on AR (androgen receptor)-mediated cell growth. Celastrol can also 
downregulate AR expression in human prostate cancer LNCap cells to induce 
apoptosis [337, 343]. In breast cancer, celastrol modulated the expression of 
ER-α (estrogen receptor-α) and induced apoptosis in MCF7 and T47D human 
breast cancer cells [412] and also decreased the stability of ErbB2 , in ErbB2 
overexpressing breast cancer cells and induced apoptosis [390]. 
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1.3.3. Anticancer effects of celastrol in vivo 
1.3.3.1. Celastrol inhibits tumor growth in vivo 
 Animal models are indispensable for the evaluation of 
chemotherapeutic/chemopreventive agents to bring these agents safely into the 
clinical trials. Celastrol has been tested in various animal models of 
inflammation and cancer [326]. Inhibition of tumor growth is an important end 
point in using of animal models to evaluate their efficacy. Celastrol inhibited 
tumor growth in human prostate cancer nude mice xenograft model [337, 406], 
human breast cancer xenograft model [371], human and mouse melanoma 
tumors and reduced the number of lung metastases in syngeneic and xenograft 
mouse models [378], human pancreatic cancer [342], glioma [413] and CML 
xenograft  mice models [411].  
 
1.3.3.2. Celastrol potentiates the tumor growth inhibitory effects of TRAIL 
chemokine and radiotherapy in vivo  
  
 Xenograft mice models are often used to evaluate the combination 
therapy of cancer. Celastrol showed enhanced anti-tumor activity with 
radiotherapy in prostate cancer xenograft mice model [403] and human lung 
cancer nude mice xenograft model [391]. Celastrol also potentiated the anti-
tumor activity of the cytokine TRAIL in 95-D xenograft mice [399] and 
SW620 xenograft mice model [400].  
 
1.3.3.3. Celastrol inhibits angiogenesis in vivo 
 Celastrol downregulated VEGFR1 and VEGFR2 and decreased the 
MVD of human xenograft glioma model [413], inhibited VEGF-induced 
angiogenesis in matrigel plug assay, aortic ring assay [406], and inhibited 
angiogenesis in chick chorioallantoic membrane assay and in vivo matrigel 
plug assay  [404]. Celastrol decreased the MVD in intracranial glioma in rats in 
combination with adeno-associated virus-mediated recombinant angiostatin 
[414] and in combination with X-ray radiation it caused significant reduction 
of angiogenesis in PC-3 xenograft mice model [403]. 
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1.3.3.4. Celastrol inhibits metastasis in vivo 
  RIP1-Tag2 (rat insulin promoter- SV40 Large T antigen transgene) is a 
mouse model of pancreatic islet carcinoma metastasis. Celastrol caused 
reduction of  metastatic tumors in the mesenterium and inhibition of the tumors 
in the pancreas resulting in prolongation of longevity [342]. In the rat W256 
model of osteolytic bone metastases, celastrol decreased the size of osteolytic 
bone leisons, reduced the trabacular bone loss, increased the trabacular 
separation and decreased the number of osteoclasts [410]. In xenograft and 
syngenic mice models of human melanoma, celastrol decreased the lung 
metastasis [378]. Celastrol was also found to reduce the lung metastases in 
mouse melanoma model  [376]. 
 
1.3.4. Pharmacokinetic studies with celastrol 
 In a pharmacokinetic study done using Sprague-Dawley rats, it was 
revealed that the oral bioavailability of celastrol was poor. However, when the 
whole extract of Tripterygium wilfordii was given as a tablet, bioavailability of 
celastrol increased dramatically, suggesting that other components of the plant 
extract somehow increase the bioavailability of celastrol. Interestingly, female 
rats exhibited better oral bioavailability profile when compared to male rats 
significantly [415]. It is customary to modify the drug formulation to improve 
the pharmacokinetic profile of a drug without modulating the bioactive 
component of the drug. Accordingly, liposomal formulations of celastrol had 
better bioavailability, distribution profile, greater efficacy and fewer side 
effects in nude mice xenograft model of glioma [416]. Celastrol-loaded 
polymeric nanomicelles were prepared and it was demonstrated using in vitro 
experiments that these polymeric nanomicelle formulations showed gradual 
release over 24 hrs. However, this formulation remains to be evaluated in 
animal models [417]. The efficacy of celastrol nanoparticles have been tested 
in human retinoblastoma xenograft model of mice [375] and in suture-induced 
corneal neovascularisation model of rats [418]. 
 Interaction of any therapeutic agent with liver enzymes represents an 
important pharmacokinetic study analyzing the metabolism of the drug and its 
potential interactions with other drugs. Celastrol has been shown to inhibit the 
  74 
liver enzyme UDP-glucuronosyltransferase (UGT) 1A7 [419], UGT1A6 and 
UGT2B7 [420], UGT 1A3 [421]. In addition, celastrol has also been shown to 
inhibit intestinal UGT1A8 and UGT1A10, which will lead to increase in the 
plasma concentrations of co-administered drugs which are metabolized by 
these enzymes [422]. So, it is prudent that the possibilities of celastrol-
mediated drug-drug interactions are considered while conducting combination 
studies in animal models and while planning future clinical trials. 
 
1.3.5. Toxicological analysis of celastrol 
 Systematic toxicological analyses of celastrol are yet to be conducted. 
However, in the various animal models that have been tested so far, celsatrol 
was not found to cause any obvious side effects, except in one study where 
authors noticed about 10% weight loss of celastrol-treated RIP1-Tag2 
transgenic mice [342]. Zebra fish embryo model is commonly used to analyze 
the teratogenic potential of therapeutic agents. Celastrol was found to cause tail 
malformation [423] and cardiotoxicity [424] in zebra fish embryo. The above 
findings warrant a systematic study of side effects, toxic effects and teratogenic 
effects of celastrol. 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1. Cell lines 
 The human MM cell lines U266 and RPMI 8226 were bought from 
ATCC. RPMI-8226-Dox-6 (a doxorubicin-resistant clone), RPMI-8226-LR-5 
(a melphalan-resistant clone) and RPMI-8226 Vel-R (a bortezomib resistant 
clone) were kindly provided by Prof. Chng Wee Joo, Department of Medicine, 
Yong Loo Lin School of Medicine, National University of Singapore. All the 
MM cells were cultured in RPMI 1640 (Rosewell Park Memorial Institute) 
medium containing 1X antibiotic-antimycotic with 10% FBS.  All cell lines 
used were grown and passaged in a humidified incubator at 37°C with 5% CO2. 
 
2.1.2. Cell culture reagents 
RPMI 1640 - Life Technologies (Carlsbad, CA) 
0.4% trypan blue vital stain - Life Technologies (Carlsbad, CA)  
Antibiotic-antimycotic mixture - Life Technologies (Carlsbad, CA) 
FBS (fetal bovine serum) - BioWest (Miami, FL, USA) 
ThinCert 8-µm pore size tissue culture insert - Greiner Bio-one ThinCertsTM, 
NC, USA. 
 
2.1.3. Test compounds 
Celastrol - Alexis Biochemicals (San Diego, CA) 
50 mM stock of celastrol with purity greater than 98% was prepared and stored 
in -20° C.  
Bortezomib (Velcade, PS341) - LC Laboratories (Woburn, MA, USA) 
Thalidomide - Sigma-Aldrich Chemical Co. (St. Louis, MO)
 
DTT (Dithiothreitol) - Sigma-Aldrich Chemical Co. (St. Louis, MO)
 
GSH (Glutathione reduced) - Sigma-Aldrich Chemical Co. (St. Louis, MO)
 
GSSG (Glutathione oxidized) - Sigma-Aldrich Chemical Co. (St. Louis, MO)
 
Vit C (Ascorbic acid) - Sigma-Aldrich Chemical Co. (St. Louis, MO) 
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SP600125 - Sigma-Aldrich Chemical Co. (St. Louis, MO)
 
 
2.1.4. Reagents and chemicals 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] reagent 
- Life Technologies (Carlsbad, CA, USA) 
SDS (sodium dodecyl sulfate) - Life Technologies (Carlsbad, CA, USA) 
Dimethylformamide -  Life Technologies (Carlsbad, CA, USA) 
CXCL12 - Pro-Spec-Tany TechnoGene Ltd. (Rehovot, Israel) 
Human recombinant IL-6 - ProSpec-TanyTechnoGene Ltd (Rehovot, Israel) 
The Live/Dead Viability/Cytotoxicity Assay Kit - Life Technologies (Carlsbad, 
CA)  
Nuclear extraction kit - Active Motif (Carlsbad, CA)  
NF-κB p65 DNA binding kit - Active Motif (Carlsbad, CA)  
Annexin V-FITC assay kit - Santa Cruz Biotechnology (Santa Cruz, CA) 
Propidium iodide (PI) - Sigma-Aldrich Chemical Co. (St. Louis, MO) 
RNAase - Roche (U.S.A) 
DAPI (4',6-Diamidino-2- Phenylindole, Dihydrochloride) - Santa Cruz 
Biotechnology (Santa Cruz, CA) 
Hoechst stain - Life Technologies (Carlsbad, CA, USA) 
Calcein-AM - Becton Dickinson (Bedford, MA, USA) 
Matrigel - Becton Dickinson, (Bedford, MA, USA) 
Chemiluminescence  ECL- GE Healthcare, (Little Chalfont, Buckinghamshire, 
UK) 
Trizol reagent - Life Technologies (Carlsbad, CA, USA) 
Immunohistochemistry kit - DAKO LSAB kit, Dako Corporation, (Carpinteria, 
California, USA) 
ELISA kits for TNF-α and IL-6 - R&D systems, (USA). 
 
2.1.5. Antibodies 
Antibodies purchased from Santa Cruz Biotechnology (Santa Cruz, CA) 
are as follows: 
sc-81523- anti-phospho-STAT3 (Tyr 705)  
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sc-8001-R-anti-phospho-STAT3 (Ser 727)  
sc-836 - anti-STAT5  
sc-482 - anti-STAT-3  
sc-56960 - anti-PTP1B  
sc-280 - anti-SHPTP2  
sc-101629- anti-phospho-AKT (Ser 473)   
sc-56878 - anti-AKT-  
sc-137179 - anti-GAPDH  
sc-20682 - anti-Lamin B  
sc-371 - anti-IκBα  
sc-23470-R -anti-phospho-IKKα/β (Ser 180/Ser 181)  
sc-493 - anti-Bax  
sc-832 - anti-Bak  
sc-509 - anti-Bcl-2  
sc-8392 - anti-Bcl-xL  
sc-20679 - anti-Mcl-1  
sc-11423 - anti-Bid  
sc-47750 - anti-Survivin  
sc-753 - anti-Cyclin D1  
sc-481 - anti-Cyclin E  
sc-817 - anti-p21  
sc-528 - anti-p27  
sc-57496 - anti-VEGF  
sc-40 - anti-c-Myc  
sc-19999 - anti-COX2  
sc-10737 - anti-MMP 9  
sc-7150 - anti-PARP  
sc-47778 - anti-β-actin  
sc-2005 - HRP conjugated goat anti-mouse 
sc-2004 - HRP conjugated goat anti-rabbit  
sc-2354 - HRP conjugated mouse anti-goat  
 
Antibodies purchased from Cell Signaling Technology (Beverly, MA) are 
as follows: 
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#4322 - anti-phospho-STAT5 (Tyr 694)  
#2101S - anti-phospho-Src (Tyr 416)  
#2108S - anti-Src  
#3771S - anti-phospho-JAK2 (Tyr 1007/ 1008)  
#3230S - anti-JAK2  
#2859 - anti-phospho-IκBα (Ser 32/36)  
#2684 - anti-IKKβ  
#3033 - anti-phospho-p65 (Ser 536)  
#3034 - anti-p65  
#9251S - anti-phospho-SAPK/JNK (Thr183/Tyr185)  
#9252 - anti-SAPK/JNK  
#2042 - anti-XIAP  
#9662 - anti-Caspase 3 
#9746 - anti-Caspase 8  
#9502 - anti-Caspase 9  
 
Antibody purchased from Abcam (Cambridge, MA, USA) is as follows: 
ab2074 -anti-CXCR4  
 
Antibody purchased from Life Technologies (Carlsbad, CA, USA)  is as 
follows: 
A-11012 - Goat anti-rabbit IgG-Alexa 594. 
 
2.1.6. Primers and probes  
Please refer to the appendix I. 
 
2.2. Methods 
2.2.1. In Silico Analysis 
Please refer to the appendix II.  
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2.2.2. Cell viability assay 
 The cytotoxic effect of celastrol on various myeloma cells was 
measured using MTT dye uptake method. This assay is primarily based on the 
principle that live and metabolically active cells readily take up MTT and 
reduce it to insoluble purple formazan crystals. The soluble formazan product 
can be quantified colorimetrically by measuring the absorbance at 570 nm. 
Thus this assay is useful for quantitative determination of cellular proliferation 
and viability, as it occurs only in metabolically intact cells.  Briefly, MM cells 
(5x103/ml) were incubated in triplicate in a 96-well plate in the presence or 
absence of different concentrations of celastrol in a final volume of 0.2 ml for 
different time intervals at 37°C with 5% CO2 atmosphere. Thereafter, 20 µl 
MTT solution was added to each well. After a 4 hours (hrs) incubation at 37°C, 
lysis buffer was added, cells were incubated at 37°C for 4 hrs, and the optical 
density was then measured at 570 nm using a Tecan microplate reader. The 
percentage cell viability was calculated using the following formula.  
 
Percentage cell viability = average OD of treated cells / average OD of control 
cells x 100. 
 
MTT reagent was prepared at the concentration of 5mg/ml in PBS and stored at 
4°C in the dark. Lysis buffer consisting of 20% SDS and 50% 
dimethylformamide was prepared in autoclaved water and stored at room 
temperature. 
 
2.2.3. DNA fragmentation analysis 
 DNA fragmentation analysis was carried out to detect apoptosis in test 
compounds-treated cells. Briefly, MM cells (1x106) cells were seeded and 
treated with the test compounds for the indicated time duration. Following 
treatment with the test compounds, the cells were collected, washed and 
resuspended in 1 ml of 1X PBS (phosphate buffered saline) and immediately 
fixed with 70% ice cold ethanol while vortexing the cells. The vortexing was 
done to prevent the cells from clumping together. The cells were incubated at 
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4°C for 30 minutes (min) and then were washed with 1X PBS and resuspended 
in 500 µl PI (10µg/ml)-RNAase A (1µg/ml) solution. The cells were incubated 
for another 30 min before DNA content analysis. At least 1000 events were 
analyzed with CyAn ADP flow cytometer (Dako Cytomation) with the 
excitation set at 488 nm and emission at 610 nm, after which they were 
analyzed with WINMDI software. The histogram data shows percentage of 
cells containing hypodiploid, diploid and hyperdiploid DNA content. The cells 
containing hypodiploid DNA content are considered to be apoptotic. PI 
(Propidium Iodide) was dissolved in PBS to a stock concentration of 5 mg/ml 
stored in 4°C in the dark. RNAase was dissolved in PBS to a stock 
concentration of 1 mg/ml and kept at -20°C. 
 
2.2.4. Annexin V-FITC staining 
 One of the early indicators of apoptosis is the rapid translocation of the 
membrane phospholipid phosphatidylserine from the cell’s cytoplasmic 
interface to the extracellular surface and its accumulation there, and thereby 
causing loss of membrane asymmetry that can be detected using annexin V. 
Annexin V is a phospholipid binding protein that preferentially binds to 
negatively charged phospholipids including phosphatidylserine. PI a red 
flourescent dye, stains the chromosomal components of the nucleus and does 
not permeate live cells. It is used to identify the dead cells in a given cell 
population. So, cells progressing through apoptosis can be monitored according 
to their Annexin V and PI staining pattern. Early apoptotic cells will bind 
Annexin V, but will not take up PI. As cells progress through apoptosis the 
integrity of the plasma membrane is lost, thereby allowing PI to penetrate and 
label the cells with a strong yellow-red fluorescence. Briefly, MM cells (1 x 
106) were treated with test compounds for indicated time points. Cells were 
collected, washed with PBS and resuspended with 1 ml of assay buffer. Then, 
50 µl of Annexin V FITC and 100 µl of PI were added into the cells and 
incubated in dark at room temperature for 15 min. Cells were analyzed with a 
flow cytometer (BD FACS Calibur, BD Biosciences, US) and the data obtained 
was analyzed using WINMDI software.  
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2.2.5. Live and dead assay 
 The Live/Dead Viability/Cytotoxicity Assay Kit provides a two-color 
fluorescence cell viability assay that is based on the simultaneous 
determination of live and dead cells with two probes that measure recognized 
parameters of cell viability which are intracellular esterase activity and plasma 
membrane integrity. Live cells are distinguished by the presence of ubiquitous 
intracellular esterase activity, determined by the enzymatic conversion of the 
virtually non-fluorescent cell-permeant calcein-AM to the intensely fluorescent 
calcein. The polyanionic dye calcein is well retained within live cells, 
producing an intense uniform green fluorescence in live cells 
(excitation/emission ~495 nm/~515 nm). EthD-1 (Ethidium monomer dye) 
enters cells with damaged membranes and undergoes a 40-fold enhancement of 
fluorescence upon binding to nucleic acids, thereby producing a bright red 
fluorescence in dead cells (excitation/emission ~495 nm/~635 nm). EthD-1 is 
excluded by the intact plasma membrane of live cells. Briefly, MM cells (1 x 
106) were incubated with test compounds for various times at 37°C. Cells were 
collected and washed with 1X PBS. Cells were resuspended using the working 
solution consisting of EthD-1 (4µM) and Calcein-AM (2µM) and incubated for 
45 min in the dark. After the incubation, cells were collected by centrifugation 
and the working solution was discarded. Cells are resuspended using 20 µl 
1XPBS and put on a glass slide, covered with a cover slip and cells were 
observed and captured under a fluorescence microscope (Olympus DP 70, 
Japan).  
 
2.2.6. Migration assay 
 U266 cells (50 x104/well) were plated in 300-µl cell culture media with 
and without 1µM Celastrol in the top chambers of 24-well transwell inserts 
with 8-µm pores. Cell culture medium (600 µl) containing the recombinant 
human B-cell chemoattractant CXCL12 (100 ng/ml) was added to the bottom 
chamber and incubated for 12 hrs. After incubation, the insert was removed 
and calcein-AM (5µM) was added to the wells. The cells were incubated at 
37°C for 1 hr to allow the cells to internalize Calcein-AM. The fluorescence 
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was measured (485 nm excitation, 520 nm emission). A standard curve was 
generated with cells ranging from 50000-1000 cells using Calcein-AM under 
same condition and cells number calculated from relative fluorescence of 
treated samples. 
 
2.2.7. Invasion assay 
 An invasion assay was performed with U266 cells in 24-well plates 
with polycarbonate membranes (ThinCert 8-µm pore size tissue culture insert). 
Briefly the upper chambers were coated with 50-µl matrigel in advance. 50 
x104 U266 cells in suspension were starved in serum-free RPMI-1640 for 3 hrs, 
and then loaded onto the matrigel-coated inserts in the upper chambers. The 
wells of the plate were filled with 600-µl of 10% FBS-containing cell culture 
media with 100 ng/ml CXCL12. Celastrol was added with the cells to the upper 
chamber. Plates were then incubated at 37°C for 12 hrs. At the end of the 
incubation period, Calcein-AM (5µM) was added to the wells containing 
invasive cells. The cells were incubated at 37°C for 1 hr to allow the cells to 
internalize Calcein-AM. The fluorescence was measured (485 nm excitation, 
520 nm emission). A standard curve was generated with cells ranging from 
50000-1000 cells using Calcein-AM under same condition and cells number 
calculated from relative fluorescence of treated samples. 
 
2.2.8. Preparation of cytosolic and nuclear extracts 
 Briefly, MM cells (3 x106/flask) were seeded and treated with the 
test compounds for the indicated duration. After that cells were spun at 1000 
rpm at 4 °C for 5 min and the media was removed. The cell pellet was washed 
with 10 ml of ice cold PBS. Then the cells were incubated in hypotonic buffer 
with protease and phosphatase inhibitors for 15 min, when 25µl of DTT was 
added and vortexed for 10 seconds at highest speed. Then the cell suspension 
was centrifuged for 30 seconds at 14,000 rpm in a microcentrifuge pre-cooled 
at 4ºC. The supernatant (cytoplasmic fraction) was transferred into a pre-
chilled microcentrifuge tube and stored at –80ºC until it was used. The 
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remaining nuclear pellet was resuspended in 50 µl of complete lysis buffer by 
pipetting up and down and vortexing for 10 seconds at the highest setting and 
incubating on ice over a rocking platform for about 30 min before, it was spun 
at 14,000 rpm for 5 min. The supernatant (nuclear extract) was collected, 
transferred to a pre-chilled microcentrifuge tube and stored at –80ºC until being 
used. 
 
2.2.9. Western blot analysis 
 For detection of various proteins, test compound-treated whole cell 
extracts were lysed in lysis buffer.  Thereafter, the cells in the lysis buffer were 
incubated on ice for 30 min with intermittent vortexing and were subsequently 
spun at 14,000 rpm for 10 min and resolved on a SDS gel.  After 
electrophoresis, the proteins were electrotransferred to a nitrocellulose 
membrane, blocked with 5% non-fat milk, and probed with various primary 
antibodies (1:1000) overnight at 4°C. The blot was washed, exposed to HRP-
conjugated secondary antibodies for 1 hr, and finally examined by 
chemiluminescence. The densitometric analysis of the scanned blots was done 
using Image J software and the results are expressed as fold change relative to 
the control. 
 Lysis buffer consisting of 20 mM Tris (pH 7.4), 250 mM NaCl, 2 mM 
EDTA (pH 8.0), 0.1% Triton X-100 was prepared and stored at -20°C.  
Protease inhibitors namely 0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin, 0.4 
mM PMSF, and 4 mM NaVO4 were added into the lysis buffer immediately 
before being used.  
 
2.2.10. RNA extraction and Real-time PCR analysis: 
Please refer to the appendix II. 
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2.2.11. Immunocytochemistry 
 Immunocytochemistry analysis was done to study the nuclear 
translocation of STAT3 and NF-κB. Briefly, MM cells (1 x106) were seeded 
and incubated overnight. Then the MM cells were treated with the celastrol for 
various time points. Cells were plated on a glass slide by centrifugation with 
the use of a cytospin. The glass slide was air dried for 1hr at room temperature.  
Cells were fixed with pre-chilled acetone at -20°C for 15 min. Then the slides 
were washed with 1XPBS and incubated with 0.2% Triton-X 100 in PBS for 
15 min at room temperature. After washing with 1X PBS, cells were blocked 
with 5% normal goat serum in PBS for 1 hr at room temperature. After 
washing, the cells were incubated in primary antibody (1:100 in normal goat 
serum) at 4°C. After overnight incubation and washing with 1XPBS, cells were 
incubated with goat anti-rabbit IgG-Alexa 594 (1/100) for 1 hr and 
counterstained with Hoechst (50 ng/mL) for 5 min. Then, the slides were 
mounted using the mounting medium and analyzed under a fluorescence 
microscope (DP 70, Olympus, Tokyo, Japan). Positive cells (brown) were 
quantitated using the Image-Pro plus 6.0 software package (Media Cybernetics, 
Inc.). 
 
2.2.12. NF-κB DNA binding assay 
 To determine NF-κB activation, we performed DNA binding assay. 
Briefly, the binding of NF-κB to DNA was measured in nuclear extracts with a 
fast, user-friendly, ELISA based TransAM NF-κB p65 assay kit. This assay 
uses multiwell plates coated with an unlabeled oligonucleotide containing the 
consensus binding site for NF-κB (5’-GGGACTTTCC-3’).  MM cells (2x 106) 
were treated with the indicated concentrations of test compounds for indicated 
time intervals after which, nuclear extracts were prepared using the nuclear 
extraction kit. Nuclear proteins (20 µg) were added to each well and incubated 
for 1 hr to allow NF-κB DNA binding.  Subsequently, by using an antibody 
that is directed against NF-κB p65 subunit, the NF-κB complex bound to the 
oligonucleotide is detected. A horseradish peroxidase-conjugated secondary 
antibody provided the basis for the colorimetric quantification. 
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2.2.13. Xenograft MM mouse model 
  
 
Figure 2.1. Schematic representation of in vivo experimental protocol    
One week after the tumor cell injection mice were randomized into four 
treatment groups and treatment was started. On day twenty one, the treatment 
was stopped and the mice were observed for another four days after which they 
were sacrificed. 
 
 Male athymic balb/c nude mice (BRC, Biopolis, Singapore) were 
implanted with U266 cells (2x107) subcutaneously. One week after the tumor 
cell implantation, the mice were randomized into four groups (n=5) based on 
the tumor volume. Group I (control) received corn oil 100 µl i.p. for five days a 
week, group II received 0.25 mg/kg celastrol in 100 µl corn oil for five days a 
week, group III received 0.25 mg/kg bortezomib in 100 µl corn oil i.p. weekly 
and group IV received 0.25mg/kg celastrol in 100 µl corn oil i.p. 5 days a week 
and 0. 25 mg/kg bortezomib in 100 µl corn oil administered i.p. weekly for 3 
consecutive weeks. The tumor diameters and body weight of the mice were 
monitored and measured on every third day during the duration of the 
experiment. The tumor volume was calculated using the formula [L x W2]/2, 
where W and L are the width and the length of the tumor On completion of the 
treatment period, mice were euthanized by i.p. phentobarbital (40 mg/kg b.w) 
followed by cervical dislocation and blood was collected. Then tumors were 
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dissected and subjected to histological examination. 
 
 
2.2.14. Immunohistochemical analysis of tumor tissues 
 Solid tumors from control and celastrol-treated groups were fixed with 
10% phosphate-buffered formalin, processed, and embedded in paraffin. The 
sections were cut and deparafinized in xylene, dehydrated in graded alcohol, 
and finally hydrated in water. Antigen retrieval was performed by boiling the 
slide in 10 mM sodium citrate (pH 6.0) for 30 min. Briefly, endogenous 
peroxidases were quenched with 3% hydrogen peroxide. Non-specific binding 
was blocked by incubating in the blocking reagent in the LSAB kit (Dako). 
Sections were incubated overnight with primary antibodies as follows: anti-
p65, anti-phospho-STAT3, anti-Bcl-2, and anti-VEGF (each at 1:100 
dilutions). The slides were subsequently washed several times in Tris-buffered 
saline with 0.1% Tween 20 and were incubated with biotinylated linker for 30 
min, followed by incubation with streptavidin conjugate provided in LSAB kit 
according to the manufacturer’s instructions. Immunoreactive species were 
detected using 3, 3’-diaminobenzidine tetrahydrochloride as a substrate. The 
sections were counterstained with Gill’s hematoxylin and mounted under glass 
cover slips. Images were taken using an Olympus BX51 microscope 
(magnification, X 40).  
 
2.2.15. ELISA assay  
 Blood was collected as the mice were sacrificed and sera was separated 
and stored in -80°C. Serum level of mouse TNF-α and IL-6 was measured 
using ELISA kit (R&D systems, USA) according to manufacturer's 
instructions. Briefly, 50 µl of assay diluent was added to each well and 50 µl 
standard and samples was added in the wells and incubated for 2 hrs at room 
temperature. At the end of two hrs, the contents of the wells were aspirated. 
The wells were washed with the wash buffer for five times. After that 100 µl of 
mouse TNF-α and IL-6 conjugate were added to the wells respectively and 
incubated for 2 hours at room temperature. At the end of two hrs contents of 
the wells were aspirated and the wells were washed with wash buffer. Then 
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100 µl of substrate solution was added to each well and incubated in the room 
temperature for 30 min in dark. After that 100 µl of stop solution was added to 
each well and was mixed with the substrate solution by gentle tapping. The 
optical density was measured using a microplate reader at 450 nm. The 
wavelength correction was done at 540 nm.  
 
2.3. Statistical analysis 
 Statistical analysis was performed by student’s unpaired t test. The 
probability (p) value less than 0.05 was considered statistically significant. 
When multiple comparisons were done one way ANOVA test was used and 
post-test comparisons among the groups were done using Bonferroni method. 
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3. RESULTS 
3. 1. In silico analysis of anti-myeloma effects of 
celastrol 
Please refer to the appendix I. 
 
3.2. Anti-myeloma effects of celastrol in vitro 
3.2.1. Celastrol suppresses the viability of various drug resistant 
MM cells 
  
 Anti-myeloma effect of celastrol was evaluated by assessing the cell 
viability using MTT assay. MTT assay is a colorimetric assay that is generally 
used to determine the cytotoxicity of potential pharmacological agents [425]. 
Different MM cell lines including U266, RPMI-8226-Dox6 (resistant to 
doxorubicin), RPMI 8226-LR5 (resistant to melphalan), and RPMI-8226-BR 
(bortezomib resistant) were used for these experiments. The cells were treated 
with 0, 0.1, 0.25, 0.5, 1, 2.5 and 5 µM of celastrol for 0, 1, 2, 3 and 4 days and 
subjected to MTT assay. The data obtained indicated that celastrol suppressed 
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Figure 3.2.1. Celastrol suppresses the viability of various drug resistant  
MM cells 
 
U266, RPMI-8226-Dox6, RPMI-8226-LR5, and RPMI-8226-BR cells were 
treated with 0, 0.1, 0.25, 0.5, 1, 2.5 and 5 µM of celastrol for 0, 1, 2, 3 and 4 
days and subjected to MTT assay. Cell viability in celastrol-treated group 
decreased to statistically significant levels as compared to control group (p< 
0.05) after treatment for indicated time points. Data expressed as mean + 
standard deviation (SD).  
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3.2.2. Celastrol induces apoptosis in MM cells 
3.2.2.1. Celastrol causes increased accumulation of MM cells in sub G1 
phase 
 To analyze, if the decrease in the cell viability of MM cells upon 
treatment with celastrol was due to induction of apoptosis, DNA fragmentation, 
an important hallmark of apoptosis was analyzed. Fragmentation of DNA 
which occurs during apoptosis will result in accumulation cells in subG1 (sub-
diploid) population when analyzed by FACS after PI staining. Different MM 
cells were seeded in triplicate and treated with 1 µM celastrol for indicated 
time points. Cells were then washed, fixed and stained with PI before analyzed 
by FACS. Cells with fragmented DNA will appear in the subG1 fraction of cell 
cycle profile.  Our data clearly reveals that celastrol treatment caused 
substantial accumulation of cells in subG1 phase in a time-dependent manner in 
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Figure 3.2.2.1. Celastrol causes accumulation of MM cells in sub G1 phase 
 
A. U266 cells were treated with 1 µM celastrol for 0, 12, and 24 hrs, after 
which the cells were washed, fixed, stained with PI, and analyzed for DNA 
content by flow cytometry.  
 
B. RPMI-8266 cells were treated with 1 µM celastrol for 0, 12, and 24 hrs, 
after which the cells were washed, fixed, stained with PI, and analyzed for 
DNA content by flow cytometry.  
 
C. RPMI-8226-BR cells were treated with 1 µM celastrol for 0, 24, and 48 hrs, 
after which the cells were washed, fixed, stained with PI, and analyzed for 
DNA content by flow cytometry. 
 
Representative histogram pictures with the percentage of cells in hypodiploid 
(subG1) diploid G1/G0 and hyperdiploid (S and G2M) phases for each cell line 
has been shown. 
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3.2.2.2. Celastrol causes loss of membrane integrity in MM cells 
 Loss of membrane integrity is one of the earliest features of apoptosis. 
To measure effect of celastrol on membrane integrity, we used the Live/Dead 
cell viability assay kit which determines intracellular esterase activity and 
plasma membrane integrity.  MM cells were treated with 1 µM celastrol for 0, 
6, 12, and 24 hrs and stained with EthD-1 and calcein-AM and processed as 
discussed under Materials and Methods. Live cells will exclude EthD-1 and 
allow calcein-AM which is converted by metabolically active cells to a green 
fluorescent dye when analyzed under fluorescent microscope. Dead cells will 
allow EthD-1 because of loss of membrane integrity and will appear as red 
cells when analyzed under fluorescent microscope. The green cells indicate 
live cells and the red cells indicate dead cells.  As evident from our results 
shown below, the percentage of ethidium monomer dye (red fluorescence) 
stained cells significantly increased in a time-dependent manner upon celastrol 
treatment which indicated that this triterpene can induce substantial apoptosis 

























Figure 3.2.2.2. Celastrol causes loss of membrane integrity in a time- 
dependent manner in MM cells 
 
RPMI-8266 cells were treated with 1 µM celastrol for 0, 6, 12, and 24 hrs. 
Cells were stained with Live/Dead assay reagent for 30 mins and then analyzed 
under a fluorescence microscope as described under Materials and Methods.  A 
representative image for each group is shown.  
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 3.2.2.3. Celastrol causes relatively less cell death in normal mouse 
embryonic fibroblasts 
  
 Our above mentioned results clearly show that celastrol induces 
apoptosis in MM cells. Next we went on to investigate the apoptotic effects of 
celastrol on normal cells to rule out its potential toxicity. We used mouse 
embryonic fibroblasts (MEF) and human normal breast epithelial cell line 
MCF-10A to represent non-cancer cells. To analyze the apoptotic effect of 
celastrol on these cells, we performed Live and Dead assay which detects 
intracellular esterase activity and plasma membrane integrity. MEF cells and 
MCF-10A cells were treated with 1 µM celastrol for 0, 6, 12 and 24 hrs. Live 
and Dead assay was performed as described under Materials and Methods. The 
results shown below clearly indicate that celastrol induces relatively less cell 







































































































Figure 3.2.2.3. Celastrol causes relatively less cell death in normal mouse 
embryonic fibroblasts 
 
A.  Mouse embryonic fibroblasts were treated with 1 µM celastrol for 0, 6, 12, 
and 24 hrs. Cells were stained with Live/Dead assay reagent for 30 mins and 
then analyzed under a fluorescence microscope as described under Materials 
and Methods.  A representative image for each group is shown.  
 
B.  MCF-10A cells were treated with 1 µM celastrol for 0, 6, 12, and 24 hrs. 
Cells were stained with Live/Dead assay reagent for 30 mins and then analyzed 
under a fluorescence microscope as described under Materials and Methods.  A 
representative image for each group is shown.  
 
C. Live and dead assay was performed using RPMI-8226 cells, mouse 
embryonic fibroblast cells and MCF-10A cells as mentioned above. Number of 
apoptotic cells of RPMI-8226 cells, mouse embryonic fibroblast cells and 
MCF-10A cells in 10 microscopic fields were counted. Data is represented as 
average number of apoptotic cells + SD (n=10). 
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3.2.2.4. Celastrol causes activation of caspase-3 to induce apoptosis in MM 
cells 
 
 Activation of the executioner caspases such as caspase-3 is the final 
step in the apoptotic pathway [426]. Thus activated caspase-3 can cleave its 
various substrates including PARP which will appear in its cleaved form 
during western blot analysis. MM cells were treated with 0, 0.25, 0.5, 1 and 2.5 
uM celastrol for 24 hrs and 1 µM celastrol for 0, 3, 6, 12 and 24 hrs 
respectively and western blot assay was done to detect the full length caspase-3 
and PARP. Our results indicate that there is a dose-dependent decrease in full 
length caspase-3, full length PARP and dose-dependent increase in cleaved 
PARP in both the cell lines. There was also a time-dependent decrease in full 
length caspase-3, full length PARP and a time-dependent increase in cleaved 
PARP in both the cell lines thereby indicating that celastrol induces apoptosis 
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Figure 3.2.2.4. Celastrol activates caspase-3 and causes PARP cleavage 
 
A. After treating U266 cells with 1 µM celastrol for the indicated duration, 
western blot assay was done by preparing whole-cell extracts. 30 µg protein 
was loaded and run on SDS-PAGE and transferred to nitrocellulose membrane. 
The blots were probed with anti-caspase-3 and anti-PARP antibodies. As a 
loading control, β-actin was probed after stripping the same blots. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
 
B. After treating U266 cells with 0, 0.25, 0.5, 1 and 2.5 µM concentrations of 
celastrol for indicated duration, western blot assay was done using whole cell 
extracts. 30µg protein was loaded and run on SDS-PAGE and transferred to 
nitrocellulose membrane. The blots were probed with anti-caspase-3 and anti-
PARP antibodies. As a loading control, β-actin was probed after stripping the 
same blots. The blot shown is representative of at least two independent 
experiments. Densitometric analysis was done to determine fold change in 
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3.2.2.5. Celastrol activates both extrinsic and intrinsic caspase activation 
cascade to induce apoptosis in MM cells 
 
 Apoptosis can be the result of activation of extrinsic caspase cascade or 
intrinsic caspase cascade or by both. To analyze if celastrol-induced apoptosis 
involves extrinsic pathway and or intrinsic pathway, RPMI-8226 cells were 
treated with 1 µM celastrol for 0, 3, 6, 12 and 24 hrs and western blot assay 
was done to detect the expression of both caspase-8 and caspase-9. Bid which 
is activated by caspase-8-induced cleavage can also activate caspase-9. Bid, a 
BH3 containing protein is involved in relaying caspase mediated extrinsic and 
mitochondria mediated intrinsic pathway. Upon cleavage by activated caspase-
8, the cleaved Bid causes the release of cytochrome c which in turn activates 
caspase- 9. The activity of Bid is opposed by Bcl-2 [427]. To determine if 
celastrol-induced apoptosis involves activation of Bid, western blot analysis of 
Bid was also done using specific antibodies under the same conditions used to 
detect caspase-8 and caspase-9. There was a time-dependent decrease in full 
length caspase-8 and caspase-9 and a corresponding increase in the cleaved 
band of caspase-8 and caspase-9, indicating that activation of both extrinsic 
and intrinsic apoptotic cascade is involved in the observed apoptotic effects of 
celastrol in MM cells. Also, a time-dependent decrease in the level of full 





















































Figure 3.2.2.5. Celastrol causes the activation of both extrinsic and 
intrinsic caspase cascades in MM cells 
 
After treating RPMI-8226 with 1 µM celastrol for various time points, western 
blot assay was done using whole-cell extracts. 50 µg protein was loaded and 
run on SDS-PAGE and transferred to nitrocellulose membrane. The blots were 
probed with anti-caspase-8, anti-caspase-9 and anti-Bid antibodies. As a 
loading control, β-actin was probed after stripping the same blots. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
  104 
3.2.2.6. Celastrol causes downregulation of expression of various anti-
apoptotic proteins involved in survival of MM cells  
  
 The anti-apoptotic and pro-apoptotic proteins maintain a balance which 
determines whether a cell is going to survive or undergo apoptosis [428]. To 
analyze if various anti-apoptotic proteins are downregulated during celastrol- 
induced apoptosis in MM cells, western blot analysis was performed. MM cells 
were treated with 1 µM celastrol for 0, 3, 6, 12 and 24 hrs in western blot 
analysis. Cells were harvested and western blot assay was done using specific 
antibodies to detect Bcl-2, Bcl-xL, Mcl-1, survivin and XIAP. It was found that 
celastrol can downregulate the above indicated anti-apoptotic proteins in a 
time-dependent manner in both the cell lines. It is evident from the result 
3.2.2.5 that celastrol treated cells show a decrease in full length Bid level, 
which can be explained by cleavage of caspase-8. It is interesting to note that 
celastrol treated cells also show a substantial downregulation in the expression 
of Bcl-2 family of anti-apoptotic proteins including Bcl-2, Bcl-xL, Mcl-1, as 






















Figure 3.2.2.6. Celastrol downregulates expression of various anti-
apoptotic proteins involved in survival of MM cells 
 
After treating U266 cells with 1 µM celastrol for the indicated duration, 
western blot assay was done by preparing whole-cell extracts. 50 µg protein 
was loaded and run on SDS-PAGE and transferred to nitrocellulose membrane. 
The blots were probed for shown proteins using specific antibodies. As a 
loading control, β-actin was probed after stripping the same blots. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
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3.2.2.7. Celastrol causes downregulation of expression of various anti-
apoptotic proteins involved in survival of MM cells at transcriptional level 
  
Please refer to the appendix II. 
 
3.2.2.8. Celastrol increases the expression of various pro-apoptotic 
proteins in MM cells 
 
 The balance between proapoptotic and anti-apoptotic members of the 
Bcl-2 family of proteins is a crucial factor which determines whether a cell is 
going to survive or undergo apoptosis [428]. As observed from the above 
mentioned results, a down-regulation of various Bcl-2 families of anti-
apoptotic proteins namely Bcl-2, Bcl-xL and Mcl-1 was noticed in celastrol-
treated MM cells. To analyze whether pro-apoptotic members of Bcl-2 family 
proteins are also upregulated upon celastrol-induced apoptosis in MM cells, 
U266 and RPMI-8226 cells were treated with 1 µM celastrol for 0, 3, 6, 12 and 
24 hrs. Cells were harvested and western blot assay was done using specific 
antibodies to detect the expression level of Bax and Bak proteins. Our results 
reveal that celastrol upregulates the expression of pro-apoptotic proteins Bax 
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Figure 3.2.2.8. Celastrol causes upregulation of pro-apoptotic members of 
Bcl-2 family proteins in MM cells.  
 
After treating U266 cells with 1 µM celastrol for the indicated duration, 
western blot assay was done by preparing whole-cell extracts. 50 µg protein 
was loaded and run on SDS-PAGE and transferred to nitrocellulose membrane. 
The blots were probed for shown proteins using specific antibodies. As a 
loading control, β-actin was probed after stripping the same blots. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
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3.2.2.9. Celastrol causes JNK kinase activation in MM cells 
 
 JNK kinase is a stress kinase that is often activated when cancer cells 
are exposed to chemotherapeutic agents [429, 430]. Activation of JNK kinase 
has been found to mediate apoptosis induced by various stress stimuli. Since 
celastrol caused significant apoptosis in MM cells, we aimed to determine if 
activation of JNK MAP kinase can mediate the observed apoptotic effects of 
celastrol. To analyze this possibility, western blot assay was performed to 
detect p-JNK. RPMI-8226 cells were incubated with 1 µM celastrol for the 
indicated duration of time. It is evident from the result shown below that 
celastrol induced JNK activation as early as 15 minutes after treatment without 
altering the levels of JNK protein expression (Figure A). It is also evident that 
the specific JNK inhibitor, SP600125 completely inhibited celastrol-induced 
JNK activation (Figure B). However, we found that celastrol had a minimal 
effect on the activation of p38 and p42/44MAPkinases in MM cells (data not 
shown), thereby suggesting that JNK MAP Kinase may play a pivotal role in 







































Figure 3.2.2.9. Celastrol induces JNK activation and celastrol-induced 
JNK activation is inhibited by JNK inhibitor (SP600125) 
 
A. After treating RPMI-8226 cells with 1 µM celastrol for the indicated 
duration, western blot assay was done by preparing whole-cell extracts. 50µg 
protein was loaded and run on SDS-PAGE and transferred to nitrocellulose 
membrane. The blot was probed for p-JNK using anti-p-JNK antibody. As a 
loading control, total JNK protein was probed after stripping the same blot. The 
blot shown is representative of at least two independent experiments. 
Densitometric analysis was done to determine fold change in intensity between 
treated and control groups. 
B.  RPMI-8226 cells were pretreated with 10 µM JNK inhibitor (SP600125 ) 
for 1 h and then treated with 1 µM celastrol for 2 hrs, western blot assay was 
done by preparing whole-cell extracts. 50 µg protein was loaded and run on 
SDS-PAGE and transferred to nitrocellulose membrane. The blot was probed 
for p-JNK using anti-p-JNK antibody. As a loading control, total JNK was 
probed using anti-JNK antibody after stripping the same blot. The blot shown 
is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
  110 
3.2.2.10. Inhibition of JNK activation abrogates celastrol-induced 
apoptosis in MM cells 
 
 From our previous experimental result, we understand that celastrol 
induces JNK activation. We next sought to determine whether suppression of 
JNK by a specific inhibitor of JNK blocks cell death induced by celastrol. To 
analyze this possibility SubG1 analysis was done. Cells were pre-treated with 
SP600125 and then treated with indicated concentrations of celastrol for 24 hrs. 
We next examined the effect of SP600125 on celastrol-induced apoptosis. The 
results shown below clearly suggest that inhibition of JNK activation can 
suppress apoptosis induced by celastrol.  To further confirm if celastrol 
induced apoptosis is mediated by JNK, cells were pretreated with SP600125 
and then treated with 1 µM of celastrol for indicated time duration. Western 
blot assay was done to detect the PARP level. The results show that cleaved 
PARP level increase in time dependent manner in cells treated with celastrol 
alone. Whereas, in cells treated with celastrol and SP600125 there is no 
cleavage of PAPR indicating that SP600125 abrogated celastrol induced 
apoptosis. These observations suggest that celastrol-induced apoptosis at least 





































Figure 3.2.2.10. JNK inhibition blocks celastrol-induced apoptosis 
 
A. After treating RPMI-8226 cells with indicated concentrations of celastrol 
alone and or in combination with JNK inhibitor for 24 hrs, sub G1 analysis was 
done using flow cytometry to assess the apoptotic cells. 
 
B. After treating RPMI-8226 cells with indicated concentrations of celastrol 
alone and or in combination with JNK inhibitor for 24 hrs and the cells, 
western blot assay was done by preparing whole-cell extracts. 5µg protein was 
loaded and run on SDS-PAGE and transferred to nitrocellulose membrane. The 
blot was probed for PARP using anti-PARP antibody. As a loading control, β-
actin was probed after stripping the same blots. The blot shown is 
representative of at least two independent experiments. Densitometric analysis 
was done to determine fold change in intensity between treated and control 
groups. 
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3.2.3. Celastrol modulates several proteins involved in cell cycle 
progression in MM cells 
  
 Most of the anti-cancer drugs exert their anti-cancer activity either by 
inducing apoptosis or by arresting cell cycle progression or exert both these 
activities [431]. To analyze, if celastrol can modulate the expression of various 
proteins involved in cell cycle progression, western blot analysis to detect 
levels of  cyclin D1, cyclin E, p21 and p27 was performed. Interestingly, it was 
found in our experimental results that celastrol downregulated the expression 
of several proteins involved in cell cycle progression namely cyclin D and 
cyclin E and upregulated proteins involved in cell cycle arrest namely p21 and 
























































Figure 3.2.3. Celastrol modulates the expression of proteins involved in 
cell cycle progression 
 
After treating RPMI-8266 cells with 1 µM celastrol for the indicated duration, 
western blot assay was done by preparing whole-cell extracts. 50 µg protein 
was loaded and run on SDS-PAGE and transferred to nitrocellulose membrane. 
The blots were probed for shown proteins using specific antibodies. As a 
loading control, β-actin was probed after stripping the same blots. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
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3.2.4. Celastrol downregulates the expression of proteins 
involved in myeloma angiogenesis/aggressiveness  
  
 Angiogenesis is another crucial hallmark characteristic feature of 
cancer cells, thereby increasing the aggressiveness of the cancer. [2, 3].  VEGF 
and c-Myc not only play an important role in myeloma angiogenesis but also in 
cell survival. To investigate if celastrol can modulate the expression of VEGF 
and c-Myc in MM cells, RPMI-8226 cells were treated with 1 µM celastrol for 
0, 3, 6, 12 and 24 hrs. Thereafter, western blot analysis was done using VEGF-
specific and c-Myc specific antibodies and β-actin as loading control. Our 
experimental results clearly show that celastrol at 1 µM concentration can 
downregulate the expression of both VEGF and c-Myc proteins in a time-











































Figure 3.2.4. Celastrol downregulates the expression of proteins involved 
in myeloma angiogenesis/aggressiveness 
 
After treating RPMI-8266 cells with 1 µM celastrol for the indicated duration, 
western blot assay was done by preparing whole-cell extracts. 50 µg protein 
was loaded and run on SDS-PAGE and transferred to nitrocellulose membrane. 
The blots were probed for shown proteins using specific antibodies. As a 
loading control, β-actin was probed after stripping the same blots. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
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3.2.5. Celastrol inhibits MM cell migration and invasion 
3.2.5.1. Celastrol inhibits CXCL12-induced MM cell migration 
 Migration of tumor cell is an important hallmark characteristic feature 
which is crucial to the processes of angiogenesis and to metastasis [2, 3].  We 
next analyzed if celastrol treatment can also abrogate migration potential of 
MM cells. To explore this possibility, a transwell migration assay was 
performed. In a transwell migration assay, tumor cells migrate through the 
transwell inserts with 8-um pores towards chemokine (CXCL12) containing 
outer chamber. To analyze whether, celastrol can inhibit this chemo-attractant 
stimulated migration of MM cells, U266 cells were treated with 1 µM celastrol 
and or 100 ng/ml CXCL12 for 12 hrs using transwell migration chambers. 
Migrated cells were stained with calcein-AM and the fluorescence was 
measured.  Using the standard curve, number of migrated cells was calculated 
from relative fluorescence of treated samples.  There was 40.9% inhibition in 
migration in the absence of CXCL12 (p < 0.05) and 28.37 % inhibition in 
migration in the presence of CXCL12 (p <0.05). Results of our experiments 
clearly show that celastrol can indeed inhibit CXCL12-induced myeloma cell 
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Figure 3.2.5.1. Celastrol inhibits CXCL12-induced MM cell migration 
 
U266 cells were seeded in triplicate and treated with 1 µM celastrol and or 100 
ng/ml CXCL12 for12 hrs using transwell migration chambers. Transwell 
migration towards CXCL12 was measured using calcein-AM staining and 
measuring the fluorescence intensity. Data are expressed as percentage of mean 
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3.2.5.2. Celastrol inhibits CXCL12-induced MM cell invasion 
  
 Invasive capability of tumor cells not only enables them to get into the 
circulatory system but also to spread to various parts of the body and finally to 
get distributed into various potential sites of metastasis [2, 3].  To analyze if 
celastrol can affect invasive potential of MM cells, a matrigel invasion assay 
was performed.  Matrigel chamber used in migration assay has inner and outer 
chambers. The base of the inner chamber is made up of polycarbonate 
membrane containing 8-µm pores. The outer chamber contains the chemo-
attractant (CXCL12) and the cells with greater migratory potential move 
towards the chemoattractive gradient through the pores. However, in invasion 
assay, the inner chamber is often coated with basement membrane proteins. 
Cancer cells with invasive potential move towards the chemoattractant gradient 
by invading the basement membrane.   
U266 cells were treated with 1 µM celastrol and or CXCL12 (100 ng/ml) for 
12 hrs in matrigel invasion chambers. Invaded myeloma cells were stained with 
calcein-AM and the fluorescence was measured.  Using the standard curve, 
number of invaded cells was calculated from relative fluorescence of treated 
samples.  There was 35.53% inhibition in the invasive potential in the absence 
of CXCL12 (p < 0.05) and 37.82 % reduction in the invasive potential in the 
presence of CXCL12 (p < 0.05). It was found that celastrol can significantly 
inhibit CXCL12-induced myeloma cell invasion in a statistically significant 
manner.  
The migration assay just measures the movement of cells across a 
polycarbonate membrane with pores, while the invasion assay analyzes 
movement across the polycarbonate membrane coated with matrigel. So in the 
invasion assay, the degradation of matrigel by the cells is also taken into 
consideration.  The cells with migration potential will not be counted in 
invasion assay if the cells do not have invasion potential. So even if the 
inhibition percentage for migration and invasion looks similar, the migration is 
not the only factor contributing to the invasive potential of tumor cells. 





Figure 3.2.5.2. Celastrol inhibits CXCL12-induced MM cell invasion 
 
U266 cells were seeded in triplicate and treated with 1 µM celastrol and or 100 
ng/ml CXCL12 for 12 hrs in matrigel invasion chambers. Matrigel invasion 
towards CXCL12 was measured by staining the cells with calcein-AM and 
measuring the fluorescence intensity. Data are expressed as percentage of mean 
cell invasion + SD relative to the control group.  
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3.2.5.3. Celastrol downregulates the expression of various proteins 
involved in MM cell migration and invasion  
 
 Several proteins have been reported to be involved in the orchestration 
of migration and invasion processes in tumor cells [432].  Among these, 
CXCR4 and MMP-9 are the two key molecules, which play crucial role in 
migration and invasion of various tumor cells, including MM [433, 434]. To 
analyze if celastrol-induced inhibition of migration and invasion also involves 
modulation of CXCR4 and MMP-9 expression, U266 cells were treated with 1 
µM celastrol for 0, 3, 6 and 12 hrs. Whole cell extract was prepared, separated 
using SDS-page and probed for CXCR4 and MMP-9 using specific antibodies. 
It was found that celastrol substantially downregulated CXCR4 and MMP-9 in 
a time-dependent manner. These results clearly establish the anti-
migratory/anti-invasive potential of celastrol through the suppression of 


































Figure  3.2.5.3. Celastrol downregulates the expression of proteins 
involved in MM cell migration and invasion  
 
U266 cells were treated with 1 µM celastrol for the indicated time points, 
western blot assay was done by preparing whole-cell extracts. 50 µg protein 
was loaded and run on SDS-PAGE and transferred to nitrocellulose membrane. 
The blots were probed for shown proteins using specific antibodies. As a 
loading control, β-actin was probed after stripping the same blots. The blot 
shown is representative of at least two independent experiments. Densitometric 
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3.3. Identification of celastrol as a novel inhibitor of 
STAT3 activation pathway 
3.3.1. U266 cells express constitutively active STAT3 
 As discussed in the introduction, constitutive activation of transcription 
factor, STAT3 plays an important role in progression of many cancers 
including MM. To analyze the expression and activation profile of STAT3 in 
human MM cell lines, various MM cells including U266, RPMI-8226, RPMI-
8226-Dox6, RPMI-8226-LR5, and RPMI-8226-BR were used and western blot 
analysis was done to detect the basal expression level of p-STAT3 (Tyr-705) 
and STAT3. (Hereafter in this thesis, p-STAT3 indicates tyrosine 
phosphorylation of STAT3 at 705 residue unless stated otherwise). Our 
experimental results clearly confirm that U266 cells express substantial levels 
of constitutively phosphorylated STAT3. On the contrary, although RPMI-
8226 cells express STAT3, these cell lines do not display phosphorylated levels 





















































Figure 3.3.1.  Basal level of p-STAT3 and STAT3 expression in MM cell 
lines 
 
Whole cell extracts of different human MM cells including U266, RPMI-8226, 
RPMI-8226-Dox6 cells, RPMI-8226-LR5, and RPMI-8226-BR were prepared. 
50µg protein was loaded and run on SDS-PAGE and transferred to 
nitrocellulose membrane. The blot was probed for p-STAT3 using anti-p-
STAT3 antibody. As a loading control, total STAT3 and β-actin proteins were 
probed after stripping the same blot. The blot shown is representative of at least 
two independent experiments. Densitometric analysis was done to determine 
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3.3.2. Treatment with cytokine IL-6 induces STAT3 
phosphorylation in RPMI-8226 cells and its resistant clones   
 
 As observed in the above indicated experimental results, RPMI-8226 
clones do not constitutively phosphorylate STAT3 under basal conditions. 
However, it has been reported that these cells can phosphorylate STAT3 upon 
induction with cytokines such as, IL-6. To confirm this, RPMI-8226 cells were 
treated with indicated concentrations of IL-6 for 15 mins and in another set of 
experiments RPMI-8226 cells were treated with 10 ng/ml of IL-6 for indicated 
time points. Thereafter, western blot assay was done to detect IL-6-induced 
phosphorylation of STAT3. Our experimental findings clearly show that IL-6 
can induce phosphorylation of STAT3 in a time and dose-dependent manner.  
 To analyze the phosphorylation profile of STAT3 in resistant clones of 
RPMI- 8226 cells western blot assay was performed. RPMI-8226 cells, RPMI-
8226-Dox6 cells (resistant to doxorubicin), RPMI 8226-LR5 cells (resistant to 
melphalan), and RPMI-8226-BR (resistant to bortezomib) were treated with 10 
ng/ml of IL-6 for 15 mins and western blot assay was performed using p-
STAT3 specific antibodies. Our experimental results clearly reveal that 
analogous to RPMI-8226 cells, the resistant clones of RPMI-8226 cells also 

























  126 
Figure 3.3.2. RPMI-8226 cells and its resistant clones phosphorylate 
STAT3 upon induction with IL-6 
 
A.  RPMI-8226 cells were treated with 10 ng/ml of IL-6 for 0, 5, 10, 15, 30 and 
60 mins and whole cell extract was prepared. 50 µg protein was loaded and run 
on SDS-PAGE and transferred to nitrocellulose membrane. The blot was 
probed for p-STAT3 using anti-p-STAT3 antibody. As a loading control, total 
STAT3 protein was probed using anti-STAT3 antibody after stripping the same 
blot. The blot shown is representative of at least two independent experiments. 
Densitometric analysis was done to determine fold change in intensity between 
treated and control groups. 
 
 
B. RPMI 8226 cells were treated with 0, 5, 10, 25 and 50 ng/ml of IL-6 for 15 
mins and whole cell extract was prepared. 50 µg protein was loaded and run on 
SDS-PAGE and transferred to nitrocellulose membrane. The blot was probed 
for p-STAT3 using anti-p-STAT3 antibody. As a loading control, total STAT3 
was probed using anti-STAT3 antibody after stripping the same blot. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
 
C. RPMI 8226 cells, RPMI 8226-Dox6 cells, RPMI 8226-LR5 cells, and 
RPMI-8226-BR were treated with 10 ng/ml of IL-6 for 15 mins and whole cell 
extracts were prepared. 50 µg protein was loaded and run on SDS-PAGE and 
transferred to nitrocellulose membrane. The blot was probed for p-STAT3 
using anti-p-STAT3 antibody. As a loading control, total STAT3 was probed 
using anti-STAT3 antibody after stripping the same blot. The blot shown is 
representative of at least two independent experiments. Densitometric analysis 
was done to determine fold change in intensity between treated and control 
groups. 
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3.3.3. Celastrol inhibits the constitutive phosphorylation of 
STAT3 in a dose- and time-dependent manner in MM cells 
  
 To analyze whether above observed anti-myeloma effects of celastrol 
are associated with inhibition of constitutive STAT3 activation, U266 cells 
were treated with 0, 0.5, 1, 2.5, 5 µM celastrol for 4 hrs and western blot 
analysis was done to detect the level of p-STAT3 and STAT3. Our 
experimental results demonstrate that celastrol can inhibit constitutive 
phosphorylation of STAT3 in a dose-dependent manner in U266 cells with 
minimal effect on total STAT3 levels. 
 For time kinetics study, U266 cells were treated with 2.5 µM celastrol 
for 0, 30, 60, 120 and 240 mins and western blot assay was done to detect p-
STAT3 and STAT3 expression levels. Total STAT3 served as loading control. 
Our experimental findings reveal that celastrol inhibits constitutive 
phosphorylation of STAT3 in a time-dependent manner with minimal effect on 




































Figure 3.3.3. Celastrol inhibits the constitutively activated STAT3 in a 
dose- and time-dependent manner 
 
A. U266 cells were treated with 0, 0.5, 1, 2.5 and 5 µM celastrol for 4 hrs and 
whole cell extract was prepared. 50 µg protein was loaded and run on SDS-
PAGE and transferred to nitrocellulose membrane. The blot was probed for p-
STAT3 using anti-p-STAT3 antibody. As a loading control, total STAT3 was 
probed using anti-STAT3 antibody after stripping the same blot. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
B. U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 
mins and whole cell extract was prepared.  50 µg protein was loaded and run 
on SDS-PAGE and transferred to nitrocellulose membrane. The blot was 
probed for p-STAT3 using anti-p-STAT3 antibody. As a loading control, total 
STAT3 was probed using anti-STAT3 antibody after stripping the same blot. 
The blot shown is representative of at least two independent experiments. 
Densitometric analysis was done to determine fold change in intensity between 
treated and control groups. 
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3.3.4. Celastrol inhibits IL-6-induced phosphorylation of 
STAT3 in a time-dependent manner 
 
 As demonstrated from the above experiments, RPMI-8266 cells display 
phosphorylated STAT3 expression upon stimulation with IL-6. Also, we have 
shown that celastrol can inhibit constitutive phosphorylation of STAT3 in 
U266 cells. On a similar note, we next aimed to determine whether celastrol 
has any potential effect on the IL-6-induced phosphorylation of STAT3 in MM 
cells. To analyze this possibility, RPMI-8266 cells were pretreated with 2.5 µM 
celastrol for 0, 30, 60, 120 and 240 mins and then the cells were induced with 
10 ng/ml of IL-6 for 15 mins. Western blot assay was done to detect p-STAT3 
levels.  It was found that celastrol indeed inhibited the IL-6-induced 
phosphorylation of STAT3 in a time-dependent manner with minimal effect on 




























Figure 3.3.4. Celastrol inhibits IL-6-induced phosphorylation of STAT3 in 
a time-dependent manner 
 
RPMI-8266 cells were pretreated with 2.5 µM celastrol for 0, 30, 60, 120 and 
240 mins and then the cells were induced by 10 ng/ml of IL-6 for 15 mins and 
whole cell extract was prepared. 50 µg protein was loaded and run on SDS-
PAGE and transferred to nitrocellulose membrane. The blot was probed for p-
STAT3 using anti-p-STAT3 antibody. As a loading control, total STAT3 was 
probed using anti-STAT3 antibody after stripping the same blot. The blot 
shown is representative of at least two independent experiments. Densitometric 
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3.3.5. Celastrol does not affect serine phosphorylation of STAT3 
in MM cells 
 
 In U266 cells, STAT3 can be phosphorylated at both tyrosine residue 
(Tyr-705) and serine (Ser 727) residues. From our above results, it was 
observed that celastrol can inhibit phosphorylation of STAT3 at tyrosine 705 
residue. We next proceeded to investigate whether celastrol can also modulate 
phosphorylation of STAT3 at serine 727 residue as well. To analyze this 
possibility, western blot assay was performed using p-STAT3 antibody specific 
to STAT3 serine 727 residue. Interestingly, it was found from our experimental 
results that celastrol did not substantially affect the phosphorylation of STAT3 











































Figure 3.3.5. Celastrol did not affect serine phosphorylation of STAT3 in 
MM cells 
 
U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 mins 
and whole cell extract was prepared. 50 µg protein was loaded and run on SDS-
PAGE and transferred to nitrocellulose membrane. The blot was probed for p-
STAT3 (Ser 727) using anti-p-STAT3 antibody. As a loading control, total 
STAT3 was probed using anti-STAT3 antibody after stripping the same blot. 
The blot shown is representative of at least two independent experiments. 
Densitometric analysis was done to determine fold change in intensity between 
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3.3.6. Celastrol does not affect the phosphorylation status of 
STAT5 in MM cells 
 
 STAT5 is another member of STAT family of transcription factors that 
has been implicated in pathogenesis of various cancers including MM. Since, it 
has been demonstrated from our above results, that celastrol can substantially 
inhibit phosphorylation of STAT3 in MM cells, we next determined whether 
celastrol also has an effect on the phosphorylation status of STAT5. MM cells 
were treated with various concentrations of celastrol for 4 hrs and western blot 
assay was performed to detect p-STAT5 levels. Total STAT5 protein served as 
loading control. Interestingly, it is found from our experimental results that 
celastrol did not affect the phosphorylation of STAT5 transcription factor in 
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Figure 3.3.6. Celastrol did not affect phosphorylation of STAT5 in MM 
cells 
 
A. U266 cells treated with 0, 0.5, 1, 2.5 and 5 µM celastrol for 4 hrs and whole 
cell extract was prepared. 50 µg protein was loaded and run on SDS-PAGE and 
transferred to nitrocellulose membrane. The blot was probed for p-STAT5 
using anti-p-STAT5 antibody. As a loading control, total STAT5 was probed 
using anti-STAT5 antibody after stripping the same blot. The blot shown is 
representative of at least two independent experiments. Densitometric analysis 
was done to determine fold change in intensity between treated and control 
groups. 
 
B. RPMI-8226 cells treated with 0, 0.5, 1, 2.5 and 5 µM celastrol for 4 hrs and  
whole cell extract was prepared. 50 µg protein was loaded and run on SDS-
PAGE and transferred to nitrocellulose membrane. The blot was probed for p-
STAT5 using anti-p-STAT5 antibody. As a loading control, total STAT5 was 
probed using anti-STAT5 antibody after stripping the same blot. The blot 
shown is representative of at least two independent experiments. Densitometric 
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3.3.7. Celastrol-induced inhibition of STAT3 is not majorly 
mediated via the induction of phosphatases in MM cells 
 
 STAT3 activation is tightly regulated by a family of phosphatases 
which can dephosphorylate STAT3 to inactivate it. Since celastrol inhibited the 
phosphorylation of STAT3 in MM cells, we next determined if celastrol- 
induced inhibition of STAT3 phosphorylation is mediated via phosphatases. To 
analyze this possibility, U266 cells were pretreated with indicated 
concentrations of broad spectrum phosphatase inhibitor pervanadate for 2 hrs. 
Thereafter, the cells were treated with 2.5 µM celastrol for 4 hrs and western 
blot assay was done to detect the levels of p-STAT3. Our experimental results 
indicated that treatment with pervanadate could not substantially reverse 
STAT3 inhibitory effects of celastrol in MM cells thereby, indicating that 
phosphatases are not majorly involved in the celastrol-induced inhibition of 
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Figure 3.3.7. Celastrol-induced inhibition of STAT3 is not mediated via 
the induction of phosphatases in MM cells 
 
A. U266 cells were pretreated with 10, 25 and 50 µM of pervanadate for 2 hrs. 
Thereafter, the cells were treated with 2.5 µM of celastrol for 4 hrs and whole 
cell extract was prepared. 50 µg protein was loaded and run on SDS-PAGE and 
transferred to nitrocellulose membrane. The blot was probed for p-STAT3 
using anti-p-STAT3 antibody. As a loading control, total STAT3 was probed 
using anti-STAT3 antibody after stripping the same blot. The blot shown is 
representative of at least two independent experiments. Densitometric analysis 




B. U266 cells were pretreated with 50 µM of pervanadate for 2 hrs. Thereafter, 
the cells were treated with 2.5 µM of celastrol for 4 hrs and whole cell extract 
was prepared. 50 µg protein was loaded and run on SDS-PAGE and transferred 
to nitrocellulose membrane. The blot was probed for p-STAT3 using anti-p-
STAT3 antibody. As a loading control, total STAT3 was probed using anti-
STAT3 antibody after stripping the same blot. The blot shown is representative 
of at least two independent experiments. Densitometric analysis was done to 
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3.3.8. Celastrol inhibits phosphorylation of Janus Kinase and 
Src kinase in MM cells 
  
 As discussed in the introduction section, non-receptor tyrosine kinases 
like Janus kinase and Src kinase play a critical role in the tyrosine 
phosphorylation of STAT3. As our earlier experimental findings showed that 
celastrol can substantially inhibit the tyrosine phosphorylation of STAT3 in 
MM cells, we next determined if celastrol does it so by modulating the 
activation of upstream kinases namely JAK2 and Src involved in STAT3 
activation cascade. To analyze this possibility, western blot assay was 
performed with p-JAK2 and p-Src specific antibodies. U266 cells were treated 
with 2.5 µM celastrol for 0, 30, 60, 120 and 240 mins and western blot assay 
was done to detect the levels of p-JAK2 and p-Src. interestingly, it was found 
that celastrol inhibited the phosphorylation of JAK2 and Src in a time-
dependent manner, with minimal effect on the level of non-phosphorylated 
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Figure 3.3.8. Celastrol inhibits phosphorylation of Janus Kinase and Src 
kinase in MM cells 
 
A. U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 
mins and whole cell extract was prepared. 80 µg protein was loaded and run on 
SDS-PAGE and transferred to nitrocellulose membrane. The blot was probed 
for p-JAK2 protein using anti-p-JAK2 antibody. As a loading control, total 
JAK2 was probed using anti-JAK2 antibody after stripping the same blot. As a 
loading control, β-actin was probed after stripping the same blots. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between the ratios of 
treated and control groups. 
 
B. U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 
mins and whole cell extract was prepared. 80 µg protein was loaded and run on 
SDS-PAGE and transferred to nitrocellulose membrane. The blot was probed 
for p-Src protein using anti-p-Src antibody. As a loading control, total Src was 
probed using anti-Src antibody after stripping the same blot. The blot shown is 
representative of at least two independent experiments. Densitometric analysis 
was done to determine fold change in intensity between the ratios of treated 























3.3.9. Celastrol inhibits the nuclear translocation of STAT3 in 
MM cells  
  
 As discussed previously in the introduction section, once STAT3 gets 
phosphorylated, STAT3 monomers form dimers and translocate to the nucleus 
where they bind to DNA to regulate transcriptional activation. Since, celastrol 
inhibited the phosphorylation of STAT3, we next analyzed using 
immunocytochemistry analysis whether celastrol can also affect nuclear 
translocation of STAT3 in MM cells. U266 cells were treated with 2.5 µM 
celastrol for 4 hrs. Immunocytochemistry was performed as described under 
Materials and Methods section using STAT3 specific antibodies. It is clearly 
evident from our experimental findings that in the control group, STAT3 is 
mainly found distributed in the nuclei, whereas in celastrol treated group, it 
was observed to be localized predominantly in the cytoplasm. The above data 
clearly indicates that celastrol can substantially inhibit the nuclear translocation 
of STAT3 in MM cells. 
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Figure 3.3.9. Celastrol inhibits the nuclear translocation of STAT3 in MM 
cells 
U266 cells were incubated with 2.5 µM celastrol for 4 hrs and then analyzed 
for the intracellular distribution of STAT3 by immunocytochemistry. Red 
fluorescence indicates STAT3, and blue fluorescence indicates nucleus 
(original magnification × 20). Representative image for each treatment group 
has been shown. The images were merged using Image J software. 
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3.3.10. Free thiol containing agents prevented the STAT3 
inhibitory effects of celastrol in MM cells 
  
 Since, thiol reactive moiety of celastrol is considered to be an important 
functional group for its previously reported anticancer effects, we next 
investigated, if the same moiety is also involved in the celastrol's ability to 
inhibit STAT3 phosphorylation in MM cells. To explore this possibility, we 
used various thiol containing agents including DTT (dithiothreitol) and GSH 
(glutathione reduced) which are known to react with the thiol reactive groups 
on proteins to form thioester coupled products. U266 cells were treated with 
2.5 µM celastrol and the 250 µM DTT and 2 mM GSH for 4 hrs. Non-thiol 
containing agents such as Vitamin C, (ascorbic acid, a non-thiol reducing 
agent) and GSSG (glutathione oxidized, a non-thiol analogue of GSH) were 
used as negative controls. Interestingly, we found that treatment with thiol 
containing agents at least partially reverse the celastrol-induced inhibition of 
STAT3 phosphorylation. Conversely, the non-thiol containing compounds did 
not do so, indicating that thiol reactive moiety of celastrol is at least partially 
responsible for its ability to inhibit STAT3 phosphorylation in MM cells.  
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Figure 3.3.10. Free thiol containing agents reversed the STAT3 inhibitory 
effects of celastrol in MM cells 
 
A. U266 cells were treated with 250 µM DTT and 2.5 µM celastrol for 4 hrs 
and whole cell extract was prepared. 50 µg protein was loaded and run on SDS-
PAGE and transferred to nitrocellulose membrane. The blot was probed for p-
STAT3 using anti-p-STAT3 antibody. As a loading control, total STAT3 was 
probed using anti-STAT3 antibody after stripping the same blot. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
 
B. U266 cells were treated with 0.1 mM Vit C and 2.5 µM celastrol for 4 hrs 
and whole cell extract was prepared. 50 µg protein was loaded and run on SDS-
PAGE and transferred to nitrocellulose membrane. The blot was probed for p-
STAT3 using anti-p-STAT3 antibody. As a loading control, total STAT3 was 
probed using anti-STAT3 antibody after stripping the same blot. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
 
C. U266 cells were treated with 2 mM GSH and 2.5 µM celastrol for 4 hrs and 
whole cell extract was prepared. 50 µg protein was loaded and run on SDS-
PAGE and transferred to nitrocellulose membrane. The blot was probed for p-
STAT3 using anti-p-STAT3 antibody. As a loading control, total STAT3 was 
probed using anti-STAT3 antibody after stripping the same blot. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
  147 
3.4. Effect of celastrol on NF-κB signaling cascade in 
MM cells 
3.4.1. Celastrol inhibits NF-κB activation pathway in MM cells 
3.4.1.1. Myeloma cells express constitutively activated p65 
 As discussed in the introduction section, constitutive NF-κB activation 
plays a major role in the pathogenesis of various cancers including MM. 
Human myeloma cells have been reported to express constitutively activated 
NF-κB. To confirm this finding, various MM cells including U226, RPMI-
8226 cells, RPMI-8226-Dox6 cells (resistant to doxorubicin), RPMI-8226-LR5 
cells (resistant to melphalan) and RPMI 8226-BR (resistant to bortezomib) cell 
lines were used. Nuclear extract was prepared as discussed under Materials and 
Methods section and western blot assay was done using p-p65 and p65 specific 
antibodies. Lamin B1 was used as a loading control. As shown in the figure, 
our experimental findings confirm the fact that the all the above analyzed 

















































Figure 3.4.1.1. Myeloma cells express constitutively activated p65 
 
Nuclear extracts of human MM cells including U226, RPMI-8226, RPMI 
8226-Dox6 cells, RPMI-8226-LR5, and RPMI-8226-BR cells were prepared. 
50µg protein was loaded and run on SDS-PAGE and transferred to 
nitrocellulose membrane. The blot was probed for p-p65 and p65 using specific 
antibodies. As a loading control, Lamin B was probed using anti-Lamin B 
antibody after stripping the same blot. The blot shown is representative of at 
least two independent experiments. Densitometric analysis was done to 
determine fold change in intensity between proteins obtained from U266 and 
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3.4.1.2. Celastrol inhibits the phosphorylation of IκBα and p65 proteins in 
MM cells 
 As discussed in the introduction section, NF-κB p65 subunits remain 
bound with IκBα protein in the cytoplasm. Upon activation by various stimuli, 
phosphorylation of IκBα protein leads to its ubiquitination and proteasome-
dependent degradation and thus released p65 enters the nucleus to bind with 
the DNA and transcriptionally modulate its target genes. Since celastrol has 
been reported to abrogate NF-κB activation in tumor cells, we next analyzed 
whether celastrol can also inhibit NF-κB p65 activation in MM cell lines. To 
analyze this aspect, a western blot assay was performed.  
 
 U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 
240 mins. Cytoplasmic and nuclear extracts were prepared as described under 
Materials and Methods. The extracts were separated on SDS-PAGE and 
subjected to western blot analysis. Cytoplasmic extract was used to detect p-
IκB levels. GAPDH was used as a loading control for cytoplasmic extract. It is 
evident from our experimental finding that celastrol inhibits the 
phosphorylation of IκB in a time-dependent manner. Nuclear extracts were 
used to detect p-p65. Lamin B1 was used as a loading control for nuclear 
extract. It is clearly evident from our experimental results that celastrol can 














































Figure 3.4.1.2. Celastrol inhibits the phosphorylation of IκB and p65 
proteins in MM cells 
 
A.  U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 
mins and cytoplasmic extract was prepared. 50 µg protein was loaded and run 
on SDS-PAGE and transferred to nitrocellulose membrane. The blot was 
probed for p-IκBα using anti-p-IκBα antibody. As a loading control, GAPDH 
was probed using anti-GAPDH antibody after stripping the same blot. The blot 
shown is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
B. U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 
mins and nuclear extract was prepared.  50 µg protein was loaded and run on 
SDS-PAGE and transferred to nitrocellulose membrane. The blot was probed 
for p-p65 using anti-p-p65 antibody. As a loading control, Lamin B was probed 
using anti-Lamin B antibody after stripping the same blot. The blot shown is 
representative of at least two independent experiments. Densitometric analysis 
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was done to determine fold change in intensity between treated and control 
groups. 
3.4.1.3. Celastrol inhibits the activation of upstream kinases involved 
in the NF-κB signaling cascade 
  
 As discussed previously in the introduction, IKK is involved in the 
phosphorylation of IκBα protein and thus regulate activation of p65 upon 
stimulation by external stimuli. Since, it is clearly evident from the above data 
that celastrol inhibits the phoshorylation of IκBα and p65 proteins, we next 
determined whether celastrol has any effect on the phosphorylation status and 
thus activation of IKK in MM cells. U266 cells were treated with 2.5 µM 
celastrol for 0, 30, 60, 120 and 240 mins and western blot assay was performed 
using p-IKK-α/β specific antibodies. IKK-α protein served as a loading control. 
It is clearly demonstrated from our experimental results that celastrol can 
indeed suppress the phosphorylation of IKK-α/β in a time-dependent manner in 
MM cells.  
 It has been reported that AKT may also act upstream of IKK-α/β to 
activate the NF-κB signaling pathway. Moreover, as discussed in the 
introduction section,  AKT has also been found to be involved in myeloma 
progression by mediating cell proliferation, anti-apoptosis and survival [435]. 
So, we next aimed to investigate, if celastrol can also modulate the activation 
of AKT in MM cells. To analyze this possibility, U266 cells were treated with 
2.5 µM celastrol for 0, 30, 60, 120 and 240 mins and western blot assay was 
performed using p-AKT specific antibodies, AKT serving as loading control. It 
is evident from our experimental results that celastrol can indeed suppress the 
phosphorylation of AKT in a time-dependent manner in MM cells without 


































Figure 3.4.1.3. Celastrol inhibits the activation of upstream kinsaes 
involved in the NF-κB signaling cascade  
 
A. U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 
mins and whole cell extract was prepared. 50 µg protein was loaded and run on 
SDS-PAGE and transferred to nitrocellulose membrane. The blot was probed 
for p-IKK-α/β using anti-p-IKK-α/β antibody. As a loading control, IKK-α was 
probed using anti-IKK-α antibody after stripping the same blot. The blot shown 
is representative of at least two independent experiments. Densitometric 
analysis was done to determine fold change in intensity between treated and 
control groups. 
 B. U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 
mins and whole cell extract was prepared. 50 µg protein was loaded and run on 
SDS-PAGE and transferred to nitrocellulose membrane. The blot was probed 
for p-AKT using anti-p-AKT antibody. As a loading control, AKT was probed 
using anti-AKT antibody after stripping the same blot. The blot shown is 
representative of at least two independent experiments. Densitometric analysis 
was done to determine fold change in intensity between treated and control 
groups. 
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3.4.1.4. Celastrol treatment abrogates the nuclear translocation of p65 in 
MM cells 
 As discussed previously in the introduction section, once IκBα protein 
gets phosphorylated and degraded by ubiquitin-proteasome system, p65 
subunit enter the nucleus to bind with the DNA and to cause transactivation. 
Since, we know that celastrol inhibits the phosphorylation of IκBα, we next 
determined using immunohistochemistry analysis whether celastrol can also 
cause failure of nuclear translocation of p65 subunit in MM cells. U266 cells 
were treated with 2.5 µM celastrol for 4 hrs. Immunocytochemistry was 
performed as discussed under the Materials and Methods section using p65 
specific antibodies. It is clearly evident from our experimental findings that in 
the control group, p65 is mainly found distributed in the nuclei, whereas in 
celastrol treated group, it was observed to be localized predominantly in the 
cytoplasm. The above data clearly indicates that celastrol suppresses the 





























Figure 3.4.1.4. Celastrol treatment abrogates the nuclear translocation of 
p65 in MM cells  
 
U266 cells were incubated with 2.5 µM celastrol for 4 hrs and then analyzed 
for the intracelullar distribution of p65 by immunocytochemistry. Red 
fluorescence indicates p65, and blue fluorescence indicates nucleus (original 
magnification × 20). Representative image for each group has been shown. The 
images were merged using Image J software. 
 
  155 
3.4.1.5. Celastrol inhibits DNA binding ability of NF-κB in MM cells 
 Since celastrol inhibited the nuclear translocation of p65 protein which 
is evident from our earlier experiments and any transcription factor has to bind 
with DNA to transactivate it, we aimed to analyze if celastrol also inhibited the 
DNA binding ability of p65 subunits. To analyze this, U266 and RPMI-8226 
cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 mins. 
Nuclear extract was prepared and DNA binding assay was performed using 
ELISA based NF-κB p65 DNA binding assay kit as described under Materials 
and Methods section. It is evident from our experimental findings that celastrol 
significantly inhibited the DNA binding ability of NF-κB in a time-dependent 
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Figure 3.4.1.5. Celastrol inhibits DNA binding ability of NF-κB in MM 
cells 
 
A. U266 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 240 
mins. Nuclear extracts were prepared, and 20 µg of the nuclear extract protein 
was used for ELISA based DNA binding assay as described under Materials 
and Methods. Data are presented as relative DNA binding as compared to the 
control + SD. *Significant difference when compared to the control group. 
 
 
B. RPMI-8226 cells were treated with 2.5 µM celastrol for 0, 30, 60, 120 and 
240 mins. Nuclear extracts were prepared, and 20 µg of the nuclear extract 
protein was used for ELISA based DNA binding assay as described under 
Materials and Methods. Data are presented as relative DNA binding as 
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3.4.2. Celastrol augments the NF-κB inhibitory effects of 
bortezomib in MM cells 
  
 Bortezomib, a well characterized pharmacological proteasome inhibitor 
can also inhibit NF-κB pathway by increasing the availability of IκBα to bind 
with p65 subunits [435]. Since bortezomib is a standard of care for MM 
patients and reported previously to inhibit NF-κB activation in MM cells, we 
next determined whether sub-optimal concentrations of celastrol can enhance 
NF-κB inhibiting ability of bortezomib. To explore this possibility, U266 cells 
were treated with 0.5 µM celastrol and or 10 nM bortezomib for 4 hrs. Nuclear 
extract was prepared and DNA binding assay was performed using ELISA 
based NF-κB p65 DNA binding assay kit as described under Materials and 
Methods section. While the sub-optimal concentrations of celastrol and 
bortezomib alone did not affect the DNA binding ability of NF-κB, the 
combination of the two drugs significantly decreased NF-κB activity to 0.7 fold 
(*P<0.05). Thus, it is evident from our experimental findings that celastrol can 
indeed potentiate the NF-κB inhibitory effect of bortezomib in a statistically 















Figure 3.4.2.  Celastrol augments the NF-κB inhibitory effects of 
bortezomib in MM cells 
 
U266 cells were treated with 0.5 µM celastrol and or 10 nM bortezomib for 4 
hrs. Nuclear extracts were prepared and 20 µg of the nuclear extract protein 
was used for ELISA based DNA binding assay as described under Materials 
and Methods. Data are represented as relative DNA binding as compared to the 
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3.4.3. Celastrol enhances apoptosis induced by novel anti-
myeloma agents in MM cells 
  
 As discussed in the introduction section, thalidomide (an inhibitor of 
TNF-α expression), and bortezomib (a proteasome inhibitor) have been 
approved by FDA for the treatment of MM patients. Also, as evident from our 
previous experimental results celastrol can indeed potentiate the NF-κB 
inhibitory effects of bortezomib in MM cells, though reported NF-κB 
inhibition by bortezomib is considered to be only one of its proposed 
mechanism(s) of action. We next investigated whether celastrol when 
employed at suboptimal concentration can potentiate the apoptotic effect of 
thalidomide and bortezomib in MM cells. To explore this possibility, U266 
cells were treated with 0.5 µM celastrol together with different concentrations 
of either thalidomide or bortezomib; and then examined for apoptosis using 
live and dead assays, annexin V staining, and cell cycle analysis.  The results 
of live and dead (figure A), annexin V (figure B) and cell cycle analysis (figure 
C) clearly indicate that celastrol can substantially potentiate the apoptotic 
effects of both thalidomide and bortezomib in MM cells. Based on the cell 
cycle analysis isobologram-illustrated results, we found that 0.5 µM celastrol 
synergistically induced the accumulation of MM cells in sub-G1 phase when 
used in combination with 10 µg/ml thalidomide or 10 nM bortezomib for 24 











































































































Figure 3.4.3. Celastrol augments apoptosis induced by anti-myeloma 
agents in MM cells 
 
A. U266 cells were treated with 0.5 µM celastrol, and 10 µg/ml thalidomide or 
10 nM bortezomib alone or in combination for 24 hrs at 37°C.  Cells were 
stained with a Live/Dead assay reagent for 30 mins and then analyzed under a 
fluorescence microscope as described under Materials and Methods.  A 
representative image for each group is shown.  
 
B. No of apoptotic cells in three microscopic fields for each group in the above 
experiment was counted. Data is represented as mean + SD (n=3).  p value 
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C. U266 cells were treated with 0.5 µM celastrol, 10 µg/ml and 20 µg/ml 
thalidomide or 10 nM, and 20nM bortezomib alone or in combination for 
24 hrs at 37°C after which the cells were washed, fixed, stained with PI, and 
analyzed for DNA content by flow cytometry. The representative histograms 
are shown only for thalidomide (10 µg/ml), bortezomib (10 nM) alone or in 
combination with celastrol (0.5 µM). The percentage of sub-G1 population 
cells were taken for combination index (CI) calculation.  
 
D. U266 cells were treated with 0.5 µM celastrol, and 10 µg/ml thalidomide 
(left panel) or 10 nM bortezomib (right panel) alone or in combination for 
24 hrs at 37°C. Cells were incubated with anti-annexin V antibody conjugated 
with FITC and then analyzed with a flow cytometer. Data are represented as 
percentage of apoptotic cells in each group.  
 
E. Assessment on the type of combination relationship was done using the 
method developed by Chou-Talalay multiple drug effect equation. The degree 
of synergy was assessed based on CI values, where CI values of >1.0 implies 
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3.5. Celastrol potentiates the anti-myeloma effects of 
bortezomib in a xenograft MM mouse model  
3.5.1. Celastrol enhances the inhibition of tumor growth 
induced by bortezomib in vivo 
  
 To determine whether celastrol enhances the antitumor effects of 
bortezomib against MM, we developed a human MM xenograft in nude mice 
using U266 cells.  A week after implantation, the animals were randomized 
into four treatment groups based on tumor volume. Treatment was started 1 
week after tumor cell implantation and was continued up to 20 days, in 
accordance with the experimental protocol under Materials and Methods. 
Tumor diameters and body weight were measured on every third day.  Animals 
were killed 32 days after tumor cell injection and 25 days after the treatment 
start date, and the tumors were excised. We found that the tumor volume 
increased rapidly in the control group compared with the other treatment 
groups. The tumor volume in the celastrol alone group was significantly lower 
than that in the control group (p< 0.001, vehicle versus celastrol; Fig.A). When 
we analyzed if celastrol has augmented the tumor inhibition caused by 
bortezomib, we found that celastrol significantly potentiated the tumor 
inhibition induced by bortezomib (p < 0.05, bortezomib versus celastrol + 
bortezomib; Fig.A). When examined for tumor volume on different days, we 
found that tumor volume started to decrease in all the three treatment groups 
when compared to control group from day 9 onwards and the trend became 






























Figure 3.5.1. Celastrol enhances the inhibition of tumor growth induced by 
bortezomib in vivo 
 
A.  On the last day of the experimental protocol, tumor diameters were 
measured and tumor volume was calculated using the formula [L x W2]/2, 
where W and L are the width. Data is represented as mean + SD (n=5).   
 
B. Tumor diameters were measured on every third day and tumor volume was 
calculated using the formula [L x W2]/2, where W and L are the width. Data 
are represented as mean + SD (n=5). 
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3.5.2. Celastrol exhibits no obvious side effects in vivo  
 
 To determine if celastrol caused any serious side effects in vivo, mice 
were closely observed throughout the treatment duration. Interestingly, we did 
not notice any obvious side effects throughout our experiment. Body weight 
was measured on every third day as a parameter of side effects and the results 
are shown in the figure below. As can be inferred from our findings, celastrol 
did not cause any significant weight loss in mice upon administration, thereby 












































Figure 3.5.2. Celastrol exhibits no obvious side effects in vivo 
 
Body weight was measured on every third day during the experimental 




  170 
3.5.3. Celastrol downregulates the expression of p-STAT3 and 
p65 in vivo in a MM xenograft mouse model 
  
 It is clearly evident from our in vitro experiments that celastrol inhibits 
STAT3 and p65 activation in MM cells. Since celastrol alone and in 
combination with bortezomib significantly decreased the tumor volume in MM 
xenograft mouse model, we next determined whether celastrol alone and in 
combination with bortezomib can modulate STAT3 and p65 activation under in 
vivo conditions as well. To explore this possibility, immunohistochemistry 
assay was performed using tumor tissues from all four treatment groups 
excised as described under Materials and Methods. As evident from our 
experimental results shown below, celastrol alone and also in combination with 
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Figure 3.5.3. Celastrol donwregulates p-STAT3 and p65 expression in vivo 
in a MM xenograft mouse model 
 
A. Tumor tissues obtained were subjected to immunohistochemistry using p-
STAT3 specific antibodies as described under Materials and Methods section. 
Images were taken using an Olympus BX51 microscope (magnification ×40). 
Representative image for each group is shown above. Positive cells (brown) 
were quantitated using the Image-Pro plus 6.0 software package (Media 
Cybernetics, Inc.). 
 
B. Tumor tissue obtained was subjected to immunohistochemistry using p65 
specific antibodies as described under Materials and Methods section. Images 
were taken using an Olympus BX51 microscope (magnification ×40). 
Representative image for each group is shown above. Positive cells (brown) 
were quantitated using the Image-Pro plus 6.0 software package (Media 
Cybernetics, Inc.). 
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3.5.4. Celastrol modulates the expression of various proteins 
involved in myeloma progression in vivo in a MM xenograft 
mouse model 
  
 It was observed in our in vitro experiments that celastrol can 
downregulate the expression of various proteins involved in MM survival, 
metastasis and angiogenesis. Since celastrol alone and in combination with 
bortezomib decreased significantly decreased the tumor volume in MM 
xenograft mouse model, we next determined whether celastrol alone and in 
combination with bortezomib can affect Bcl-2 and VEGF protein expression in 
vivo. To explore this possibility, immunohistochemistry assay was performed 
using tumor tissues excised from all four treatment groups under Materials and 
Methods. As evidenced from our experimental results, celastrol alone and also 
in combination with bortezomib significantly downregulated the expression of 
Bcl-2 and VEGF expression in tumor tissues. This data clearly indicates the 
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Figure 3.5.4. Celastrol modulates the expression of proteins involved in 
myeloma progression in vivo in a MM xenograft mouse model 
 
 
A. Tumor tissues obtained were subjected to immunohistochemistry using Bcl-
2 specific antibody as described under Materials and Methods section. Images 
were taken using an Olympus BX51 microscope (magnification ×40). 
Representative image for each group is shown above. Positive cells (brown) 
were quantitated using the Image-Pro plus 6.0 software package (Media 
Cybernetics, Inc.). 
 
B. Tumor tissues obtained were subjected to immunohistochemistry using 
VEGF specific antibody as described under Materials and Methods section. 
Images were taken using an Olympus BX51 microscope (magnification ×40). 
Representative image for each group is shown above. Positive cells (brown) 
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3.5.5. Celastrol alters the cytokine profile in vivo in a MM 
xenograft mouse model 
 
 As discussed in the introduction, pro-inflammatory cytokines such as, 
IL-6 and TNF-α play a crucial role in myeloma progression by not only acting 
on myeloma cells but also on various cells present in the bone marrow 
microenvironment. Novel therapies including thalidomide modulate myeloma 
progression at least partially by altering the cytokine profile. Since, so far our 
experimental findings clearly suggest the potential of celastrol as a promising 
anti-myeloma agent, we next sought to determine if celastrol has an effect on 
the pro-inflammatory cytokine profile both as a single agent and also in 
combination with bortezomib. Blood was collected as the mice were sacrificed 
and sera were separated.  ELISA assay was done to measure the serum IL-6 
and TNF-α level as discussed under Materials and Methods. As shown from 
our experimental findings below, celastrol alone and also in combination with 
bortezomib decreased the serum IL-6 and TNF-α level significantly, which 


































A. TNF-α level was measured using the ELISA kit as described under 
Materials and Methods section. Data is presented as mean + SD. * Significant 
difference as compared to the control, p<0.05. 
 
B. IL-6 level was measured using the ELISA kit as described under Materials 
and Methods section. Data is presented as mean + SD. * Significant difference 
as compared to the control, p<0.05. 
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4. DISCUSSION 
 
4.1. Anti-myeloma effects of celastrol in vitro  
 
 MM is a B cell malignancy characterised by abnormal proliferation of 
plasma cells with low proliferative index. It is often preceded by the two 
premalignant conditions MGUS and SMM [4].  MM is common among elderly 
male [7]. MM is the second most common hematological malignancy next only 
to non-Hodgkin’s lymphoma, contributing 1% of all neoplasias [9]. According 
to Singapore General Hospital website as dated on October 2011, about 80 new 
patients with MM are diagnosed every year. 
 Treatment of MM involves bone marrow transplantation for those who 
are eligible and those who are not eligible for the bone marrow transplantation 
are treated with chemotherapy [306]. The common front line agents used are 
alkylating agent melphalan, corticosteroid dexamethasone, immunomodulatory 
agent thalidomide and second generation immunomodulatory agent 
lenalidomide and the proteasome inhibitor bortezomib [307]. The relapsed and 
refractory MM are treated with bortezomib-thalidomide-dexamethasone 
combination, lenalidomide-bendamustine-dexamethasone combination, 
carfilzomib and pamolidomide [308, 309]. However, there remains an urgent 
need to develop novel anti-myeloma agents because despite the availability of 
various targeted therapies, MM still remains an incurable disease. Most of the 
patients relapse after initial response or develop chemoresistance. Moreover, 
most of the available drugs have severe dose-limiting toxicity [310]. 
Consequently, there are many drugs that are currently being investigated in 
preclinical and clinical studies to improve the disease outcome [307, 310]. 
  Plant derived medicinal compounds are good source of 
alternative therapy. Interest in medicinal plants is gaining momentum in the 
last few decades. Various native medicinal systems like Ayurveda (India) and 
Chinese natural medicine are based on plant derived medicinal products [436]. 
The extract of the medicinal plant T. wilfordii (Thunder of God Vine) has been 
used in Chinese natural medicine for inflammatory conditions like arthritis, 
fever and edema. Various in vitro and in vivo preclinical and clinical studies 
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prove the effectiveness of this plant extract in various inflammatory conditions 
[322]. Celastrol is one of the active compounds found in this plant extract that 
has attracted great interest among the scientific community over the last decade 
because of its diverse anti-inflammatory and anti-cancer properties [326]. 
 
4.1.1. Celastrol induces cell death in MM cells  
 
 Resisting cell death is considered to be one of important hallmark 
capabilities of cancer cells. Most of the anti-cancer drugs eventually inhibit 
tumor growth by inducing cell cycle arrest and or apoptosis  [2, 3]. We 
observed that celastrol decreased the viability of a wide variety of MM cells, 
including ones resistant to doxorubicin, melphalan and bortezomib. Celastrol 
not only induced apoptosis in U266 and RPMI-8226 cells but also in 
bortezomib resistant clone of RPMI-8226. Celastrol-induced cell death in 
RPMI-8226 cell line resistant to bortezomib that was comparable to its 
observed effect on drug-sensitive counterpart. Celastrol increased the number 
of apoptotic cells as demonstrated by annexin V staining, TUNEL, live-dead 
assay, and DNA fragmentation assays. In accordance with the previous studies 
which investigated the apoptotic effect of celastrol in numerous cancers, our 
study shows that celastrol induced cell death unequivocally in MM cells [326]. 
Concurrent with our study [437], another study using MM cell model also 
reported that celastrol indeed induces programmed cell death in MM cells 
[364]. Interestingly, we found that celastrol induced relatively less death in 
mouse embryonic fibroblasts and human breast epithelial cell line MCF-10A 
which were used as a representative of non-tumor cells, thereby indicating that 
it can preferentially targets cancer cells. 
 Exposure to ionizing radiation, conventional chemotherapy, TRAIL 
ligand and thalidomide and its other immunomodulatory agents induce 
apoptosis by caspase-8-mediated extrinsic apoptotic pathway, while 
dexamethasone induces apoptosis by caspase-9-mediated intrinsic apoptotic 
pathway. However, proteasome inhibitor bortezomib can induce apoptosis by 
both intrinsic and extrinsic pathways [437]. Along this line, we further 
investigated the apoptotic pathways involved in celastrol-induced apoptosis.  In 
accordance with other studies done in breast cancer and lung cancer cell lines 
  180 
[394, 395], celastrol-induced apoptosis was found to involve both caspase-8- 
mediated extrinsic apoptotic pathway and caspase-9-mediated intrinsic 
apoptotic pathway.  
 
4.1.2. Celastrol activates JNK MAP kinase to induce apoptosis 
in MM cells 
 
 JNK is one of the MAPKs activated in cells in response to cytokines 
and exposure to environmental stresses resulting in cellular proliferation, 
differentiation and apoptosis [429]. Various environmental stresses including 
ionising radiation and chemotherapeutic agents induce JNK. c-Jun and c-Fos 
are proteins which are activated after being phosphorylated by JNK. These two 
proteins form dimers with each other to activate AP-1 transcription factor 
which than mediates the downstream effects of JNK.   Whether activated JNK 
induces cellular proliferation or induces apoptosis is context dependent.  When 
inducing apoptosis JNK can induce apoptosis through both caspase-8- 
dependent extrinsic pathway or caspase-9-dependent intrinsic pathway [430]. 
JNK activation is also needed for apoptosis induced by chemotherapeutic 
agents [438]. Since celastrol acted as a cytotoxic agent in MM cells, we further 
investigated if celastrol-induced apoptosis is also mediated through JNK 
activation. We found that celastrol induced JNK phosphorylation as early as 15 
minutes after treatment without altering the levels of JNK protein expression. 
Further, we investigated if celastrol-induced activation of JNK is involved in 
celastrol- induced apoptosis. It was found that suppression of JNK activation 
by the specific JNK inhibitor SP600125 partially blocked celastrol- induced 
apoptosis, indicating that activation of JNK is at least partially necessary for 
celastrol-induced apoptosis. In melanoma cells, celastrol was found to activate 
JNK and increase the transcriptional activity of c-Jun to inhibit the melanoma 
cell proliferation. Moreover, in the presence of JNK inhibitor celastrol failed to 
inhibit the melanoma cell growth [378].  However, we did not investigate the 
downstream effects of celastrol on c-jun, c-Fos expression in our study. 
 Numerous studies have shown that celastrol induces ROS [389, 390, 392, 401]. 
JNK has been found to be an important mediator of ROS-induced apoptosis 
[439]. Along this line, while our manuscript was under review [440], it was 
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reported by another group that celastrol induced ROS and celastrol-induced 
ROS lead to activation of JNK which in turn induced apoptosis [392]. However, 
whether celastrol-induced activation of JNK in MM cells is mediated by 
induction of ROS in MM cells is yet to be investigated.  
 
4.1.3. Celastrol alters the balance between pro-apoptotic and 
anti-apoptotic proteins to favour apoptosis  
  
 Evasion of apoptosis or development of acquired resistance to apoptosis 
is a hallmark capability of cancer cells which is almost universal to all human 
cancers [2]. U226 cells display upregulated expression of anti-apoptotic 
proteins which leads to their inherent resistance to apoptosis [222]. 
Interestingly, celastrol downregulated the expression of Bcl-2 family of anti-
apoptotic proteins including Bcl-2, Bcl-xL and Mcl-1 and IAP (Inhibitors of 
apoptotic protein), including survivin and XIAP in both U266 and RPMI-8226 
cell lines. Moreover, celastrol was found to upregulate the expression of pro-
apoptotic members Bcl-2 family of proteins including Bax and Bak. This 
alteration in anti-apoptotic and pro-apoptotic proteins might lead to celastrol-
induced apoptosis. These observations are in agreement with a recent report in 
which celastrol was shown to downregulate the expression of Bcl-2 and induce 
Bax expression in breast cancer cell lines [394]. 
 
4.1.4. Celastrol modulates the expression of proteins involved in 
cell cycle progression 
 
 Insensitivity to anti-growth signal hallmark capability of cancer cells 
enable these to evade the anti-growth signals present in the environment. Most 
of the anti-growth signals control the regulation of cell cycle in order to 
prevent the cells from multiplying in an uncontrolled manner [2]. Cyclin D1 
and cyclin E are required for the progression of cells from the G1 phase to the 
S-phase of the cell cycle [441]. Cyclin D is dysregulated in almost all types of 
MM and is considered to be one of the early initiating event in MM 
pathogenesis [19]. Interestingly, in our study celastrol suppressed the 
expression of both cyclin D1 and cyclin E in a time-dependent manner in 
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RPMI-8226 cells. The expression of the cyclin-dependent kinase inhibitors p21 
WAF1/CIP1
 and p27, which block cell cycle progression by inhibiting the activity 
of cyclin/Cdk2 complexes, was also upregulated by celastrol. These 
observations are in agreement with the studies  done with human monocytic 
leukemia cells and glioma cells in which celastrol was observed to 
downregulate cyclin D1 expression to cause G0/G1 arrest and upregulate the 
expression of cell cycle progression inhibitors p21 and p27 to cause G2/M 
arrest respectively [338, 346].  
 
4.1.5. Celastrol modulates the expression of proteins involved 
MM angiogenesis/aggressiveness  
 
 Angiogenesis hallmark capability of cancer cells enable the tumors to 
outgrow the 100 µm diameter limit, within which cells survive by diffusion of 
oxygen from nearby capillaries. This process is initiated by angiogenic switch 
in which the balance between proangiogenic and antiangiogenic factors is 
tipped towards angiogenesis [2]. In MM, there is dysregulated bone marrow 
angiogenesis [107, 108]. Moreover, increase in bone marrow angiogenesis is 
correlated with disease progression [111, 112]  and disease activity [109, 110]. 
Dysregulation of c-Myc is considered to play an important role both in 
myeloma initiation and progression [36, 37]. It is considered that dysregulated 
c-Myc exerts its role in myeloma pathogenesis by inducing bone marrow 
angiogenesis [442]. VEGF is secreted both by MM and bone marrow stromal 
cells which in turn stimulate IL-6 secretion by stromal cells, thus stimulating 
paracrine growth of MM cells. c-Myc mediates anigogenesis by inducing 
autocrine secretion of VEGF by MM cells [443]. So, we sought to assess the 
anti-angiogenic potential of celastrol if any, by its effect on the expression of 
mediators of MM angiogenesis namely c-Myc and VEGF in RPMI-8226 cells. 
Interestingly, we found that celastrol downregulated the expression of these 
two proteins in a time-dependent manner, indicating its potential role in 
inhibiting myeloma angiogenesis, thereby MM progression.  
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4.1.6. Celastrol inhibits MM cell migration, invasion and 
modulates the expression of proteins involved in these cellular 
processes 
 
 CXCL12/CXCR4 axis mediates myeloma cell migration and thus, 
homing to the bone marrow [178]. In 5TMM model, inhibition of CXCR4 
results in 20% reduction in tumor load [179]. Moreover, CXCR4 expression is 
correlative with disease progression [187].  Along this line, we sought to 
investigate whether celastrol has any effect on MM cell migration. We found 
using transwell migration chamber assay that celastrol can inhibit CXCL12- 
induced migration of myeloma cell. CXC12/CXCR4 axis is also involved in 
invasion of myeloma cell which is mediated by MMP-9 protein [179]. So, we 
also investigated if celastrol can inhibit myeloma cell invasion using matrigel 
invasion assay. We further observed that celastrol inhibits CXCL12-induced 
myeloma cell invasion. Interestingly, celastrol-induced inhibition of myeloma 
cell migration and invasion are associated with time-dependent downregulation 
of both CXCR4 and MMP-9 expression.   
 
4.2. Celastrol suppresses STAT3 signaling casacde in 
MM cells 
 Resistant to apoptosis hallmark capability is crucial in the pathogenesis 
of myeloma, especially since it is a cancer with low proliferative index [444]. 
IL-6/JAK/STAT3 pathway is considered to enable this hallmark capability to 
myeloma cells by upregulating anti-apoptotic proteins [219, 222]. Since, 
celastrol downregulated anti-apoptotic proteins and induced myeloma cell 
apoptosis, we next aimed to investigate if celastrol modulated IL-
6/JAK/STAT3 pathway. We found out celastrol inhibited both constitutive and 
IL-6 inducible tyrosine phosphorylation of STAT3 and nuclear translocation of 
STAT3. Involvement of negative regulators of STAT3, especially SHP-1 
protein tyrosine phosphatases has also been implicated in the constitutive 
activation of STAT3 [50]. Many natural agents have been found to modulate 
IL-6/JAK/STAT3 pathways by upregulating SHP-1 [235, 247, 445, 446]. On a 
similar note, we aimed to explore the involvement of phosphatases in celastrol-
induced inhibition of tyrosine phosphorylation of STAT3, if any. Our 
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experimental findings proved that celastrol does not involve protein tyrosine 
phosphatases in its ability to inhibit tyrosine phosphorylation of STAT3.  
 
 STAT3 is phoshporylated at both tyrosine and serine residues [447]. 
Tyrosine phosphorylation of STAT3 is executed by receptor tyrosine kinases 
and non-receptor tyrosine kinases like JAK and Src kinase, where as serine 
phosporylation of STAT3 is carried out by MAPK kinases including JNK and 
ERK. Most of the growth factors regulate serine phosphorylation of STAT3 by 
ERK signaling, though IL-6 is also reported to serine phosphorylate STAT3 via 
an ERK independent mechanism. JNK is involved in stress induced serine 
phosphorylation of STAT3 [448]. There are conflicting reports about the role 
of serine phosphorylated STAT3 in the transcriptional activity of STAT3. Wen 
et al., had previously indicated that either the presence or absence of serine 
phosphorylation does not affect the DNA binding ability of STAT3 [449].  
However, earlier reports suggest that serine phosphorylation is essential for 
maximum transcriptional activity of STAT3 [450]. Chung et al., have 
previously reported that serine phosphorylation of STAT3 can negatively 
regulate its tyrosine phosphorylation, thus abrogating the DNA binding ability 
of STAT3 [448]. The role of serine phosphorylation in the oncogenic potential 
of STAT3 is established by employing diethylnitrosamine-induced mouse 
hepatocarcinogenesis model. So, we aimed to investigate if celastrol also 
inhibited the serine phosphorylation of STAT3 using serine phosphorylation 
specific antibodies. We found out that celastrol specifically inhibited tyrosine 
phosphorylation of STAT3 with minimal effect on serine phosphorylation. 
JNK is also known to negatively regulate tyrosine phosphorylation of STAT3 
through both serine phosphorylation-dependent and serine phosphorylation-
independent mechanisms.  
 
 STAT5, an another member of STAT family of transcription factors, 
has also been implicated in myeloma pathogenesis and is mainly activated by 
IGF [451]. So, we aimed to investigate if celastrol can also modulate STAT5 
activation in MM cells. Interestingly, we found that celastrol does not have any 
effect on phosphorylation of STAT5. These findings indicate that celastrol is a 
specific blocker of STAT3 tyrosine phosphorylation. So, we next proceeded to 
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investigate whether celastrol affects any upstream kinases involved in the 
tyrosine phosphorylation of STAT3. We found out that celastrol can inhibit 
activation of both JAK2 and Src kinases involved in the tyrosine 
phosphorylation of STAT3. Our group has also confirmed the STAT3 
inhibiting ability of celastrol in HCC cell lines and in human HCC xenograft 
mouse model. In HCC cell lines, celastrol not only inhibited constitutive and 
IL-6-induced phosphorylation of STAT3 but also blocked its transcriptional 
activity as evidenced from the luciferase reporter assay [452].  
 Quinone methide moiety of celastrol is considered to be an important 
functional group involved in its observed pharmacological activities. Quinone 
methide functional group is also known to react with thiols [346, 352]. So, we 
sought to investigate if celastrol-induced inhibition of tyrosine phosphorylation 
of STAT3 is mediated through the quinone methide moiety, using various 
cellular and non-cellular thiols. Our experimental findings clearly indicate that 
thiol reactive functionality of celastrol is necessary for its observed inhibitory 
effects on STAT3 activation.  
 In sum, we report for the first time that celastrol could suppress both 
constitutive and inducible STAT3 activation in MM cells, concomitant with 
inhibition of upstream Src and JAK2 kinases.   Previous studies have indicated 
that JAK2 and Src kinases cooperate to mediate constitutive activation of 
STAT3 [453, 454].  Our observations also suggest that celastrol may block 
cooperation of Src and JAK2 involved in tyrosine phosphorylation of STAT3. 
This study further analyzes and proves that thiol reactive functionality of 
celastrol is necessary for its observed inhibitory effects on STAT3 tyrosine 
phosphorylation.  Overall, it was found that this triterpene could suppress both 
constitutive and inducible STAT3 activation leading to the other downstream 
effects as confirmed through the corroboration between the experimental and 
predictive data.    
4.3. Celastrol inhibits NF-κB activation pathway in MM 
cells  
 NF-κB plays myriad role in myeloma pathogenesis. NF-κB enables 
sustained proliferation of myeloma cells by stimulating bone marrow stromal 
cells to secrete IL-6, thereby promoting paracrine growth and proliferation of 
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MM cells [77]. NF-κB confers MM cells resistance to apoptosis by 
upregulating members of IAP including XIAP and survivin [455]. NF-κB also 
aids in evasion of growth suppressors by upregulating cyclin D1 and there by 
leading to cell cycle progression [435]. Moreover, constitutive activation of 
NF-κB is proved to be essential for myeloma survival [298]. NF-κB is 
considered to be involved in bone marrow angiogenesis [456, 457]. NF-κB has 
also been found to be involved in myeloma cell migration and invasion [458].  
 In agreement with previous reports [286, 293, 459], we found that MM 
cell lines expressed constitutively activated NF-κB. Since, in our study 
celastrol downregulated the expression of IAP members of anti-apoptotic 
proteins including survivin and XIAP, induced apoptosis, downregulated the 
expression of proteins involved in angiogenesis, inhibited myeloma cell 
migration/invasion and downregulated the expression of proteins involved in 
myeloma cell migration and invasion, we hypothesized that celastrol may 
affect the master transcription factor NF-κB, that plays a key role in 
proliferation, survival, invasion and angiogenesis in MM cells. Our 
experimental findings indeed show that celastrol inhibits phosphorylation of 
IκB, thereby preventing nuclear translocation of NF-κB p65 subunit and NF-
κB DNA binding activity in a time-dependent manner. These observations are 
in agreement with an another study published [364] concurrent with our study 
[363] showing that celastrol can indeed inhibit nuclear translocation of p65 
subunit in MM cells. Though, total NF-κB activity is the combination of 
canonical and alternative pathway activity [295] and both the pathways are 
dysregulated in MM [291], but interestingly dysregulated alternative pathway 
can also transduce signals through IKK-β in MM, thereby indicating the 
importance of targeting IKK-β activation [276]. Along this line, we sought to 
investigate if celastrol can also target phosphorylation of IKK-β, an upstream 
kinase involved in NF-κB activation. Interestingly, our study showed that 
celastrol inhibited IKK-α/β activation in time-dependent manner.  Although 
there are previous studies which indicate celastrol inhibits IKK-α/β, those 
studies analyzed the effect of celastrol on either TNF-α-induced IKK-α/β in 
human myeloid KBM-5 cells [372] or IL-1β and TNF-α-induced IKK-α/β in 
W256 mammary sarcoma cells [369], Therefore, this is the first study to show 
inhibition of constitutive IKK-α/β activation by celastrol. However, whether 
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celastrol modulates constitutive IKK-α/β activation directly or indirectly via 
suppression of other important upstream kinases such as TAK1, MEKK1, NIK 
etc needs additional investigation.  
       AKT is constitutively activated in MM cells [460] and since it mediates 
various processes involved in MM progression AKT pathway is considered to 
be an important therapeutic target in the treatment of MM [79]. AKT has been 
found to be involved in MM progression by mediating cell proliferation [84, 
461], anti-apoptosis [84, 462] and cell migration [463]. Interestingly, our study 
also shows that celastrol can inhibit the phosphorylation of AKT. It has been 
established that AKT can act upstream of NF-κB signalling cascade to 
positively regulate its activation [455]. Thus, it is feasible that celastrol-
induced inhibition of both IKK-α/β and AKT activation could be involved in 
the suppression of NF-κB activation pathway. 
 NF-κB inhibition is considered to be at least one of the mechanisms of 
action of the novel proteasome inhibitor bortezomib that is approved for MM 
treatment [290]. Since celastrol was observed to inhibit NF-κB pathway 
activation in our study, we further investigated if celastrol potentiated 
bortezomib-induced inhibition of NF-κB activation. Our experimental results 
demonstrate that celastrol indeed potentiates the bortezomib-induced NF-κB 
inhibition in MM cells. 
 Whether celastrol-induced inhibition of STAT3 and NF-κB activation as 
observed in MM cell lines are linked with each other is not clear as of yet. 
However, there is an evidence to suggest that STAT3 activation might 
positively regulate NF-κB activity by preventing its nuclear export [464]. 
However, activation of STAT3 and NF-κB pathway are mediated by different 
cytokines. STAT3 pathway is activated by IL-6 cytokine; whereas, NF-κB 
pathway is primarily activated by TNF-α and B cell growth factors.  
Interestingly, erythropoientin-activated JAK2 kinase has been shown to 
positively regulate NF-κB activity. Hence, it is conceivable that celastrol-
mediated inhibition of these two master transcription factors might be related 
through its ability to abrogate JAK2 kinase activation [465]. Our study also 
demonstrates that thiol reactive quinone methide functional group of celastrol 
is involved in the inhibition of STAT3. Thus, it would be interesting to analyze 
if the same functional group also mediates the inhibition of NF-κB as observed 
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upon celastrol treatment. 
 Based on our predictive analysis, inhibition of NF-κB and STAT3 can be 
attributed as the potential downstream effects of HSP90 inhibition and HO-1 
induction by celastrol in MM cells. Interestingly, a study by Malara et al., 
showed that simultaneous inhibition of both STAT3 and NF-κB is necessary 
and sufficient to induce apoptosis in U266 cells, which exhibit constitutive 
activation of  both STAT3 and NF-κB pathway [242]. Our study propose and 
prove that celastrol at micromolar concentrations effectively block these two 
pathways to induce MM cell apoptosis. 
 
4.4. Celastrol potentiates the apoptosis induced by novel 
targeted therapies in MM cells 
            Celastrol has been recently reported to enhance TRAIL-induced cell 
death [399, 401] and TNF-α-induced apoptosis [371, 372]. Celastrol has also 
been found to potentiate the apoptotic effects of gambogic acid in human oral 
carcinoma cell line Tca8113 [374], temozolomide in melanoma [373], and 
conventional chemotherapeutic agents (daunorubicin and cytarabine) in K-562 
and Jurkat T human leukemia cells [402]. It also synergistically induced 
apoptosis in combination with ErbB2-targeted therapeutics (trastuzumab and 
lapatinib) in ErbB2 overexpressing breast cancer cells [390] and sensitized 
taxol-resistant HeLa cells to paclitaxel [384]. However, so far there are no 
reports to analyze the apoptotic effects of celastrol in combination with 
targeted anti-MM drugs. Interestingly, our studies show for the first time that 
celastrol synergistically induces apoptosis in combination with either the 
bortezomib or thalidomide as deducted from Chou-Talalay multiple drug effect 
equation. The plausible explanation for this synergistic effect could be myriad. 
As evidenced from our studies and other reports published previously, celastrol 
can inhibit NF-κB pathway, although via distinct mechanisms in diverse tumor 
cell types. Both bortezomib [466] and thalidomide [467] are known to inhibit 
NF-κB activation cascade. Therefore, it is conceivable that celastrol-
bortezomib and celastrol-thalidomide combination might cooperatively inhibit 
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NF-κB pathway that may lead to observed synergistic effect on apoptosis. 
Moreover, both bortezomib and celastrol are known to act as proteasome 
inhibitors. Thus, these two agents might cooperatively modulate various 
proteins that are degraded by ubiquitin-proteasome system and are involved in 
the survival and progression of myeloma. However, there exists one interesting 
difference between pharmacological actions of bortezomib and celastrol; 
Bortezomib treatment upregulate HSP90 and this upregulated HSP90 is 
considered to be a stress response by which tumor cells manage to recover 
from the cytotoxic effects of bortezomib [435]. Inhibition of HSP90 by HSP09 
inhibitors enhances bortezomib-induced apoptosis [468]. Consequently, many 
HSP90 inhibitors are currently being tested in combination with bortezomib to 
achieve greater clinical efficacy [469]. Interestingly, celastrol is a bonafide 
HSP90 inhibitor [342, 344, 345, 350, 353]. Therefore, celastrol induced 
inhibition of HSP90 that is upregulated by bortezomib treatment can be another 
plausible mechanism for the synergism exhibited by these two agents. 
Inhibition of IL-6-mediated signaling in combination with bortezomib has also 
been shown to exhibit synergistic apoptosis [470]. Hence, celastrol-induced 
inhibition of STAT3 activation pathway can also account for the observed 
synergy with celastrol-bortezomib combination in MM cells. 
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Figure 4.1. Schematic diagram depicting inhibition of STAT3 and NF-κB 
pathways by celastrol in MM cells 
 
STAT3 plays crucial role in myeloma pathogenesis by upregulating Bcl-2 
members of anti-apoptotic proteins which confer myeloma cells resistance to 
apoptosis. In MM, STAT3 pathways are mainly activated by cytokines present 
in the bone marrow microenvironment. These cytokines activate the non-
receptor tyrosine kinases JAK2 and Src which in turn can phosphorylate 
STAT3 to induce its nuclear translocation and DNA binding. In MM, NF-κB 
pathway is dysregulated by both activating mutations and cytokines present in 
the BMME. Thus dysregulated NF-κB pathway mainly channels through 
canonical pathway which is mediated by IKK-β. NF-κB governs many 
processes involved in myeloma progression including resistance to apoptosis, 
proliferation, angiogenesis, migration and invasion by regulating the indicated 
players. Celastrol suppresses STAT3 activation pathway by inhibiting 
upstream JAK2 and Src kinases. Inhibition of NF-κB pathway by celastrol is 
found to be mediated by abrogation of IKK-α/β and AKT activation. Overall, 
inhibition of these two important pro-inflammatory transcription factors by 
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celastrol can account for its observed anti-proliferative, apoptotic, anti-invasive 
and antiangiogenic effects in MM cells. 
 
4.5. Anti-myeloma effects of celastrol in vivo 
4.5.1. Celastrol potentiates the inhibition of tumor growth 
induced by bortezomib in a xenograft nude mouse model 
 
 To analyze the anti-myeloma effects of celastrol in vivo, we established 
human MM xenograft nude mouse model by subcutaneously injecting U226 
cells. Xenograft mouse model is the most commonly used animal model to test 
the efficacy of anticancer drugs. This model is relatively easy to establish and 
allow easy monitoring of the tumor volume [312]. Several anti-myeloma 
agents that have been approved recently by FDA for the treatment of MM has 
been tested in xenograft model before being tested in clinical trials [313]. 
Though, various studies have been done to analyze the in vivo effects of 
celastrol in various tumor models, this is the first study to analyze the in vivo 
effects of celastrol alone and also in combination with bortezomib in MM. In 
our study, celastrol alone inhibited MM tumor growth when compared to 
control group. In accordance with our in vitro studies, celastrol also potentiated 
the tumor growth inhibition induced by bortezomib in statistically significant 
manner. These observations are in agreement with studies conducted in human 
prostate cancer [337, 406], breast cancer [371], melanoma [378], pancreatic 
cancer [342],  glioma [413], and CML xenograft mouse models [411], where 
celastrol significantly inhibited tumor growth in vivo as single agent. Though, 
there have been previous studies to analyze the effect of celastrol in 
combination with TRAIL cytokine in lung cancer [399], and colon cancer 
xenograft mouse models [400] as well as with radiotherapy in prostate [403] 
and lung cancers [391], this is the first study to analyze the effect of celastrol in 
combination with an approved targeted therapy (bortezomib) in vivo in a tumor 
model of haematological malignancy.  
 
  192 
4.5.2. Celastrol in combination with bortezomib inhibits the 
expression of STAT3 and NF-κB p65 in tumor tissues 
 
 As mentioned previously, combined and simultaneous inhibition of 
STAT3 and  NF-κB is sufficient and necessary for induction of apoptosis in 
myeloma cells [242]. Since, celastrol as a single agent induced apoptosis in 
vitro and inhibited tumor growth in vivo, we also aimed to investigate if 
celastrol-induced abrogation of tumor growth correlated with the modulation of 
STAT3 and NF-κB activation. Interestingly, we found that celastrol inhibited 
the expression of both p-STAT3 and NF-κB in mouse xenograft model. Also, 
though the effect of bortezomib on STAT3 activation cascade is not well 
characterized as it is on NF-κB, our study demonstrates that celastrol in 
combination with bortezomib can inhibit expression of both p-STAT3 and NF-
κB, which is associated with greater inhibition of tumor growth. These 
observations are in agreement with the studies showing that inhibition of IL-6- 
mediated pathway in MM can indeed potentiate the apoptosis induced by 
bortezomib [470].  
 
 
4.5.3. Celastrol in combination with bortezomib downregulates 
the expression of proteins involved in myeloma progression in 
vivo 
 
 Since celastrol in combination with bortezomib inhibited MM tumor 
growth and was associated with the inhibition of expression of p-STAT3 and 
NF-κB, we aimed to investigate if celastrol-bortezomib combination was 
associated with downregulation of survival/angiogenic proteins involved in 
myeloma progression and regulated by these two transcription factors. 
Interestingly, we found that both celastrol alone and bortezomib alone 
downregulated the expression of Bcl-2 and VEGF proteins in tumor tissues. 
However, the celastrol-bortezomib combination exhibited substantially better 
inhibition than when both the compounds were used as a single agent at 
suboptimal doses. This observation is in accordance with the greater inhibition 
of tumor growth and in the expression of STAT3 and NF-κB transcription 
factors exhibited by the combination treatment group. 
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4.5.4. Celastrol in combination with bortezomib modulates 
cytokine profile in vivo 
 
 IL-6 cytokine drives myeloma progression by simultaneously activating 
JAK/STAT3, MAPK/ERK and PI3K/AKT pathways [435]. Moreover, serum 
levels of IL-6 and soluble IL-6 receptor has been proven to be a prognostic 
marker for tumour load, disease progression and survival [65-69]. Likewise, 
TNF-α is also involved in myeloma cell survival and progression [435]. 
Moreover, TNF-α secreted by MM cells act on the bone marrow stromal cells 
to stimulate the latter to secrete IL-6 which in turn aids in paracrine growth of 
MM cells [76, 77, 168]. Bortezomib has been shown to modulate cytokine 
profile favoring MM cell death [435]. On a similar note, we aimed to 
investigate if celastrol and bortezomib combination can cause modulation of 
cytokines in the sera derived from MM xenograft mouse model. Interestingly, 
we noted that celastrol alone decreased the serum level of both IL-6 and TNF-α 
when compared to the control group. However, celastrol-bortezomib 
combination treatment group showed a greater decrease in these cytokine 
levels. Thus, these findings suggest that by modulating cytokine levels celastrol 
might alter the interaction between MM cells and BMME thereby favouring 













Figure 4.2. Schematic diagram showing celastrol-induced inhibition of 
various characteristics hallmark features of MM 
 
Celastrol inhibits resistance to apoptosis by downregulating anti-apoptotic 
proteins and upregulating pro-apoptotic proteins, suppresses sustaining 
proliferative signaling by inhibiting STAT3/NF-κB activation pathways, 
inhibits evasion of growth suppressors by downregulating cyclin D1 and cyclin 
E, and upregulating p21 and p27 expressions,  modulates angiogenic signal by 
downregulating the expression of VEGF /c-Myc, and abrogates CXCL12-
induced migration/invasion by downregulating the expression of CXCR4 and 
MMP-9. However, it is possible that celastrol may still modulate several other 











Figure 4.3. Schematic diagram representing the molecular mechanism(s) 
of celastrol-induced apoptosis in MM cells 
 
MM cells have upregulated expression of anti-apoptotic members of Bcl-2 
family of proteins namely Bcl-2, Bcl-xL and Mcl-1 by virtue of the activated 
STAT3 pathway. Constitutively active NF-κB pathway also contributes to MM 
cell survival by upregulating members of IAP family of proteins namely 
survivin and XIAP. Celastrol activates both caspase-8-mediated extrinsic 
apoptotic pathway and caspase-9-mediated intrinsic apoptotic pathway. 
Celastrol treatment induces JNK activation which can mediate its apoptotic 
effects in MM cells. The dashed lines indicate how JNK can possibly mediate 
celastrol-induced apoptosis. Celastrol also aids in apoptosis by inhibiting both 
STAT3 and NF-κB activation pathways. However, whether STAT3, NF-κB 
and JNK proteins can directly interact with each other needs additional 
investigation. 
  196 
5. CONCLUSIONS  
 
 In summary, our study shows for the first time that celastrol exhibits 
potent anti-myeloma effects including induction of apoptosis, inhibition of 
expression of various proteins involved in cell cycle progression, suppression 
of expression of proteins involved in angiogenesis, as well as abrogation of 
chemokine-induced migration and invasion. We also provide mechanistic 
evidences, namely induction of JNK by which celastrol can induce apoptosis in 
MM cells. This study also establishes celastrol as a novel inhibitor of STAT3 
transcription factor, an unexplored pharmacological property of this triterpene. 
We also identified the key functional groups of celastrol responsible for its 
observed STAT3 inhibitory effects. Moreover, we also validate that celastrol 
can indeed inhibit NF-κB cascade through the modulation of constitutive IKK-
α/β and AKT activation in MM cells. These findings were found to be in 
agreement with the in silico analysis data provided by Cell works Inc. We also 
demonstrate that celastrol can significantly potentiate NF-κB inhibitory 
potential of bortezomib in MM cells. In addition, we provide evidence showing 
that celastrol can synergistically induce apoptosis in combination with novel 
anti-myeloma agents. Finally, we demonstrate the significant potentiation of 
anti-myeloma effects of bortezomib by celastrol in a xenograft MM mouse 
model without any substantial side effects. Our in vivo data also confirms 
inhibition of p-STAT3, NF-κB and downregulation of 
survival/angiogenic/inflammatory biomarkers by celastrol alone and also in 
combination with bortezomib mediates its observed anti-myeloma effects. Also, 
when examined in CD138+ plasma cells isolated from patients with MM, we 
found that celastrol suppressed the viability in a dose-dependent manner, 
suggesting its enormous clinical potential for MM treatment. 
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6. FUTURE DIRECTIONS 
 
           Analysis of effects of celastrol on MM cells co-cultured with bone 
marrow stromal cells will help to elucidate its effect on the interaction between 
MM cells and BMME. Elucidation of detailed molecular mechanisms of action 
by which celastrol can modulate multiple cell signal transduction cascades will 
provide novel insights into its potential therapeutic uses. Moreover, these 
proposed experiments will also help to analyze the potential effect of celastrol 
on cell adhesion mediated drug resistance. SCID-Rb MM xenograft model can 
be employed to analyze the effect of celastrol on the interaction between MM 
cells and BMME in vivo. Cultured MM cells do not exactly resemble human 
MM pathological process. So, it would be prudent to confirm the anti-myeloma 
effects of celastrol in plasma cells isolated from MM patients. Additionally the 
effect of this triterpene should also be investigated in peripheral blood 
mononuclear cells to rule out potential toxicities. Also, detailed 
pharmacokinetic and toxicological studies in suitable mouse models should be 
performed to facilitate the rapid use of celastrol from bench to bedside research.   
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2.2.1. In Silico Analysis 
 
 The Cellworks (Cellworks, USA) tumor cell platform provides a 
dynamic and transparent view of human cellular physiology at the proteomics 
abstraction level.  The virtual tumor cell platform consists of a dynamic and 
kinetic representation of the signaling pathways underlying tumor physiology 
at the bio-molecular level.  The platform has been co-related against an 
extensive set of pre-defined in vitro and in vivo studies [1].  
 
2.2.2. Platform Description  
 
 The virtual tumor cell platform consists of a dynamic and kinetic 
representation of the signaling pathways underlying tumor physiology at the 
bio-molecular level.  All the key relevant protein players and associated gene 
and mRNA species with regard to tumor related signaling are comprehensively 
included in the system with their relationship quantitatively represented.  
Pathways and signaling for different cancer phenotypes comprise 75 major 
signaling networks with more than 3900 intracellular molecules.  The platform 
comprises of crucial oncogenic proteins including EGFR, PDGFRA, FGFR, c-
MET, VEGFR and IGF-1R, cell cycle regulators, mTOR signaling, p53 
signaling cascade, cytokine pathways like IL1, IL4, IL6, IL12, TNF, lipid 
mediators, and tumor metabolism.  The modeling of the time-dependent 
changes in the fluxes of the constituent pathways has been done utilizing 
modified ordinary differential equations (ODE) and mass action kinetics.  The 
platform has been correlated against an extensive set of pre-defined in vitro and 
in vivo studies. 
 
2.2.3. Study Details 
 
 The base line used for the study was a BRAF-over expressed, RB1 and 
P53 mutant, aligned to U266 cell line [472, 473]. The following studies were 
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conducted in disease state and the biomarker trends evaluated as percentage 
change from disease values. 
• HSP90 activity was inhibited by 80% 
• NF-κB activation was inhibited by 80%  
• HO-1 expression was induced by 2 folds 
• A combination of the HSP90 and NF-κB inhibition, NF-κB inhibition 
and HO-1 induction, HSP90 inhibition with HO-1 induction and all the 
three in combination was also tested along with the above three 
individual experiments 
The results for the above studies individually or in combination were analyzed 
across known biomarker trends for celastrol and the trends were compared with 
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3. RESULTS 
 
3. 1. In silico analysis of anti-myeloma effects of 
celastrol 
 
3.1.1. Predictive analysis of anti-myeloma effects of celastrol 
upon HSP90 activity knock-down along with HO-1 induction:   
 
 Predictive analysis data related to the potential anti-myeloma effects of 
celastrol under in silico conditions was kindly provided by Cellworks Group 
Inc.  California, USA. For predictive analysis, the HSP90 activity was inhibited 
by 55% and 92% along with the induction of HO-1 expression by 2 folds, in a 
BRAF (gene that codes for B-Raf) over-expressed, RB1 (retinoblastoma1 gene) 
and p53 mutant virtual tumor cell aligned to U266 cell.  Fig. 3.1.1 A, illustrates 
a high-level view of the virtual tumor cell platform.  Fig. B, upper panel clearly 
shows that knocking down HSP90 activity by 55% and 92% along with HO-1 
induction causes a reduction in NF-κB activity. Active phosphorylated STAT3, 
JAK2 and Src all show a reduction (Fig B, lower panel), and also all the key 
survival markers including Bcl-2, Bcl-xL, XIAP and survivin (BIRC5) showed 
a decrease with HSP90 inhibition (Fig C, upper panel). Also, increased 
predictive trends were observed for the apoptotic markers cleaved caspase-3 
and cleaved-PARP1 (Fig. C, lower panel). Only HO-1 induction and HSP90 
inhibition resulted in abrogation of STAT3 and NF-κB activity. Moreover, the 
predicted modulation for various oncogenic proteins by celastrol co-related 
with our experimental results. Thus, findings of this in silico model supports 
our central hypothesis that celastrol might modulate diverse oncogenic proteins 








































  234 
Figure 3.1.1. Predictive analysis of anti-myeloma effects of celastrol upon 
HSP90 activity knock-down along with HO-1 induction 
 
A. The figure illustrates a high-level view of the Cellworks group Inc. virtual 
tumor cell platform.  
 
B.  The figure in the upper panel illustrates the percentage reduction in NF-κB 
activity following HSP90 inhibition and HO-1 induction. The figure in the 
lower panel illustrates the percentage reduction in phosphorylated STAT3, 
JAK2 and Src kinases.  
 
C. The figure in the upper panel, illustrates the percentage reduction in the 
various survival markers- Bcl-2, Bcl-xL, XIAP and survivin. The figure in the 
lower panel illustrates the percentage increase in caspase-3 and cleaved-
PARP1 and the increasing trend of these markers supports the increase in 
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2.1.6. Primers and probes  
 
Primers and probes used in this study were obtained from Applied Biosystems 
(Foster City, CA, USA) and are as follows: 
Human Bcl-2  
Human Bcl-xL  
Human Survivin  
Human Mcl-1  





2.2.10. RNA extraction and Real-time PCR analysis 
 
 Trizol reagent was used for RNA extraction. Briefly, for a 50µl 
reaction, 10µl of RT product was mixed with 1x TaqMan® Universal PCR 
Master mix, 2.5µl of 20x TaqMan probes for Bcl-2, Bcl-xl, survivin, and Mcl-1 
respectively, 2.5µl of 20x 18S RNA TaqMan probe as the endogenous control 
for each targeting gene, and topped up to 50 µl with sterile water. A negative 
control for RT, in which sterile water replaced the RNA template, was 
included. Another control, where RT mix was replaced with sterile water, was 
included to check for DNA contamination. Real-time PCR was done using 
7500 Fast Real-Time PCR System (ABI PRISM 7500, Applied Biosystems, 
Foster City, CA, USA) with a protocol that consists of 50°C for 2 min, 95°C 
for 10 min, followed by 40 cycles of denaturing at 95°C for 15 seconds and 
extension at 60°C for 1 min. Results were analyzed using Sequence Detection 
Software version 1.3 provided by Applied Biosystems. Relative gene 
expression was obtained after normalization with endogenous human GAPDH 
and determination of the difference in threshold cycle (Ct) between treated and 
untreated cells using 2-∆∆Ct method.     
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3. RESULTS 
 
3.2.2.7. Celastrol causes downregulation of expression of various anti-




It is evident from our western blot results that celastrol causes downregulation 
of the expression of various prosurvival proteins. To analyze if the celsatrol- 
induced downregulation of the prosurvival proteins, occurs also at 
transcriptional level real time PCR analysis was also done. U266 cells were 
treated with 1 µM celastrol for 0, 2, 4 and 6 hrs and real time PCR assay was 
done as described under Materials and Methods. The results clearly reveal that 
celastrol down-regulates the expression of various indicated proteins at the 

























Figure 3.2.2.7. Celastrol causes downregulation of expression of various 
anti-apoptotic proteins involved in survival of MM cells at transcriptional 
level 
 
U266 cells were treated with 1 µM celastrol for the indicated time intervals, 
after which RNA samples were extracted and used for real time PCR with 18S 
RNA as endogenous control.  Results were analyzed using Sequence Detection 
Software version 1.3 provided by Applied Biosystems. Relative gene 
expression was obtained after normalization with endogenous 18S RNA and 
determination of the difference in threshold cycle (Ct) between treated and 
untreated cells using 2-∆∆Ct method. The results shown are representative of 
two independent experiments.   
 
 




Isolation and culture of primary MM plasma cells 
  
 Primary cells were obtained from bone marrow aspirates of MM 
patients after informed consent and with ethical approval from the NUS IRB. 
Peripheral blood mononuclear cells were separated with RBC lysis buffer and 
subsequently CD138+ plasma cells were isolated using magnetic cell 
sorting  with CD138+ EasySep magnetic nanoparticles (Stemcells Technologies, 
Singapore) according to manufacturer's instructions. Purified CD138+ patient 
cells were grown in IMDM, Glutamax (Gibco, Life 
Technologies), supplemented with 20% fetal bovine serum (FBS), 100 U/mL 
penicillin and 100 µg/mL streptomycin, 10ng/mL of IL-6 (Militenyi Biotech, 
Surrey UK) and 100 ng/mL of rhIGF-1(R&D Systems, Abingdon, 
Oxford,UK). All the cells were grown at 37°C in a humidified atmosphere with 




Celastrol suppresses the viability of CD138+ primary MM plasma cells 
isolated from patients in a dose-dependent manner 
 
 Since celastrol suppresses the viability of a variety of human MM cell 
lines and tumor growth in xenograft MM model, we next aimed to investigate 
if celastrol can also affect the viability of CD138+ cells isolated from the 
patients. CD138+ cells isolated from MM patients were treated with 0, 1, 2.5 
and 5 µM of celastrol for 72 hrs and thereafter MTT assay was performed to 
analyze the viability as described in Materials and Methods section in the main 
body of this thesis. It is evident from the results shown below that celastrol can 
substantially suppress the viability of CD138+ cells in a dose-dependent 
manner in all the five tested patients samples. 
 
 








Figure 1: Celastrol suppresses the viability of CD138+ MM plasma cells in 
a dose-dependent manner 
 
CD138+ cells were isolated from MM patients as described above in the 
Methods section. Cells were thereafter treated with the indicated concentrations 
of celastrol for 72 hrs and MTT assay was performed. Data is represented as 
the relative viability of each treatment group as compared to the control for 
each patient sample. 
 
 
